

From: [O'Malley, Devin M. EOP/OVP](#)
To: [O'Malley, Devin M. EOP/OVP](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Love, Kelly A. EOP/OVP](#)
Subject: Items for Clearance
Date: Saturday, March 14, 2020 5:03:52 PM

Hi everyone-

It's been a busy week, especially the last couple of days. We appreciate everyone's patience, especially if they experienced delays in getting approval from us during this time. I also want to thank everyone for giving us considerable amount of lead time to review items that you send for clearance. We understand that there will certainly be times where rush review is needed, but definitely appreciate when we have a few hours to look at something. If you are still waiting on clearance for certain items, please resubmit them to the appropriate members of our team now.

On a related note, starting on Monday, the schedule for Task Force related meetings is shifting a bit. This means that Katie and I, and other members of the team, will be harder to get ahold of from the hours of 9:00 am – 11:30 am (instead of 4:00 pm – 6:30 pm). Please consider this when thinking about reviews/clearances. We will also adjust the morning call to a time TBD.

As always, please feel free to call me whenever you have an issue, think something can be done better, or have an idea. We appreciate hearing from you.

Thank you for all you are doing!

Devin

Devin M. O'Malley

(b) (6)

From: [Finnen, April](#)
To: [2019-nCoV FDA IMG JIC Press](#)
Cc: [Lynch, Sarah](#); [2019-nCoV FDA IMG JIC Leadership](#)
Subject: OMA - heads up on VP clearance - FW: NICCL Meeting Call-Out 3.27.2020
Date: Friday, March 27, 2020 2:45:02 PM
Attachments: [image001.png](#)
[image002.png](#)
[ESF15_NICCL_Summary_v2_FINAL_20200327.pdf](#)
[image004.png](#)

From today's NICCL call (full notes attached):

Communications/Messaging Clearance

The Office of the Vice President request you adhere to the following guidance when reviewing press statements, internal/external comms, media appearance requests, etc.

The email address is: DL.OVP.CommsCOVID@ovp.eop.gov

SUBJECT LINE:	APPROVAL: [SUBJECT AND TYPE OF DOCUMENT; e.g., CDC HOSPITAL GUIDANCE PRESS RELEASE; FDA)
GUIDANCE DOCUMENT:	Please use URGENT APPROVAL for short fuse items (i.e., < 1 hour)
Information needed in the Body of email:	
TYPE OF DOCUMENT:	[PRESS RELEASE/EMPLOYEE EMAIL/WEBSITE UPDATE/PRESS INQUIRY/ETC]
DEADLINE:	[DATE/TIME]
REVIEWED BY:	[NAME OF OTHER DEPARTMENT/AGENCY]

From: Brubach, April <April.Brubach@fda.hhs.gov>
Sent: Friday, March 27, 2020 1:22 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>
Subject: NICCL Meeting Call-Out 3.27.2020

NICCL Meeting Call-Out 3.27.2020

WH Comms: *Preparing for Apple to launch its app today, it is a feature that will help people really find the path for what they should do if they have symptoms. It is very user-friendly, that will be something that the Apple team and White House will announce today in conjunction with HHS and CDC.*

(b) (5) [REDACTED] It will be a helpful tool for the public to help them understand what their potential symptoms may mean and what steps they should take to keep their household healthy and safe. That will be one of the main news items this evening and I will let the Vice President's office give further updates on the task force as of today and this weekend.

April Brubach, 301-512-0780

From: FEMA-ESF15-Coordination <FEMA-ESF15-Coordination@fema.dhs.gov>
Sent: Friday, March 27, 2020 1:07 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>; Clark, Alaina <alaina.clark@cisa.dhs.gov>; Glenn, Amanda <Amanda.Glenn@cisa.dhs.gov>; Palczewski, Andrew (OS) <Andrew.Palczewski@hhs.gov>; ALFONSO-ROYALS, ANGELICA <ANGELICA.ALFONSO-ROYALS@hq.dhs.gov>; Trevino, Anna <anna.trevino@fema.dhs.gov>; Tatem, Anne (OS) <Anne.Tatem@hhs.gov>; CERAOLO, ANTHONY <ANTHONY.CERAOLO@hq.dhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; BOZA-HOLMAN, SOFIA <SOFIA.BOZA-HOLMAN@hq.dhs.gov>; McPherson, Brendan <Brendan.McPherson@hq.dhs.gov>; Glauser, Brittany (OS) <Brittany.Glauser@hhs.gov>; Brown, Lynn <lynn.brown@fema.dhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; Daniels,

Carla L (OS) <Carla.Daniels@hhs.gov>; Castro, Carmen <carmen.castro@fema.dhs.gov>; carol_danko@ios.doi.gov; McCormick, Chad <Chad.McCormick@fema.dhs.gov>; Howlett, Christine <christine.howlett@fema.dhs.gov>; christopher.b.logan.mil@mail.mil; cole_rojewski@ios.doi.gov; Corbin, Susan <Susan.Corbin@hq.dhs.gov>; Coronavirus-Communicators@state.gov; Bradway, Courtney B (OS) <Courtney.Bradway@hhs.gov>; Dracoulis, Danielle <danielle.dracoulis@fema.dhs.gov>; Stellar, Dante <Dante.Stellar@fema.dhs.gov>; Johnston, Darcie (OS) <Darcie.Johnston@hhs.gov>; Passey, David <david.passey@fema.dhs.gov>; Bauer, Debra <Debra.Bauer@fema.dhs.gov>; DMcGaan@doc.gov; Armstrong, Earl <Earl.Armstrong@fema.dhs.gov>; engagement@hhs.gov; eoevent337@cdc.gov; Erickson, Scott <Scott.Erickson@hq.dhs.gov>; Wiecezorek, Erin <Erin.Wiecezorek@cisa.dhs.gov>; Beck, Gary (OS) <Gary.Beck@hhs.gov>; Genevieve.Giaccardo@bia.gov; Josey, Herbert <Herbert.Josey@cisa.dhs.gov>; HOULTON, TYLER <TYLER.HOULTON@hq.dhs.gov>; isaac.l.taylor.mil@mail.mil; Bass, Jackita D <jackita.bass@cisa.dhs.gov>; Muhammad, Janell M (OS) <Janell.Muhammad@hhs.gov>; Moore, Jeanie <jeanie.moore@cisa.dhs.gov>; Sherman, Jennifer (OS) <Jennifer.Sherman@hhs.gov>; Campora, Jenny W <Jenny.Campora@fema.dhs.gov>; jesus.garcia3@usda.gov; jesus.garcia3@usda.gov; Gountanis, John <John.Gountanis@hq.dhs.gov>; Twomey, John K (OS) <John.Twomey@HHS.GOV>; john_bockmier@ios.doi.gov; Osborne, Jonathan (OS) <Jonathan.Osborne@hhs.gov>; Cox, Jordan (OS) <Jordan.Cox@hhs.gov>; WESTMORELAND, JOSEPH A (OPR) <JOSEPH.A.WESTMORELAND@CBP.DHS.GOV>; Ayala, Juan <juan.ayala@fema.dhs.gov>; Stecker, Judy (OS) <Judy.Stecker@hhs.gov>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Nolan, Kathryn <kathryn.nolan@fema.dhs.gov>; Willcuts, Kathryn <Kathryn.Willcuts@cisa.dhs.gov>; Benacci, Kevin <Kevin.Benacci@cisa.dhs.gov>; Kittrie, Zachary <Zachary.Kittrie@fema.dhs.gov>; Kkilgore@doc.gov; Kneeper@bbg.gov; kpietranton@fbi.gov; Krikava, Richard <Richard.Krikava@fema.dhs.gov>; Kristan Nevins <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Kristina Baum <[\(b\) \(6\)@ostp.eop.gov](mailto:(b) (6)@ostp.eop.gov)>; Kuhns, Daniel (OS) <Daniel.Kuhns@hhs.gov>; Lange, John <John.Lange@hq.dhs.gov>; lashonda.walker@usda.gov; lashonda.walker@usda.gov; Laura Schlapp <laura.a.schlapp.civ@mail.mil>; Laura.J.Brown@faa.gov; Trueman, Laura (OS) <Laura.Trueman@hhs.gov>; Lauren Gorey <lgorey@doc.gov>; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Kotwicki, Lauren (OS) <Lauren.Kotwicki@hhs.gov>; LBGALLAGHER@fbi.gov; leslie.lankster@fns.usda.gov; leslie.lankster@fns.usda.gov; Levine.Carolyn@epa.gov; lhagee@fbi.gov; Litzow, Elizabeth <elizabeth.litzow@fema.dhs.gov>; Ortega, Lorena <lorena.ortega@fema.dhs.gov>; Lori.Irving@dot.gov; Lucero, Mark <Mark.Lucero@fema.dhs.gov>; Lujan, Maria <maria.lujan@fema.dhs.gov>; Lynne.Donahue@usdoj.gov; Macaulay Porter <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; MALIN, STEPHANIE <STEPHANIE.MALIN@cbp.dhs.gov>; mallory bloun <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; RASCHER, MALLORY <MALLORY.RASCHER@hq.dhs.gov>; Mancha, Patricia <Patricia.Mancha@fema.dhs.gov>; Marc Short <Marc.t.short@ovp.eop.gov>; Marc.Raimondi@usdoj.gov; Margaret.Schaefer@dhs.gov; mark hinkle <mark.hinkle@ssa.gov>; Mark Mchale <mark.mchale@gsa.gov>; Mark.Ballesteros@va.gov; Weber, Mark (OS) <Mark.Weber@hhs.gov>; Mary.A.Brandenberger@usdoj.gov; Mary.E.Markos@usace.army.mil; Mary.E.Markos@usace.army.mil; Matt Schuck <Matthew.J.Schuck@hud.gov>; Matt Sheehey <mshheehey@peacecorps.gov>; Matthew Lahr <matthew.lahr@dni.gov>; Matthew.Borgia@noaa.gov; Matthew.Burrell@gsa.gov; Maura.Beard@nctc.gov; McBride, Scott A LCDR <Scott.A.McBride@uscg.mil>; McCachrenC@state.gov; McCulloch, Robert <robert.mcculloch@fema.dhs.gov>; MCKENZIE MELISSA M <melissa.mckenzie@usss.dhs.gov>; MCMURRAY JULIA <Julia.Dagostino@usss.dhs.gov>; McNeil, Elizabeth <elizabeth.mcneil@fema.dhs.gov>; Meddie.Brown@gsa.gov; Media Inquiry <MediaInquiry@HQ.DHS.GOV>; media@ucia.gov; mediarelations@fcc.gov; Cardin, Megan <Megan.Cardin@fda.hhs.gov>; McSeveney, Megan <Megan.McSeveney@fda.hhs.gov>; Megan.O'Kane@dhs.gov; Meghan Burris <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Meghan.Rodgers@oc.usda.gov; Wilkins, Melissa <melissa.wilkins@fema.dhs.gov>; Good-Cohn, Meredith (CMS) <Meredith.Good-Cohn@cms.hhs.gov>; Merry Lin <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; MGuarracino@supremecourt.gov; Heck, Mia (OS) <Mia.Heck@hhs.gov>; Michael Abboud <abboudmc@state.gov>; Michael Dubray <dubraymr@state.gov>; Pratt, Michael (OS) <Michael.Pratt@hhs.gov>; Dailey, Michael A <Michael.A.Dailey@cisa.dhs.gov>; Michael.Birmingham@dni.gov; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Michael.P.Knight@usdoj.gov; Michael.w.Dendas@hud.gov; Michawn Rich <Michawn.rich@usda.gov>; Michawn.Rich@osec.usda.gov; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Michelle Dawi <[\(b\) \(6\)@ho.eop.gov](mailto:(b) (6)@ho.eop.gov)>; Michelle.Coghill@usdoj.gov; Michelle.Hindmarch@hq.doe.gov; Michelle.laver@nnsa.doe.gov; Midgett, Amy LT <Amy.Midgett@uscg.mil>; Mike Korbey <mike.korbey@ssa.gov>; Mike.Illenberg@oc.usda.gov; MILHOAN CATHERINE L <catherine.milhoan@usss.dhs.gov>; Miller, Bennett <Bennett.Miller@hq.dhs.gov>; Mina, Peter <Peter.Mina@hq.dhs.gov>; mira.lezell@dot.gov; Mizelle, Chad <Chad.Mizelle@hq.dhs.gov>; Harris, Missy J (NIH) <mjharris@mail.nih.gov>; MNLowry@fbi.gov; Molly Block <block.molly@epa.gov>; molly.meiners@treasury.gov; Morgan Bedan <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Morgan Ortagus <OrtagusMD@state.gov>; msgaine@cybercom.mil; Msiegel@doc.gov; msimms2@peacecorps.gov; Nalepa, Jessica <jessica.nalepa@fema.dhs.gov>; nancy gonzalez <nancy.gonzalez@ssa.gov>; NASON MICHAEL C <michael.nason@usss.dhs.gov>; Best, Natalia <Natalia.Best@hq.dhs.gov>; Natalie Hurst <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; NationalJIC@dhs.gov; Lemar, Naweed (OS) <Naweed.Lemar@hhs.gov>; nctcpao@nctc.gov; Ndidi.Mojay@va.gov; Nelson, Jason <Jason.Nelson2@fema.dhs.gov>; NewsMedia@nps.gov; ng.ncr.ngb-arng.mbx.ngbjoccpa@mail.mil; Pottebaum, Nicholas (who.eop.gov) <Nicholas.D.Pottebaum@who.eop.gov>; Nicholas.Goodwin@ios.doi.gov; nicole tiggemann <nicole.tiggemann@ssa.gov>; nicole.peckumn@dc.gov; Nicole.Schwegman@pacom.mil; nigel.holderby@redcross.org; Thomas, Nkosi <Nkosi.Thomas@hq.dhs.gov>; nlpitto@nsa.gov; nc.peterson@ncspecialstaff.mbx.usnorthcom-pa-omb@mail.mil; NOC SWO Restricted <NOC.SWO.Restricted@hq.dhs.gov>; NOC.NDD@hq.dhs.gov; Noelker, Tim <tnoelker@cns.gov>; npo@fbi.gov; NSAmedia@nsa.gov; Imhoff, Olivia (who.eop.gov) <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Olshanski, Thomas <Thomas.Olshanski@fema.dhs.gov>; opa@hq.dhs.gov; osd.pa.dutyofficer@mail.mil; Overton, Kristina <kristina.overton@fema.dhs.gov>; owen.morgan@dot.gov; pacom.i0pac.duty.pao@navy.mil; pacrisisresponse@state.gov; Pallas, Charissa M <Charissa.M.Pallas@ice.dhs.gov>; pamela Pennington <pamela.pennington@gsa.gov>; Pamela.s.kunze@mail.mil; Conrad, Patricia L (NIH) <conradpa@niaid.nih.gov>; El-

Hinnawy, Patricia <Patricia.ElHinnawy@fda.hhs.gov>; Brennan, Patrick (OS) <Patrick.Brennan@hhs.gov>; Patrick.h.cordova@mail.mil; Paul.F.Smith@usps.gov; Formoso, Paula (OS) <Paula.Formoso@hhs.gov>; Gutierrez, Paula <paula.gutierrez@fema.dhs.gov>; Paulk-Buchanan, Crystal <crystal.paulk-buchanan@fema.dhs.gov>; PAYNE, LAWRENCE R <LAWRENCE.R.PAYNE@cbp.dhs.gov>; Payton, Crystal <Crystal.Payton@fema.dhs.gov>; Peter Hoffman <[Peter.Hoffman@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Peter Carr <Peter.Carr@usdoj.gov>; Cassell, Peter <Peter.Cassell@fda.hhs.gov>; Peter Knudson <Peter.Knudson@ntsb.gov>; Peter Krug <Peter.krug@uspto.gov>; Peterson, Mark J <Mark.Peterson2@fema.dhs.gov>; Peterson1W@state.gov; Phillips, James M <James.M.Phillips@hq.dhs.gov>; Phillips, Kimberly <Kimberly.Phillips@fema.dhs.gov>; PicardVM@state.gov; Pierce, Bradley <bradly.pierce@fema.dhs.gov>; Pinkham, Dennis <Dennis.Pinkham@fema.dhs.gov>; pio@supremecourt.gov; PKaplan@ftc.gov; Platt, Michael E CAPT <Michael.E.Platt@uscg.mil>; Pooja Jhunjunwala <pjhunjunwala@usaid.gov>; press.office@ssa.gov; PressOffice@dot.gov; Privatesector@hq.dhs.gov; Public.Affairs@socom.mil; publicaffairs.pacom@navy.mil; publicaffairs@doc.gov; Purdy, Adoratia <adoratia.purdy@fema.dhs.gov>; qig3@cdc.gov <qig3@cdc.gov>; Quinn, Cameron <Cameron.Quinn@hq.dhs.gov>; Rachel Semmel <[Rachel.Semmel@omb.eop.gov](mailto:(b) (6)@omb.eop.gov)>; Nutter, Rachel <rachel.nutter@fema.dhs.gov>; rachel_levin@ios.doi.gov; Raini.W.Brunson@usace.army.mil; Ramsay, Cindy <cindy.ramsay@fema.dhs.gov>; Semke, Rand <Rand.Semke@hq.dhs.gov>; randy.ready@pacom.mil; Raymond, Joe W CAPT <Michael.W.Raymond@uscg.mil>; rcparker@usaid.gov; Readinger, Jeff <Jeff.Readinger@HQ.DHS.GOV>; Rebecca Miller <rebecca.miller@treasury.gov>; Armstrong, Rebekah W (OS) <Rebekah.Armstrong@hhs.gov>; Reinhold, Kent R CDR <Kent.R.Reinhold@uscg.mil>; Renee Hudson <[Renee.Hudson@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Richard.a.crusan.civ@mail.mil; Richardson, Yasamie <yasamie.richardson@fema.dhs.gov>; Richardson.RobinH@epa.gov; Rideaux.Chantra.d@dol.gov; Rob <robbinse@state.gov>; Robert Bozzuto <bozzuto.robert.F@DOL.gov>; robert.l.perino.mil@mail.mil; <[Robert.Bozzuto@omb.eop.gov](mailto:(b) (6)@omb.eop.gov)>; Robert.Nadeau@noaa.gov; robert.sperling@hq.dhs.gov; Robert.Tuttle@hq.dhs.gov; Robinson1A2@state.gov; Rochelle.Cohen@fcc.gov; Rodriguez.Juan@dol.gov; ronald.mclendon6.civ@mail.mil; Rossie, Camilla <Camilla.Rossie@fema.dhs.gov>; RRMuhammad@fbi.gov; Russell, Anthony L CAPT <Anthony.L.Russell@uscg.mil>; Russell.Oneill@gsa.gov; Russell.Newell@ios.doi.gov; Clemens, Ruth <Ruth.Clemens@cisa.dhs.gov>; Ryan Essman <ressman@usaid.gov>; Ryan Kaldahl <kaldahlrm@state.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Ryan, Charles <charles.ryan@fema.dhs.gov>; Samantha Schwab <[Samantha.Schwab@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; samuel.r.souvannason.ctr@mail.mil; Samuels, Jessie <Jessie.Samuels@fema.dhs.gov>; SAPP, STEPHEN <STEPHEN.SAPP@cbp.dhs.gov>; <[STEPHEN.SAPP@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Sara.L.Eguren@irs.gov; Sendek, Sara <Sara.Sendek@cisa.dhs.gov>; Arbes, Sarah C (OS) <Sarah.Arbes@hhs.gov>; sarah.case-herron@dc.gov; Sauerhage.Maggie@epa.gov; SSCI_Press@state.gov; Scott Calhoun <Scott.calhoun@dot.gov>; Blakeman, Scott (OS) <Scott.Blakeman@hhs.gov>; Scott.Smullen@noaa.gov; sean.mcmaster@dot.gov; sean.poole@dot.gov; seth.unger@treasury.gov; sfontaine@usaid.gov; Shaylyn.Hynes@hq.doe.gov; Shefveland, Alan <Alan.Shefveland@fletc.dhs.gov>; Sheila.Johnston@pacom.mil; SHORT, CHERIE <CHERIE.SHORT@hq.dhs.gov>; Myrie, Simone (OS) <Simone.Myrie@hhs.gov>; Simons, Michael <michael.simons@tsa.dhs.gov>; Siwarfield@cns.gov; SMITH, LAUREL <LAUREL.SMITH@CBP.DHS.GOV>; Smith, Yvonne <yvonne.smith@fema.dhs.gov>; Snyder, Elizabeth <Elizabeth.Snyder@fema.dhs.gov>; Socialmedia@faa.gov; southcom.miami.sc-cc.list.cmd-public-affairs@mail.mil; Sscott@cns.gov; Sshero@fbi.gov; Ecoffey, Stacey (OS) <stacey.ecoffey@hhs.gov>; Palosky, Stacey (OS) <Stacey.Palosky@hhs.gov>; StanfordAD@state.gov; StarrKL@state.gov; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; Stephanie Grisham <[Stephanie.Grisham@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Stephanie.c.fila@hud.gov; Zumwalt, Steven <Steven.Zumwalt@fema.dhs.gov>; Stmckee@fbi.gov; Stoneking, Daniel <Daniel.Stoneking@fema.dhs.gov>; Streeter, Ryan <Ryan.Streeter@hq.dhs.gov>; Strouse, Philip <Philip.Strouse@fema.dhs.gov>; Carlson, Sue <Sue.Carlson@fema.dhs.gov>; Sunset.r.Belinsky.mil@mail.mil; Susan Varga <[Susan.Varga@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Susan.b.miller@nctc.gov; Susanna.Marking-Stockl@uscg.gov; Sellman, Suzanne (OS) <Suzanne.Sellman@hhs.gov>; SWIFT, HEATHER <HEATHER.SWIFT@hq.dhs.gov>; Tagliento, Marc <Marc.Tagliento@fema.dhs.gov>; Broido, Tara (OS) <Tara.Broido@hhs.gov>; Bradley, Tasha (OS) <Tasha.Bradley@hhs.gov>; taylor.l.weeks@nasa.gov; TdJagerson@fbi.gov; Terrence.Hayes@va.gov; Terrence.Sutherland@sba.gov; t-hannen3@cranfordnj.org; Corry, Thomas (CMS) <Thomas.Corry@cms.hhs.gov>; Thompson, Christa <Christa.Thompson@fletc.dhs.gov>; Foster, Timothy (OS) <Timothy.Foster@hhs.gov>; timothy_williams@ios.doi.gov; <[timothy_williams@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Vitek, Traci (OS) <Traci.Vitek@hhs.gov>; tracy.a.ograde-walsh.civ@mail.mil; Travis.Edwards@ice.dhs.gov; trhanna@nsa.gov; Troye, Olivia <Olivia.Troye@nsc.eop.gov>; Trupo.Michael@dol.gov; TUTONI VINCENT A <vincent.tutoni@ussf.dhs.gov>; Urbani, Adrien <adrien.urbani@fema.dhs.gov>; usagovemergency@gsa.gov; USCIS EXA NICCL Group <USCISEXANICCLGroup@uscis.dhs.gov>; Venture, Veronica <Veronica.Venture@HQ.DHS.GOV>; Vermette, Joseph <Joseph.Vermette@fema.dhs.gov>; veronica.davison.civ@mail.mil; Walsh, Brett <brett.walsh@fema.dhs.gov>; Ward, Erin <Erin.Ward@fema.dhs.gov>; Web Publishing <WebPublishing@HQ.DHS.GOV>; Wehagen, Robby <robby.wehagen@fema.dhs.gov>; Crozer, William (who.eop.gov) <[William.Crozer@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Wilson, Thomas <thomas.wilson2@fema.dhs.gov>; Witmer, Wade <Wade.Witmer@fema.dhs.gov>

Subject: NICCL Summary 3.27.2020

Good afternoon,

Attached is the NICCL Summary for today's call. Thank you for your agency's participation.

Best,

Alexa Fortuna

Emergency Management Specialist | FEMA ESF 15 Coordination | Office of External Affairs

Mobile: <[b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>

FEMA-ESF15-Coordination@fema.dhs.gov

Federal Emergency Management Agency
[fema.gov](https://www.fema.gov)

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Cacomo, Stephanie](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Manchester, Brittney](#); [Felberbaum, Michael](#); [Caliguiri, Laura](#)
Subject: Re: flag--media response re: n95 sterilization
Date: Sunday, March 29, 2020 1:58:40 PM

I wouldn't post unless you are going to have something to announce tonight or tomorrow

Sent from my iPhone

On Mar 29, 2020, at 1:34 PM, Cacomo, Stephanie
<Stephanie.Cacomo@fda.hhs.gov> wrote:

Hi folks—

Flagging for you that we want to get some information for reporters on an issue that POTUS raised re: N95s. Basically, our team is working quickly!

POTUS tweet:


Hope the FDA can approve Mask Sterilization equipment ASAP. As per Governor

[@MikeDeWine](#)

, there is a company in Ohio,

[@Battelle](#)

, which has equipment that can sterilize masks quickly.



Stephanie Cacomo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: 3/23/2020 7:54:17 PM
To: Henning, Alexa A. EOP/WHO [Katherine.A.Henning@who.eop.gov]; Love, Kelly A. EOP/OVP (b)(6); Hahn, Julia A. EOP/WHO [Julia.A.Hahn@who.eop.gov]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]; Daravi, Roma S. EOP/WHO [Roma.S.Daravi2@who.eop.gov]; O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]; Gidley, Hogan H. EOP/WHO [Hogan.Gidley@who.eop.gov]; McGuffee, Tyler A. EOP/OVP (b)(6); Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Montesi, Janet (b)(6); Litzow, Elizabeth (b)(6); Baker, Brittany G. EOP/WHO [Brittany.G.Baker@who.eop.gov]; Caccamo, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Caliguir, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Sherman, Jennifer (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=96ea669491654aba8d4ea6816279e040-HHS-Jennife]

Subject: Principal Media Prep: Primetime/Morning/Daytime Shows
Location: Dial-In: (202) 395-6392 | Code: (b)(6)

Start: 3/23/2020 8:15:00 PM
End: 3/23/2020 8:45:00 PM
Show Time As: Tentative

Recurrence: (none)

Hi all—

This will be a media prep for any principals doing primetime/morning/daytime shows. Please forward this invite to your respective principal's scheduler.

Dr. Hahn

- Tucker Carlson Tonight
- Topics: Therapeutics—vaccines, drugs for treatment Recent press release, CDC just posted information for clinicians treating coronavirus patients, Regulatory flexibility—(b)(5)

Dr. Fauci

- Hannity
- Topics:

Dr. Birx

- NBC TODAY
- Topics: latest government guidelines and social distancing, update on where things stand in combating the virus, any new discoveries about the virus/possible treatments going forward, supplies and working with states
- FBN Mornings w/ Maria
- Topics: the latest on COVID-19, message to millennials

Administrator Gaynor

- ABC Good Morning America
 - Topics:
- FNC Fox & Friends
 - Topics:

Larry Kudlow

- Varney & Co.
 - Topics: Economy, stimulus package, Hill negotiations

If you have any conflicts, please let us know asap.

Thank you,
Ninio

From: O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]
Sent: 3/19/2020 2:05:38 PM
To: Caccamo, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Hall, Bill (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e56218361cd4ffbacdd06ac2d7b809d-HHS-bill.ha]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]; Fetalvo, Ninio J. EOP/OVP (b)(6)
CC: Murphy, Ryan (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c844c911312452e901760ebdd0f3820-HHS-Ryan.Mu]; Oakley, Caitlin B (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b8feed045e954557aa1e0052f925865f-HHS-Caitlin]; McKeogh, Katherine (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c3facab3fd03480f8553892121fd2009-HHS-Katheri]; Caliguiri, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; Felberbaum, Michael [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4819a643ca2945cdb1a2631b83e69673-Michael.Fel]
Subject: RE: FDA release on chloroquine

(b) (5)

From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 2:01 PM
To: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b)(6) >
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b) (5)

. Just clarifying.

Stephanie Caccamo

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: (b)(6)
stephanie.caccamo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>

MULTI-HHS-FDA-20-0400, 20-0415-D, HHS-FDA-20-0498-G-000010

Date: March 19, 2020 at 1:53:15 PM EDT

To: Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>, Hall, Bill (OS) <bill.hall@hhs.gov>, Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>, Fetalvo, Ninio J. EOP/OVP

<(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>, Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>, McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>, Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>, Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

One more: (b) (5)

(b) (5)

To: (b) (5)

From: Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>

Sent: Thursday, March 19, 2020 1:37 PM

To: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

Will do. With that edit, can we issue?

Stephanie Cacco

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: (b)(6)
stephanie.cacco@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>

Sent: Thursday, March 19, 2020 1:35 PM

To: Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

This release goes right into the quote from (b) (5) about "today's actions," (b) (5)
(b) (5) Recommend moving (b) (5).

From: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Sent: Thursday, March 19, 2020 1:24 PM

To: O'Malley, Devin M. EOP/OVP <(b)(6)>; Miller, Katie R. EOP/OVP <(b)(6)>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura (FDA/OC)

<Laura.Caliguiri@fda.hhs.gov>; Caccamo, Stephanie (FDA/OC) <Stephanie.Caccamo@fda.hhs.gov>

Subject: FDA release on chloroquine

All...FDA is ready to issue this. Please let us know if we have the green light. Bill

William Hall

Deputy Assistant Secretary for Public Affairs (Public Health)

Office of the Assistant Secretary for Public Affairs

U.S. Department of Health & Human Services

Washington, DC

Direct: 202-690-6344

Mobile: (b)(6)

Email: bill.hall@hhs.gov

>>>www.hhs.gov<<<



From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: 3/17/2020 10:11:36 AM
To: Caliguiri, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC: Cacco, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Murphy, Ryan (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c844c911312452e901760ebdd0f3820-HHS-Ryan.Mu]; Hall, Bill (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e56218361cd4ffbaccdd06ac2d7b809d-HHS-bill.ha]; MacInnis, Hannah F. EOP/OVP (b)(6)
Subject: RE: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

+Hannah for potential amplification on op-ed

From: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Sent: Tuesday, March 17, 2020 10:10 AM
To: Fetalvo, Ninio J. EOP/OVP (b)(6); O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Cc: Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>
Subject: RE: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

Can't get into call -all circuits busy – quick update we have enforcement discretion on food inspection guidance coming out today, working through some Q&A on safety/packaging, pushing out support for blood centers and Dr. Hahn's oped on fraud published in USAToday this am.

From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: Monday, March 16, 2020 5:17 PM
To: Fetalvo, Ninio J. EOP/OVP (b)(6)
Cc: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Love, Kelly A. EOP/OVP (b)(6)
Subject: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

Notes from Daily Coronavirus Comms Sync

5:00 PM Monday, March 16, 2020

OVP Comms

- (b)(5)

HHS

(b)(5)

NIH

(b)(5)

CMS

(b)(5)

(b) (5)

Surgeon General

(b) (5)

DHS

(b) (5)

FEMA

(b) (5)

DOT

(b) (5)

State

(b) (5)

USAID

(b) (5)

DOD

(b) (5)

HUD

(b) (5)

Treasury

(b) (5)

USDA

(b) (5)

Energy

(b) (5)

Labor

(b) (5)

VA

(b) (5)

NASA

(b) (5)

NSC

(b) (5)

(b) (5)

DNI

(b) (5)

SSA

(b) (5)

###

From: Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
Sent: 4/3/2020 11:05:14 AM
To: Holt, Brandon T. EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Clancy, Carolyn [Carolyn.Clancy@va.gov]; Klote, Mary M. [Mary.Klote@va.gov]; Justice, Amy [Amy.Justice2@va.gov]; Bates, Jack (BISL) [Jack.Bates@va.gov]; Francis, Joe [Joe.Francis@va.gov]; Quinn, John F. (NDS) [John.Quinn@va.gov]; Box, Tami [Tamara.Box@va.gov]; Ramoni, Rachel [Rachel.Ramoni@va.gov]; Muralidhar, Sumitra [Sumitra.Muralidhar@va.gov]; Brouillette, Dan [dan.brouillette@hq.doe.gov]; Dabbar, Paul [paul.dabbar@hq.doe.gov]; Abernethy, Amy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c84171967c724ee799bb2658197086bc-Amy.Abernet]; Watson, Ian D. EOP/OSTP (b) (6)@ostp.eop.gov; Waterman, Paige E. EOP/OSTP (b) (6)@ostp.eop.gov; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Fabina, Lauren C. EOP/NSC (b) (6); Ruggiero, Anthony J. EOP/NSC (b) (6); Tully, Ryan M. EOP/NSC (b) (6); Kratsios, Michael J. EOP/OSTP (b) (6)@ostp.eop.gov; Parker, Lynne E. EOP/OSTP (b) (6)@ostp.eop.gov
CC: Hennessey, Millicent S. EOP/NSC (b) (6); Ferro, Phil J. EOP/NSC (b) (6)
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Hi all,

I'm adding Michael Kratsios and Lynne Parker re the data mining piece.

Kelvin

From: Holt, Brandon T. EOP/NSC <Brandon.T.Holt@nsc.eop.gov>
Sent: Friday, April 3, 2020 10:36 AM
To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>; Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>; Fabina, Lauren C. EOP/NSC <Lauren_C._Fabina@nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC <Anthony.J.Ruggiero@nsc.eop.gov>; Tully, Ryan M. EOP/NSC <Ryan.M.Tully@nsc.eop.gov>
Cc: Hennessey, Millicent S. EOP/NSC <Millicent.S.Hennessey@nsc.eop.gov>; Ferro, Phil J. EOP/NSC <Philip.J.Ferro@nsc.eop.gov>
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good morning all,

Could we please lock in this call for 12:30pm? Please see call-in information below. Thank you!

Participant Dial-In: (202) 395-6392
Participant Code (b) (6)

Best,
Brandon

Brandon T. Holt
Office of the National Security Advisor
D: 202-456-8705

From: Ferro, Phil J. EOP/NSC <Philip.J.Ferro@nsc.eop.gov>

Sent: Friday, April 3, 2020 10:30 AM

To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>; Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>; Fabina, Lauren C. EOP/NSC <Lauren_C._Fabina@nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC <Anthony.J.Ruggiero@nsc.eop.gov>; Tully, Ryan M. EOP/NSC <Ryan.M.Tully@nsc.eop.gov>

Cc: Holt, Brandon T. EOP/NSC <Brandon.T.Holt@nsc.eop.gov>; Hennessey, Millicent S. EOP/NSC <Millicent.S.Hennessey@nsc.eop.gov>

Subject: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good Morning Colleagues,

First off, thank you for your robust support to get this initiative off the ground as quickly as possible. The objective is for VA, DoE, and FDA to (b) (5)

[REDACTED]

[REDACTED]

We would like to convene a call this afternoon to coordinate efforts. Brandon Holt who works for APDNSA Pottinger will work with you and your staff to schedule this call. To this end, please feel free to have your staff respond to Brandon. We will send out an agenda shortly.

Please let me know if you have any questions or if I may be of assistance.

All the best,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
202.456.1222 (O) (b) (6) (cell)
Philip.J.Ferro@nsc.eop.gov

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6) ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]
Subject: Call: rural testing and surveillance
Location: (202) 395-6392, (b) (6) #
Start: 3/30/2020 8:00:00 PM
End: 3/30/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Birx, Redfield, Verma, Hahn, Fauci, Grogan, Jernigan (CDC)

Attendees (via video conference): Bresee (CDC), Payne (CDC), TBD

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (202) 456-5984 | Mobile: (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]; Brandt, Kimberly (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c27a38a5cf444a9eb4db07014d44f848-HHS-Kimberl]; Moody-Williams, Jean D (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=da4cc691c5f14ba0886d5ff37a036b04-HHS-jean.mo]; Wright, David R (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1532ec98b0c4119b022ba89a7fdb336-HHS-David.W]; Ling, Shari (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=758ba0f601cc4764bda74f5936c87aff-HHS-Shari.L]; Shulman, Evan T (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=263f8a0b23224a2ebb72335688eee1a2-HHS-Evan.Sh]; Hittle, Matthew (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8372c80ded364f19bedb4a769a5fbe09-HHS-Matthew]; Meier, Patricia (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cac8c4884f9d4365a0df1c4a4db0b828-HHS-Patrici]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Dr. Birx, Dr. Redfield, Administrator Verma, Dr. Hahn, Dr. Fauci, Joe Grogan, Dr. Jernigan (CDC)

Attendees (via video conference/phone):

CDC: Dr. Joseph Bresee, Becky Payne

CMS: Kim Brandt, Jean Moody-Williams, David Wright, Shari Ling, Evan Shulman, Matthew Hittle, Patricia Meier

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (b) (6) | Mobil (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]; Brandt, Kimberly (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c27a38a5cf444a9eb4db07014d44f848-HHS-Kimberl]; Moody-Williams, Jean D (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=da4cc691c5f14ba0886d5ff37a036b04-HHS-jean.mo]; Wright, David R (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1532ec98b0c4119b022ba89a7fdb336-HHS-David.W]; Ling, Shari (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=758ba0f601cc4764bda74f5936c87aff-HHS-Shari.L]; Shulman, Evan T (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=263f8a0b23224a2ebb72335688eee1a2-HHS-Evan.Sh]; Hittle, Matthew (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8372c80ded364f19bedb4a769a5fbe09-HHS-Matthew]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Dr. Birx, Dr. Redfield, Administrator Verma, Dr. Hahn, Dr. Fauci, Joe Grogan, Dr. Jernigan (CDC)

Attendees (via video conference/phone):

CDC: Dr. Joseph Bresee, Becky Payne

CMS: Kim Brandt, Jean Moody-Williams, David Wright, Shari Ling, Evan Shulman, Matthew Hittle

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (6)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (6)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office (b) (6) | Mobile (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Good evening,
Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**. This meeting would take place in a conference room that has VTC capabilities (location TBD). I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (b) (6) | Mobile: (b) (6) [no text]
Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Conway, Kellyanne E. EOP/WHO [KAC@who.eop.gov]
Subject: Confirmed -- [post press briefing] Health Strategy Meeting re: reopening
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Agenda:

- Opening Remarks [AMB Deborah Birx, M.D.]
- HHS Briefing [Paul Mango, HHS Deputy Chief of Staff]
- Group Discussion
- Next Steps [AMB Deborah Birx, M.D.]
- Closing Remarks [AMB Deborah Birx, M.D.]

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Jared Kushner
Paul Mango
Brian Harrison
Joseph Grogan (by phone)
Kellyanne Conway

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]

Subject: Confirmed -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Jared Kushner
Paul Mango
Brian Harrison
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]
Subject: Confirmed -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Brian Harrison
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: [(b) (6)]
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)]@who.eop.gov; Merkel, Theo W. EOP/WHO [(b) (6)]@who.eop.gov; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)]@who.eop.gov; Giuliani, Andrew H. EOP/WHO [(b) (6)]@who.eop.gov; Sugarman, AJ J. EOP/WHO [(b) (6)]@who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)]@who.eop.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd] (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS (b) (6)]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf6245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/31/2020 7:30:00 AM
End: 3/31/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@omb.eop.gov]; Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: (202) 395-6392,,, [(b) (6)] #
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] (b) (6) Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]

Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 10:08:14 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC [(b) (6) (b) (6)] Kanapathy, Ivan J. EOP/NSC [(b) (6) (b) (6)] Hooker, Allison M. EOP/NSC [(b) (6) (b) (6)] Sinclair, Michael R. EOP/NSC [(b) (6) (b) (6)]
Subject: FDA/EOP Call on Exports
Location: Dial-in 202-395-6392; (b) (6)
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Roosevelt Room for internal participants
Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]

Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Tentative

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/31/2020 7:30:00 AM

End: 3/31/2020 8:00:00 AM

Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6)]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9bafce245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/30/2020 8:00:00 PM

End: 3/30/2020 8:30:00 PM

Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Tentative
Recurrence: (none)

Good evening,
Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**. This meeting would take place in a conference room that has VTC capabilities (location TBD). I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: (b) (6) [no text]
Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/21/2020 12:02:10 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: McGuffee, Tyler A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]
Subject: A couple of edits
Attachments: dbInformation for Clinicians on Therapeutic Options for COVID-19 Patients for posting 03212020.docx

(b) (5)

. Thank you

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/14/2020 7:51:59 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: FW: China Export Ban

From: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Sent: Monday, April 13, 2020 10:31 PM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Boyd, Charlton J. EOP/WHO <Charlton.J.Boyd@who.eop.gov>; Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: RE: China Export Ban

I went through these. If I can get case by case updates I can try to intercede. A lot of these are anecdotal. (b) (5)

[REDACTED]

JK

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 8:13 PM
To: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Cc: Boyd, Charlton J. EOP/WHO <Charlton.J.Boyd@who.eop.gov>; Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: FW: China Export Ban

Jared, see the list below, most critically (b) (5)

[REDACTED]

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Monday, April 13, 2020 3:05 PM
To: Hahn, Stephen <SH1@fda.hhs.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: China Export Ban


Sir – attached are talkers I built with NSC on the (b) (5)

[REDACTED]

(b) (5)

[REDACTED]

(b) (5)



From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/31/2020 12:32:58 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]
Subject: Re: Schedule of therapies coming on line

Pages 2 and 3 of the document I gave you yesterday.

S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 31, 2020 at 11:25:28 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: Re: Schedule of therapies coming on line

You mean the CTAP document? He also wanted a flow chart with when therapies come on line and how many people could treated?

Sent from my iPhone

On Mar 31, 2020, at 11:04 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Yes I handed it to you yesterday at the 2 pm meeting. I tried to email it multiple times yesterday (as I mentioned) but couldn't get through the WH gateway. I'm ready to present whenever you want me to do so

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 31, 2020 at 10:45:20 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: Schedule of therapies coming on line

Steve, have you guys made any progress on the chart that Liddell requested laying out the schedule Of therapies coming on line?

Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/25/2020 6:11:01 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]
Subject: RE: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

I'll let Bob and Deb respond from a public health point of view. An antibody test is essential for detecting high titers that will enable both convalescent plasma and hyperimmune globulin. both are promising therapies.
S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 5:57:48 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: RE: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Yes that's right. It's an antibody test (b) (5)

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Wednesday, March 25, 2020 4:01 PM
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: Re: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

We don't know anything about this particular test, but if they met the conditions under the recent guidance, which are pretty straightforward, the US government could purchase them for distribution to locations where there is a healthcare worker.

One other thing. The test Mr. Martin refers to appears to be an antibody test not a diagnostic test for COVID-19. It's important to know that under the recent guidance companies can notify us that they are entering the market but we do not have scientific insight into how the tests perform. We have been working with other companies to expedite antibody testing.

We are very happy to provide additional information as well as technical assistance to anyone wishing to purchase these tests.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 25, 2020 at 2:46:32 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Steve

From: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Date: Wednesday, March 25, 2020 at 2:45 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>
Subject: FW: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

John Martin of former Gilead fame told me that Fosun, a Chinese company that he knows well has a \$3 point of care antibody test and the ability to make a ton of them. (b) (5)

From: Lyons, Derek S. EOP/WHO <Derek.S.Lyons@who.eop.gov>
Sent: Wednesday, March 25, 2020 2:30 PM
To: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: FW: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

(b) (5)

From: News Alerts <NewsAlerts@WHO.eop.gov>
Sent: Wednesday, March 25, 2020 2:28 PM
Subject: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Coronavirus test: UK to make 15-minute at-home kits available within days

The Independent

Kate Ng

March 25, 2020

><https://www.independent.co.uk/news/uk/home-news/coronavirus-test-uk-kit-home-nhs-cases-symptoms-public-health-england-a9424741.html><

'Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community,' says Public Health England director

New 15-minute home test kits for coronavirus will be made available to the British public within days, said a Public Health England (PHE) director.

Thousands of tests will be sold in chemists such as Boots or delivered by Amazon to people with symptoms who are self-isolating as soon as next week.

Professor Sharon Peacock, director of the national infection service at PHE, told MPs on the science and technology committee once the tests are cleared, they will be "distributed to the community".

Matt Hancock, the health secretary, said the government bought millions of the tests on Tuesday and is ordering millions more.

The antibody test involves pricking a finger and analysing a drop of blood in a device that looks like a pregnancy test. It will only tell the person if they have had Covid-19, not if they currently have it.

The test will detect the presence of the antibodies IGM, which emerges in the early stages of infection, and IGG, which increases during the body's response to the virus.

Ms Peacock said the tests would "absolutely" be available within days, rather than weeks or months, when asked by MPs.

She said: "Several million tests have been purchased for use. These are brand new products. We have to be clear they work as they are claimed to do.

"Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community."

Currently, only patients admitted to hospital are being routinely tested for Covid-19. Between 5,000 to 6,000 people are being tested a day, but the government plans to increase this to 25,000 tests a day within four weeks.

The new antibody tests could help the UK achieve what the World Health Organisation (WHO) has urged governments to do, which is to "test, test, test".

Tedros Adhanom Ghebreyesus, director-general of the WHO, said: "We cannot stop this pandemic if we do not know who is infected."

The antibody tests are also being ordered across Europe and Southeast Asia, said Ms Peacock.

"We are not alone in doing this," she added.

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/26/2020 8:11:20 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Did Abbott file on its Alere platform

Yes, for sure

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 26, 2020 at 7:50:09 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Did Abbott file on its Alere platform

Let me know – (b) (5)

[REDACTED]

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Thursday, March 26, 2020 at 7:30 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Subject: Re: Did Abbott file on its Alere platform

They tell us today

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 26, 2020 at 5:55:36 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Did Abbott file on its Alere platform

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/25/2020 12:38:31 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: When can you present CTAP to the TF?

Yes, pre-brief Thursday. Colin can you make sure that happens?

S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 11:52:38 AM EDT
To: Rom, Colin <Colin.Rom@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: When can you present CTAP to the TF?

Ok. So pre brief Thursday?

Sent from my iPhone

> On Mar 25, 2020, at 11:51 AM, Rom, Colin <Colin.Rom@fda.hhs.gov> wrote:

>

> Will be ready to announce to task force on Friday

>

> -----Original Message-----

> From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>

> Sent: Wednesday, March 25, 2020 11:22 AM

> To: Hahn, Stephen <SH1@fda.hhs.gov>

> Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>

> Subject: When can you present CTAP to the TF?

>

> I'm getting pressed to schedule it.

>

> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/12/2020 6:29:00 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: The Reagents come from Germany

We are in constant contact in the manufacturers of reagents and while we have not had anyone reach out to us about this issue, we are looking into it. I've spoken to Jeff Shuren's team and they will specifically reach out about this.
Steve

Sent from my iPad

> On Mar 11, 2020, at 9:10 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
>
> Guys, I'm being told that the reagents for the tests come from Germany and they have put export controls on everything covid-19. (b) (5)
>
> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/8/2020 9:13:31 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
CC: Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbddd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; Caro Rivera, Juan A. EOP/WHO [Juan.A.CaroRivera@who.eop.gov]; Watson, Ian D. EOP/OSTP [Ian.D.Watson@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [Paige.E.Waterman@ostp.eop.gov]; Shuren, Jeff [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44335a0c2f834535bc8713dfd643905e-Jeff.Shuren]; Flannery, Ellen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f3a88f0ebdf24b898ccd4814707daedf-Ellen.Flann]
Subject: Re: Devices for surface testing

Very good question. We'll investigate.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 7, 2020 at 8:20:04 PM EST
To: Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Redfield, Robert R (CDC) <olx1@cdc.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>, Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>, Bonner, Maria K. EOP/WHO <Maria.K.Bonner@who.eop.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>, Caro Rivera, Juan A. EOP/WHO <Juan.A.CaroRivera@who.eop.gov>, Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>, Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>
Subject: Re: Devices for surface testing

With Steve Hahn from FDA

Sent from my iPhone

> On Mar 7, 2020, at 8:17 PM, Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov> wrote:
>
> I'm copying Ian and Paige at OSTP to get their thoughts. We also can engage our new National Academy committee.
>
> Kelvin
>
>
>> On Mar 7, 2020, at 8:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
>>
>> Can we (b) (5) ?
>>
>> We've been (b) (5)

(b) (5)

>>

>> If we (b) (5)

>>

>> Michael or Kelvin, should (b) (5)

>> Joe

>>

>> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/12/2020 5:05:08 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Working on testing strategy

Deb,
This is good.

Some minor comments - (b) (5)

(b) (5)

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 12, 2020 at 4:49:22 PM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA) <nelson.l.michael2.civ@mail.mil>
Subject: Re: Working on testing strategy

Sorry – here you go

From: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Date: Sunday, April 12, 2020 at 1:04 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>
Cc: "Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA)" <nelson.l.michael2.civ@mail.mil>
Subject: Working on testing strategy

Just a draft – all comments welcomed. (b) (5)

Please review. Also Steve (b) (5). Deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/13/2020 8:39:31 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: list of essential tests and items from China

Ok thx

Sent from my iPhone

On Apr 13, 2020, at 8:36 AM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

Individual items

Sent from my iPhone

On Apr 13, 2020, at 8:24 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Joe,
Thank you. Do you want (b) (5)? Keagan, let's talk.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 13, 2020 at 8:23:50 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: list of essential tests and items from China

Can you get me a list (b) (5)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 5:15:07 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
CC: Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]
Subject: Re: Haines masks

Ok thx

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 7, 2020 at 5:14:11 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Kadlec, Robert P (OS) <Robert.Kadlec@hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>
Subject: Re: Haines masks

I think (b) (5).

Sent from my iPhone

On Apr 7, 2020, at 5:08 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Bob

A question arose today at the task force (b) (5)

Jeff,

(b) (5)

Dr. Birx is aware and could possibly provide insight.

Thx

Steve

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 7:46:54 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: Question

I'll check although I do know that there is a ton of variability.
S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 7, 2020 at 7:46:26 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Question

Pretty sweet. When it reads high thru put is there (b) (5) ?

Sent from my iPhone

On Apr 7, 2020, at 7:44 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

FYSA

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Date: April 6, 2020 at 7:52:46 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Question

Does this work?

SPONSOR	PRODUCT (link to authorization letter)	DESCRIPTION
DIAGNOSTICS		
Center for Disease Control and Prevention	CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel	- Developed by CDC and initially distributed to public health labs across the country - High throughput - Can only be run in high complexity labs
Wadsworth – New York State Public Health	New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR	Developed by Wadsworth based on CDC's

	Diagnostic Panel	published protocol - Run in qualified labs across New York State - High throughput - Can only be run in high complexity labs
Roche Molecular Systems, Inc.	cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Life Technologies (a part of Thermo Fisher Scientific, Inc.)	TaqPath™ COVID-19 Combo Kit, 100 Rxn, TaqPath™ COVID-19 Combo Kit, 1,000 Rxn	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Laboratory Corporation of America	COVID-19 RT-PCR Test	- Developed and run in LabCorp labs only; not for broad lab distribution. - High throughput - Can only be run in high complexity labs
Hologic, Inc.	Panther Fusion SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Quest Diagnostics Infectious Disease, Inc.	SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR	- Developed and run in Quest labs only; not a kit for distribution. - High throughput - Can only be run in high complexity labs
Quidel Corporation	Lyra® SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Abbott Molecular, Inc.	Abbott RealTime SARS-CoV-2 assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
GenMark Diagnostics, Inc.	ePlex SARS-CoV-2 Test	- Reagents commercially distributed as a kit to labs - Can run up to 24 specimens at the same time - Can be run in a moderate or high complexity lab
DiaSorin Molecular LLC	Simplexa COVID-19 Direct	Reagents commercially distributed as a kit to labs

		• Can run 1 specimen at a time • Can be run in a moderate or high complexity lab
Primerdesign Ltd.	Primerdesign Ltd COVID-19 genesig Real-Time PCR	• Reagents commercially distributed as a kit to labs • Requires separate RNA extraction kit and extraction platform not provided with reagents (GenoXtract) • High throughput • Can only be run in high complexity labs
Cepheid	Xpert Xpress SARS-CoV-2 test	• Reagents commercially distributed as a kit to labs • Can run up to 2,000 samples per day • Can be run in a clinical lab or at the Point of Care (POC) near the patient
Mesa Biotech Inc.	Accula SARS-CoV-2 Test	• Reagents commercially distributed as a kit to labs • Runs one specimen at a time • Can be run in a clinical lab or at the Point of Care (POC) near the patient
BioFire Defense, LLC	BioFire COVID-19 Test	• Reagents commercially distributed as a kit to labs • Can run 264 tests per day • Can be run in moderate or high complexity labs
PerkinElmer, Inc.	PerkinElmer New Coronavirus Nucleic Acid Detection kit	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Avellino Labs USA	AvellinoCoV2 test	• Developed and run in Avellino labs; not distributed to other labs • Run in a high complexity lab
BGI Genomics Co. Ltd.	Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Luminex Molecular Diagnostics, Inc.	NxTAG CoV Extended Panel Assay	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab

Abbott Diagnostics Scarborough, Inc.	ID NOW™ COVID-19	- Reagents commercially distributed as a kit - Requires a specific platform (ID NOW), of which there are 18,000 installed across the US - All-in-one; does not require separate RNA extraction kit - Runs one specimen at a time; each takes <13 minutes - Can be run in a clinical lab or at the Point of Care (POC) near the patient
NeuMoDx Molecular, Inc.	NeuMoDx SARS-CoV-2 Assay	- Reagents commercially distributed as a kit - Can run 288 or 96 samples at once, depending on the instrument, and takes 80 minutes per sample - Can be run in high and moderate complexity labs
QIAGEN GmbH	QIAstat-Dx Respiratory SARS-CoV-2 Panel	- Detects multiple other respiratory viral (17) and bacterial (3) organisms - Reagents commercially distributed as a kit to labs - Runs one specimen at a time and takes one hour - Can be run in high and moderate complexity labs
EUA for COVID-19 LDTs	Laboratory developed tests that are authorized are listed below and hyper link to letter granting inclusion under EUA	- Authorizes the use of LDTs that meet certain criteria. - Authorized tests can be used in the lab that developed the test and that is high complexity.
Massachusetts General Hospital (Mass Gen) Diagnostic Molecular Laboratory-Northwestern Medicine Infectious Disease Diagnostics Laboratory-Children's Hospital of Philadelphia Yale New Haven Hospital, Clinical Virology Laboratory		
Cellex Inc.	Serology Test qSARS-CoV-2 IgG/IgM Rapid Test	- The first serological test authorized under EUA. - Detects SARS-CoV-2 antibodies in blood. - Rapid test, provides results in 15-20 minutes.
Ipsium Diagnostics	COV-19 IDx assay	- Uses commercially available reagents - Can only be run in high complexity labs
Becton, Dickinson & Company (BD)	BioGX SARS-CoV-2 Reagents for BD MAX System	Reagents commercially distributed as a kit to labs

		- Fully automated, 8 samples per hour - Can be run in moderate and high complexity labs
ScienCell Research Laboratories	<u>ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit</u>	- Qualitative detection kit for nasal/oral/BAL - Testing is limited to laboratories certified to perform high complexity tests
Co-Diagnostics, Inc.	<u>Logix Smart Coronavirus Disease 2019 (COVID-19) kit</u>	- Qualitative detection of upper and lower respiratory tract fluids - Testing is limited to laboratories certified to perform higher complexity tests

Sent from my iPhone

On Apr 6, 2020, at 6:43 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

For task force

Does CDRH have a list of major approved diagnostic COVID tests and what platform is used for each?

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 8:21:14 AM
To: Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC: Conway, Kellyanne E. EOP/WHO [KAC@who.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]; Hicks, Hope C. EOP/WHO [Hope@who.eop.gov]; Rinat, Ory S. EOP/WHO [Ory.S.Rinat@who.eop.gov]; Troye, Olivia EOP/NSC [Olivia.Troye@nsc.eop.gov]
Subject: Re: Convalescent plasma program

Not sure about the HHS approach but happy to coordinate.

(b) (5)

. Peter, can you add?

Thanks
Steve

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 7, 2020 at 8:18:56 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Conway, Kellyanne E. EOP/WHO <KAC@who.eop.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Marks, Peter <Peter.Marks@fda.hhs.gov>, Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>, Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>, Troye, Olivia EOP/NSC <Olivia.Troye@nsc.eop.gov>
Subject: Re: Convalescent plasma program

+others.

Yes my only concern is that (b) (5)

My immediate question is (b) (5) dont want (b) (5)

Sent from my iPhone

On Apr 7, 2020, at 8:13 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

KelleyAnne, Joe and Katie,

The convalescent plasma program has ramped up and we are working hard to identify donors. There is a significant shortfall of plasma because of the need to identify additional donors. D (b) (5)

(b) (5)

(b) (5)

We should know more about this today.

In the meantime, we would like to work with you to develop PSAs and other forms of communication to identify donors. We have developed language for a PSA. Is this something we should work through with you?

Thanks
Steve

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/7/2020 1:21:55 PM
To: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: RE: Question

Do you (b) (5) ? So

?
.....

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Tuesday, April 7, 2020 1:19 PM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Question

Defining High Throughput

- As with many performance terms, there is no well accepted definition.
- High through put typically means that many samples can be run in parallel.
- Many EUA's are run on a 96 well plate format therefore you can run a **max of apx. 90 patient samples in one run.**
- Run times can vary widely depending on the technology the lab is using but **typically 3-4 hours per instrument is a good average.**
- If the lab adds automation and multiple instruments the throughput and time to result can be improved quickly.

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Tuesday, April 7, 2020 7:46 AM
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Question

Pretty sweet. When it reads (b) (5) ?

Sent from my iPhone

On Apr 7, 2020, at 7:44 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

FYSA

Date: April 6, 2020 at 7:52:46 PM EDT
 To: Hahn, Stephen <SH1@fda.hhs.gov>
 Subject: Re: Question

Does this work?

SPONSOR	PRODUCT (link to authorization letter)	DESCRIPTION
DIAGNOSTICS		
Center for Disease Control and Prevention	CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel	- Developed by CDC and initially distributed to public health labs across the country - High throughput - Can only be run in high complexity labs
Wadsworth – New York State Public Health	New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel	- Developed by Wadsworth based on CDC's published protocol - Run in qualified labs across New York State - High throughput - Can only be run in high complexity labs
Roche Molecular Systems, Inc.	cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Life Technologies (a part of Thermo Fisher Scientific, Inc.)	TaqPath™ COVID-19 Combo Kit, 100 Rxn, TaqPath™ COVID-19 Combo Kit, 1,000 Rxn	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Laboratory Corporation of America	COVID-19 RT-PCR Test	- Developed and run in LabCorp labs only; not for broad lab distribution. - High throughput - Can only be run in high complexity labs
Hologic, Inc.	Panther Fusion SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Quest Diagnostics Infectious Disease, Inc.	SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR	- Developed and run in Quest labs only; not a kit for distribution. - High throughput - Can only be run in high complexity labs

Quidel Corporation	<u>Lyra® SARS-CoV-2 Assay</u>	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in high complexity labs
Abbott Molecular, Inc.	<u>Abbott RealTime SARS-CoV-2 assay</u>	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in high complexity labs
GenMark Diagnostics, Inc.	<u>ePlex SARS-CoV-2 Test</u>	• Reagents commercially distributed as a kit to labs • Can run up to 24 specimens at the same time • Can be run in a moderate or high complexity lab
DiaSorin Molecular LLC	<u>Simplexa COVID-19 Direct</u>	• Reagents commercially distributed as a kit to labs • Can run 1 specimen at a time • Can be run in a moderate or high complexity lab
Primerdesign Ltd.	<u>Primerdesign Ltd COVID-19 genesig Real-Time PCR</u>	• Reagents commercially distributed as a kit to labs • Requires separate RNA extraction kit and extraction platform not provided with reagents (GenoXtract) • High throughput • Can only be run in high complexity labs
Cepheid	<u>Xpert Xpress SARS-CoV-2 test</u>	• Reagents commercially distributed as a kit to labs • Can run up to 2,000 samples per day • Can be run in a clinical lab or at the Point of Care (POC) near the patient
Mesa Biotech Inc.	<u>Accula SARS-CoV-2 Test</u>	• Reagents commercially distributed as a kit to labs • Runs one specimen at a time • Can be run in a clinical lab or at the Point of Care (POC) near the patient
BioFire Defense, LLC	<u>BioFire COVID-19 Test</u>	• Reagents commercially distributed as a kit to labs • Can run 264 tests per day

		• Can be run in moderate or high complexity labs
PerkinElmer, Inc.	PerkinElmer New Coronavirus Nucleic Acid Detection kit	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Avellino Labs USA	AvellinoCoV2 test	• Developed and run in Avellino labs; not distributed to other labs • Run in a high complexity lab
BGI Genomics Co. Ltd.	Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Luminex Molecular Diagnostics, Inc.	NxTAG CoV Extended Panel Assay	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Abbott Diagnostics Scarborough, Inc.	ID NOW™ COVID-19	• Reagents commercially distributed as a kit • Requires a specific platform (ID NOW), of which there are 18,000 installed across the US • All-in-one; does not require separate RNA extraction kit • Runs one specimen at a time; each takes <13 minutes • Can be run in a clinical lab or at the Point of Care (POC) near the patient
NeuMoDx Molecular, Inc.	NeuMoDx SARS-CoV-2 Assay	• Reagents commercially distributed as a kit • Can run 288 or 96 samples at once, depending on the instrument, and takes 80 minutes per sample • Can be run in high and moderate complexity labs
QIAGEN GmbH	QIAstat-Dx Respiratory SARS-CoV-2 Panel	• Detects multiple other respiratory viral (17) and bacterial (3) organisms • Reagents commercially distributed as a kit to labs • Runs one specimen at a time and takes one hour

		Can be run in high and moderate complexity labs
EUA for COVID-19 LDTs	Laboratory developed tests that are authorized are listed below and hyper link to letter granting inclusion under EUA	- Authorizes the use of LDTs that meet certain criteria. - Authorized tests can be used in the lab that developed the test and that is high complexity.
Massachusetts General Hospital (Mass Gen) Diagnostic Molecular Laboratory-Northwestern Medicine Infectious Disease Diagnostics Laboratory-Children's Hospital of Philadelphia Yale New Haven Hospital, Clinical Virology Laboratory		
Cellex Inc.	Serology Test qSARS-CoV-2 IgG/IgM Rapid Test	- The first serological test authorized under EUA. - Detects SARS-CoV-2 antibodies in blood. - Rapid test, provides results in 15-20 minutes.
Ipsium Diagnostics	CoV-19 IDx assay	- Uses commercially available reagents - Can only be run in high complexity labs
Becton, Dickinson & Company (BD)	BioGX SARS-CoV-2 Reagents for BD MAX System	- Reagents commercially distributed as a kit to labs - Fully automated, 8 samples per hour - Can be run in moderate and high complexity labs
ScienCell Research Laboratories	ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit	- Qualitative detection kit for nasal/oral/BAL - Testing is limited to laboratories certified to perform high complexity tests
Co-Diagnostics, Inc.	Logix Smart Coronavirus Disease 2019 (COVID-19) kit	- Qualitative detection of upper and lower respiratory tract fluids - Testing is limited to laboratories certified to perform higher complexity tests

Sent from my iPhone

On Apr 6, 2020, at 6:43 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

For task force

Does CDRH have a list of major approved diagnostic COVID tests and what platform is used for each?

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/11/2020 6:32:09 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Redd, Stephen C (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bb0e6496f1af42ce9f8e0d4f92fae009-HHS-scr1-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Gastfriend, Daniel Z. EOP/OMB (b) (6) (b) (6)
Subject: As an alert and maybe it can (b) (5)

(b) (5)

Q: What happens if I do not have the extraction platform referenced in the authorization of CDC's EUA-authorized test?

A: FDA believes that the CDC's EUA-authorized test could be used with the following extraction platforms which FDA cleared with the CDC's RNA-based influenza panel:

- **Roche MagNA Pure LC**

Kit: Roche MagNA Pure Total Nucleic Acid Kit

Protocol: Total NA External Lysis

Recommendation(s): Add 100 µL of sample to 300 µL of pre-aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 µL). Elution volume is 100 µL.

- **Roche MagNA Pure Compact**

Kit: Roche MagNA Pure Nucleic Acid Isolation Kit I Protocol: Total_NA_Plasma100_400

Recommendation(s): Add 100 µL of sample to 300 µL of pre-aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 µL). Elution volume is 100 µL.

- **Roche MagNA Pure 96**

Kit: Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit

Protocol: Viral NA Plasma Ext Lys SV Protocol

Recommendation(s): Add 100 µL of sample to 350 µL of pre-aliquoted External Lysis Buffer (supplied separately) (total input sample volume is 450 µL). Proceed with the extraction on the MagNA Pure 96. (Note: Internal Control = None). Elution volume is 100 µL.

- **QIAGEN QIAcube with the QIAamp DSP Viral RNA Mini Kit**

Kit: QIAGEN QIAamp® DSP Viral RNA Mini Kit

Recommendations: Utilize 140 µL of sample and elute with 100 µL of buffer.

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/11/2020 6:27:29 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Any chance (b) (5)

From: Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
Sent: 3/8/2020 9:48:47 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; Caro Rivera, Juan A. EOP/WHO [Juan.A.CaroRivera@who.eop.gov]; Watson, Ian D. EOP/OSTP [Ian.D.Watson@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [Paige.E.Waterman@ostp.eop.gov]
Subject: Re: Devices for surface testing

NIST has some protocols too.

On Mar 8, 2020, at 9:27 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Thanks, Joe. Preliminary read but happy to have a conversation.

We don't think (b) (5)

We think that (b) (5)

We are aware (b) (5). Let us know how we can help further.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 7, 2020 at 8:20:04 PM EST
To: Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Redfield, Robert R (CDC) <olx1@cdc.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>, Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>, Bonner, Maria K. EOP/WHO <Maria.K.Bonner@who.eop.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>, Caro Rivera, Juan A. EOP/WHO <Juan.A.CaroRivera@who.eop.gov>, Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>, Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>
Subject: Re: Devices for surface testing

With Steve Hahn from FDA

Sent from my iPhone

> On Mar 7, 2020, at 8:17 PM, Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov> wrote:
>
> I'm copying Ian and Paige at OSTP to get their thoughts. We also can engage our new National Academy committee.
>
> Kelvin
>
>
>> On Mar 7, 2020, at 8:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
>>
>> Can we (b) (5)?
>>
>> We've been (b) (5)
>>
>> If we need (b) (5)
>>
>> Michael or Kelvin, should (b) (5)
>> Joe
>>
>> Sent from my iPhone

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: (202) 395-6392,,, [(b) (6)]
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 10:08:14 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@[b] (6)]; Ruggiero, Anthony J. EOP/NSC [b] (6) [b] (6) Kanapathy, Ivan J. EOP/NSC [b] (6) [b] (6) Hooker, Allison M. EOP/NSC [b] (6) [b] (6) Sinclair, Michael R. EOP/NSC [b] (6) [b] (6)

Subject: FDA/EOP Call on Exports

Location: Dial-in 202-395-6392; [b] (6)

Start: 4/9/2020 2:00:00 PM

End: 4/9/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Roosevelt Room for internal participants

Participant Dial-In: (202) 395-6392

Participant Code: [b] (6)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 6:34:08 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: EUA for diagnostics

Glad to talk. I have a couple of ideas

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 26, 2020 at 4:30:28 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Yes we should talk further (b) (5)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Sent from my iPhone

On Apr 26, 2020, at 2:30 PM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

Perfect. Thank you. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Sunday, April 26, 2020 at 2:28 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Re: EUA for diagnostics

Our EUAs are for specific tests and specific lab developers/manufacturers. They require a prescription by a healthcare provider. The indication is for individuals who are 'suspected of COVID19 by their health care provider.' They don't have to be symptomatic. The wording was intended to mirror CDC guidelines. AS the guidelines change we could and would change the indication. As we change the populations of the individuals that we intend to test, the performance of the test may be different than what was provided in the validation data.

Glad to talk further.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 12:26:30 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Is that true Steve?

Sent from my iPhone

> On Apr 26, 2020, at 12:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

>

> The EUA we issued in March for diagnostics [REDACTED] it? (b) (5)

[REDACTED]

[REDACTED]

>

> Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: HOLD - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Busy

Recurrence: (none)

5/7 Agenda

TBD

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Bix, Deborah L. EOP/NSC [Deborah.L.Bix@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO (b) (6) who.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov; Riggs, Charlotte R. EOP/WHO (b) (6) who.eop.gov; Butterfield, Nicholas W. EOP/WHO (b) (6) who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]

Subject: Therapeutics Meeting
Location: WHSR Exec

Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Busy

Recurrence: (none)

****There will be no dial-in option****

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: HOLD - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: Dial-in forthcoming

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy


Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/10/2020 7:24:55 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: HOLD - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: Dial-in forthcoming

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Tentative

Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 202-395-6392;;;(b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392


Participant Code: (b) (6)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov' [(b) (6) cms.hhs.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Confirmed - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Busy
Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 1-866-617-3597;; Participant Passcode: (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Dial-In Information

Toll-Free #1-866-617-3597

Participant Passcode: (b) (6)

Leader Passcode: (b) (6)

Attendees:

Dr. Birx

Dr. Fauci

Dr. Hahn

Dr. Redfield

Agenda:

(b) (5)

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 202-395-6392;; (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)




From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: HOLD - Follow up discussion with Dr. Birx
Attachments: FW: testing, testing, testing
Location: Dial-in forthcoming
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov' [(b) (6) cms.hhs.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: TIME CHANGE: - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 3:30:00 PM
End: 5/7/2020 4:30:00 PM
Show Time As: Tentative

Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: HOLD - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Tentative

Recurrence: (none)

5/7 Agenda

TBD

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@omb.eop.gov];
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6)] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@nsc.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]
Subject: Canceled: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Free
Importance: High

Will be combined with the Wednesday Briefing

(b) (5)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 8:52:13 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=Of1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]
CC: Kushner, Jared C. EOP/WHO [jck@who.eop.gov]
Subject: Re: Antibody tests

I did talk to Howard Zucker and his answer was that we're NOT counting the antibody + people in their case count for COVID-19. He told me that he would double check on it just to follow up

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 7:35:42 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Subject: Antibody tests

Would be great to (b) (5)

[REDACTED]

[REDACTED]

[REDACTED]. Deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 6:34:08 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: EUA for diagnostics

Glad to talk. I have a couple of ideas

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 26, 2020 at 4:30:28 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Yes we should talk further because I'm not sure I'm tracking. I know we need to husband resources but for screening DoD recruits for example that isn't as a suspicion of being infected. It's screening. There are certain settings where we may want to do the same. Say a huge meat packing plant. Getting on board a cruise ship... we should think about this. I don't want the worried well getting testing in parking lots but I also think we may want to screen a huge population that interacts all at once. At least by fall.

Sent from my iPhone

On Apr 26, 2020, at 2:30 PM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

Perfect. Thank you. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Sunday, April 26, 2020 at 2:28 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Re: EUA for diagnostics

Our EUAs are for specific tests and specific lab developers/manufacturers. They require a prescription by a healthcare provider. The indication is for individuals who are 'suspected of COVID19 by their health care provider.' They don't have to be symptomatic. The wording was intended to mirror CDC guidelines. AS the guidelines change we could and would change the indication. As we change the populations of the individuals that we intend to test, the performance of the test may be different than what was provided in the validation data.

Glad to talk further.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 12:26:30 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Is that true Steve?

Sent from my iPhone

> On Apr 26, 2020, at 12:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

>

> The EUA we issued in March for diagnostics (b) (5)

[REDACTED]

[REDACTED]


>

> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/27/2020 11:49:02 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Verma, Seema (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2096b0c1e7f04e91897765d7ee0ac336-HHS-Seema.V]
Subject: Re: Testing Strategy

I'm pulling in Seema to expand the conversation.
We've been fielding a few questions that I think are unanswered by the document.

For example, (b) (5)



Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 27, 2020 at 7:53:40 AM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: FW: Testing Strategy

Please review redline word document. I did not participate in the PPT. Deb

From: "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Date: Sunday, April 26, 2020 at 8:06 PM
To: "Meadows, Mark R. EOP/WHO" <mrmcos@who.eop.gov>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>, "Gilmartin, Kayleigh M. EOP/WHO" <Kayleigh.McEnany@who.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Boehler, Adam" <Adam.Boehler@dfc.gov>, "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Farah, Alyssa A. EOP/WHO" <Alyssa.A.Farah@who.eop.gov>, "Liddell, Christopher P. EOP/WHO" <Christopher.P.Liddell@who.eop.gov>, "Philbin, Patrick F. EOP/WHO" <Patrick.F.Philbin@who.eop.gov>, "Vought, Russell T. EOP/OMB" <Russell.T.Vought@omb.eop.gov>
Cc: "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "brad.smith@cms.hhs.gov" <brad.smith@cms.hhs.gov>, "Rader, John N. EOP/NSC" <John.N.Rader@nsc.eop.gov>, "Storch, Thomas H. EOP/NSC" <Thomas.H.Storch@nsc.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Butterfield, Nicholas W. EOP/WHO" <Nicholas.W.Butterfield@who.eop.gov>, "Dumbauld, Cassidy M. EOP/WHO" <Cassidy@who.eop.gov>, "Miller, Ovp" <Katie.R.Miller@ovp.eop.gov>, "Keller, Catherine B. EOP/WHO" <Catherine.B.Keller@who.eop.gov>, "Porter, Madison F. EOP/WHO" <Madison.F.Porter@who.eop.gov>
Subject: RE: Testing Strategy

All – Once again, thanks for your input. I've attached the latest documents. We had to implement quite a few comments from the last versions, particularly on the Word Document. My hope is that the changes did not affect the substance, but I've attached a redline for those who might need it. Please review and send any RED FLAGS no later than 700 am tomorrow.

Thanks,
Derek

From: Lyons, Derek S. EOP/WHO

Sent: Saturday, April 25, 2020 7:16 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; 'Boehler, Adam' <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>; Philbin, Patrick F. EOP/WHO <pfp2dcp@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>
Subject: RE: Testing Strategy

All – Thank you for your input over the past few days. Please find revised documents attached. We are still working on formatting, but the language should be firming up. Please let me know if you have additional comments or edits.

I've added Pat Philbin to this chain for legal review.

Derek

From: Lyons, Derek S. EOP/WHO


Sent: Friday, April 24, 2020 7:59 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Boehler, Adam <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>
Subject: Testing Strategy

All –

Please see the latest iteration of the testing documents for Monday. If possible, I would appreciate any comments/concerns about noon tomorrow so we can continue to progress. In addition to content, I believe we still need to do the following:

(b) (5)



I also think we probably need to reconvene at some point this weekend to ensure everyone is comfortable with the products before they go live on Monday. We'll work to find a time.

Derek

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/19/2020 1:50:40 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: Re: Germany antibody testing

(b) (4)

S

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 19, 2020 at 1:46:29 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Germany antibody testing

This is (b) (5)

. deb


From: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Date: Sunday, April 19, 2020 at 1:29 PM
To: Stephen Hahn <SH1@fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Subject: Fwd: Germany antibody testing

Sent from my iPhone

Begin forwarded message:

From: "Hoelscher, Douglas L. EOP/WHO" <Douglas.L.Hoelscher@who.eop.gov>
Date: April 19, 2020 at 11:11:23 AM EDT
To: "Troye, Olivia EOP/NSC" <Olivia.Troye@nsc.eop.gov>, "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Germany antibody testing

Is there (b) (4) ?



Enable All Features

Find your tools here

- Create PDF
- Edit PDF
- Export PDF
- Comment
- Organize Pages
- Enhance Scans
- Protect
- Fill & Sign

Store and share files in the Document Cloud

[Learn More](#)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/16/2020 10:28:30 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: PPV

Absolutely correct

Sent from my iPhone

On May 16, 2020, at 6:48 AM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

If you are (b) (5)

?


From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/14/2020 8:28:47 AM
To: Jones, James J. EOP/OA [James.J.Jones@oa.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov];
Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Lane, Henry C (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d904337536cf41719032a9359a1ec2ab-HHS-CLANE-n]
CC: Conley, Sean P. CDR USN WHMO/WHMU [Sean.Conley@whmo.mil]; Schmoyer, Michael W. EOP/OSTP [Michael.W.Schmoyer@ostp.eop.gov]; Hartung, Charles S. CAPT USN WHMO/WHMU [Charles.Hartung@whmo.mil];
Ludwig, Michael E. COL USA WHMO/WHMU [Michael.E.Ludwig@whmo.mil]
Subject: Re: Abbott ID Now Testing Question

James,
Here are FDA's responses:


Regarding the Q#1: (b) (5)



(b) (5)




(b) (5)



Question #2 regarding biomedical waste:

A: Although we do not have an objection, FDA would not be the agency to provide this information. We suggest (b) (5)



Glad to provide additional information regarding our answers.
Steve

From: Jones, James J. EOP/OA <James.J.Jones@oa.eop.gov>

Date: May 13, 2020 at 10:25:47 AM EDT

To: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Lane, Henry C (NIH) <clane@niaid.nih.gov>

Cc: Conley, Sean P. CDR USN WHMO/WHMU <Sean.Conley@whmo.mil>, Schmoyer, Michael W. EOP/OSTP <Michael.W.Schmoyer@ostp.eop.gov>, Hartung, Charles S. CAPT USN WHMO/WHMU <Charles.Hartung@whmo.mil>, Ludwig, Michael E. COL USA WHMO/WHMU <Michael.E.Ludwig@whmo.mil>

Subject: Abbott ID Now Testing Question

Importance: High

Team,

(b) (5). This is time sensitive and we would appreciate your input ASAP on the two questions below. We have received some input from OSD Health Affairs:

#1. For the Abbott Machines (ID NOW), (b) (5)

? (b) (5)

(b) (5)

Our OSD Health Affairs sent this:

- Per the letter of authorization and instructions for use, the Abbott ID NOW EUA PCR test is for "Authorized laboratories - laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests." AND "Other Authorized Testing Locations - patient care settings using the ID NOW Instrument."

- The FDA website on EUA assays shows the Abbott ID NOW is also a waived test, meaning a Certificate of Waiver is required but the rules on who can perform the test are relaxed (meaning it does not have to be performed by trained laboratory personnel). The device can be used in a high, moderate lab or a waived setting. Waived setting is intended to be a clinic or doctor's office setting under normal circumstances. (Ref: ><https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization><)

- Per the lab SMEs, (b) (5)

#2. Biomedical Waste - For the [REDACTED] (b) (5) [REDACTED]
[REDACTED] (b) (5) [REDACTED]
[REDACTED]
[REDACTED]

OSD Health Affairs input:

"CDC and DOT guidance advises to handle laboratory waste from testing suspected or confirmed COVID-19 patient specimens as all other biohazardous waste in the laboratory. Currently, there is no evidence to suggest that this laboratory waste needs any additional packaging or disinfection procedures.

The SARS-CoV-2 is not yet classified by category but SARS-CoV is Per DOT website
(><https://www.phmsa.dot.gov/transporting-infectious-substances/covid-19-information>):<

"The Coronavirus (COVID-19) clinical samples are a "Category B" material for transportation, defined as an infectious substance that is not in a form generally capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure to it occurs. COVID-19 contaminated waste or reusable material derived from the medical treatment of COVID-19 patients is considered regulated medical waste."

In addition the attached PowerPoint document has more detailed information on "Packaging and Shipping SARS-CoV-2 Specimens, Cultures, Isolates, and Waste" states to:

- "Ship suspected and confirmed SARS-CoV-2 patient specimens, isolates, or cultures as UN 3373 Biological Substance, Category B; specimens should be in a sealed, decontaminated primary container

- Handle laboratory waste from testing suspected or confirmed COVID-19 patient specimens as all other biohazardous waste in the laboratory.

Currently, there is no evidence to suggest that this laboratory waste needs any additional packaging or disinfection procedures".

Very Respectfully - James

JAMES J. JONES, MPAS, PhD, PA-C

Chief Medical Advisor

Executive Office of the President

RM 42 EEOB

Office: 202-395-1453

Cell: (b) (6) [REDACTED]

Email: James.J.Jones@oa.eop.gov

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/15/2020 6:01:46 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Did you all just put out an alert on Abbott ID Now

We put out additional information/guidance. Abbott did as well. We alerted the WH

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: May 14, 2020 at 8:22:43 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Did you all just put out an alert on Abbott ID Now

Sent from my iPhone

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:25:54 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]
Subject: two meetings monday

Steve, could we have two meetings Monday? Another small group follow up with Peter from today, and then our first small group with Dr. Woodcock, on (b) (5). This would be headed another big group on Wednesday.

Janet, Peter understand what Debi is looking for now, but basically it would be (b) (5). Come prepared to tell us what you need to succeed.

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 7:46:16 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]
Subject: Re: Remdesivir Distribution Plan

What will be key (b) (5)

. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Wednesday, May 6, 2020 at 7:35 AM
To: "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Lenihan, Keagan" <Keagan.Lenihan@fda.hhs.gov>, "Shah, Anand" <Anand.Shah@fda.hhs.gov>
Subject: RE: Remdesivir Distribution Plan

Kadlec is involved because this is a donation to the USG which goes through BARDA. FDA, FEMA and the WH have been working with BARDA to facilitate and follow the direction given by Deb. The distribution will not be limited to 7 states. I'm copying Keagan and Anand who have been involved from FDA's perspective.
Steve

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: May 5, 2020 at 6:14:37 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Remdesivir Distribution Plan

Will add to Task Force agenda tomorrow

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Sent: Tuesday, May 5, 2020 5:52 PM
To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Cc: Stephen Hahn (sh1@fda.hhs.gov) <sh1@fda.hhs.gov>
Subject: Re: Remdesivir Distribution Plan

I have not seen the distribution. I asked them (b) (5)

Sent from my iPhone

On May 5, 2020, at 5:45 PM, Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov> wrote:

?? (b) (5) ?

From: Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>
Sent: Tuesday, May 5, 2020 3:26 PM

To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Troye, Olivia EOP/NSC <Olivia.Troye@nsc.eop.gov>
Cc: McMillin, Virginia D. EOP/WHO <Virginia.D.McMillin@who.eop.gov>; Hodgson, Christopher M. EOP/OVP <Christopher.M.Hodgson@ovp.eop.gov>
Subject: Remdesivir Distribution Plan

Hi Marc and Olivia,

Dr. Kadlec told a couple of Senators on a call yesterday that HHS plans to make Remdesivir available in 7 states (including TN). And HHS is supposedly working with FEMA on a joint press release announcing this plan.

Are you or the Task Force tracking anything to this effect?

Thanks,
Nick

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/17/2020 10:25:40 AM
To: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Smith, Brad (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8533621f52844739852d5dd666488303-HHS-Brad.Sm]; Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA) [nelson.l.michael2.civ@mail.mil]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; CMS SV1 [SV1@cms.hhs.gov]
CC: McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Rinat, Ory S. EOP/WHO [Ory.S.Rinat@who.eop.gov]; Lyons, Derek S. EOP/WHO [Derek.S.Lyons@who.eop.gov]
Subject: Re: By Noon
Attachments: Testing Strategy.pptx

Just a rough draft of what I am working on

From: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Date: Friday, April 17, 2020 at 9:31 AM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Smith, Brad (CMS/OA)" <Brad.Smith@cms.hhs.gov>, "Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA)" <nelson.l.michael2.civ@mail.mil>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, CMS SV1 <SV1@cms.hhs.gov>
Cc: "McGuffee, Tyler Ann A. EOP/OVP" <Tyler.A.McGuffee2@ovp.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Subject: By Noon

We Need for a series of technical briefings today with you all:



Deb

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/27/2020 9:49:58 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]
Subject: Re: Testing Strategy

Included phase – Bob anything?

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Monday, April 27, 2020 at 8:29 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Fauci, Anthony S (NIH)" <afauci@niaid.nih.gov>, "Redfield, Robert R (CDC)" <olx1@cdc.gov>
Subject: Re: Testing Strategy

My comments. Sorry, I used my iPad so its a little messy.
What about this for the (b) (5) section?

(b) (5)

Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 27, 2020 at 7:53:40 AM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: FW: Testing Strategy

Please review redline word document. I did not participate in the PPT. Deb

From: "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Date: Sunday, April 26, 2020 at 8:06 PM
To: "Meadows, Mark R. EOP/WHO" <mrmcos@who.eop.gov>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>, "Gilmartin, Kayleigh M. EOP/WHO" <Kayleigh.McEnany@who.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Boehler, Adam" <Adam.Boehler@dfc.gov>, "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Farah, Alyssa A. EOP/WHO" <Alyssa.A.Farah@who.eop.gov>, "Liddell, Christopher P. EOP/WHO" <Christopher.P.Liddell@who.eop.gov>, "Philbin, Patrick F. EOP/WHO" <Patrick.F.Philbin@who.eop.gov>, "Vought, Russell T. EOP/OMB" <Russell.T.Vought@omb.eop.gov>
Cc: "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "brad.smith@cms.hhs.gov" <brad.smith@cms.hhs.gov>, "Rader, John N. EOP/NSC" <John.N.Rader@nsc.eop.gov>, "Storch, Thomas H. EOP/NSC" <Thomas.H.Storch@nsc.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Butterfield, Nicholas W. EOP/WHO" <Nicholas.W.Butterfield@who.eop.gov>, "Dumbauld, Cassidy M. EOP/WHO" <Cassidy@who.eop.gov>, "Miller, Ovp" <Katie.R.Miller@ovp.eop.gov>, "Keller, Catherine B.

EOP/WHO" <Catherine.B.Keller@who.eop.gov>, "Porter, Madison F. EOP/WHO" <Madison.F.Porter@who.eop.gov>

Subject: RE: Testing Strategy

All – Once again, thanks for your input. I've attached the latest documents. We had to implement quite a few comments from the last versions, particularly on the Word Document. My hope is that the changes did not affect the substance, but I've attached a redline for those who might need it. Please review and send any RED FLAGS no later than 700 am tomorrow.

Thanks,
Derek

From: Lyons, Derek S. EOP/WHO

Sent: Saturday, April 25, 2020 7:16 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; 'Boehler, Adam' <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>; Philbin, Patrick F. EOP/WHO <pfp2dcp@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>

Subject: RE: Testing Strategy

All – Thank you for your input over the past few days. Please find revised documents attached. We are still working on formatting, but the language should be firming up. Please let me know if you have additional comments or edits.

I've added Pat Philbin to this chain for legal review.

Derek

From: Lyons, Derek S. EOP/WHO

Sent: Friday, April 24, 2020 7:59 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Boehler, Adam <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>

Subject: Testing Strategy

All –

Please see the latest iteration of the testing documents for Monday. If possible, I would appreciate any comments/concerns about noon tomorrow so we can continue to progress. In addition to content, I believe we still need to do the following:

(b) (5)

AMERICAN
OVERSIGHT

(b) (5)

6. Others?

I also think we probably need to reconvene at some point this weekend to ensure everyone is comfortable with the products before they go live on Monday. We'll work to find a time.

Derek

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/21/2020 8:53:38 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]
Subject: Re: Nation COVID-19 Diagnostic Testing Strategy Needed to Expand Laboratory Test Capacity

Thank you Steve.

Sent from my iPhone

> On Apr 21, 2020, at 8:52 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

(b) (5)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/21/2020 8:34:02 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: What happened to peter Marks?

Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/20/2020 5:37:12 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Do we have the neutralization profile on Oxford.

Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd] (b) (6) cms.hhs.gov' (b) (6) cms.hhs.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: TIME CHANGE: - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room

Start: 5/7/2020 3:30:00 PM
End: 5/7/2020 4:30:00 PM
Show Time As: Busy

Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Liddell, Christopher P. EOP/WHO [(b) (6)@who.eop.gov]; Riggs, Charlotte R. EOP/WHO [(b) (6)@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; DeValliere, Ian C. EOP/WHO [(b) (6)@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]

Subject: Therapeutics Update

Location: WHSR

Start: 4/20/2020 2:00:00 PM

End: 4/20/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Attendees:

Dr. Hahn

Dr. Redfield

Dr. Birx

Matt Pottinger

Chris Liddell

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/11/2020 2:07:34 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 1-866-617-3597;; Participant Passcode: (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Dial-In Information

Toll-Free #1-866-617-3597

Participant Passcode: (b) (6)

Leader Passcode: (b) (6)

Attendees:

Dr. Birx

Dr. Fauci

Dr. Hahn

Dr. Redfield

Agenda:

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO (b) (6) who.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov; Riggs, Charlotte R. EOP/WHO (b) (6) who.eop.gov; Butterfield, Nicholas W. EOP/WHO (b) (6) who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]
Subject: Therapeutics Meeting
Location: WHSR JFK
Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Tentative
Recurrence: (none)

****There will be no dial-in option****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD BARDA/DOD Vaccine Briefing
Location: WHSR

Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)

[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)]] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)]] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]

Subject: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Conant, Ann M. EOP/OMB [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)] Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@[(b) (6)] Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)] Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS[(b) (6)] [(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@[(b) (6)] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@[(b) (6)] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [(b) (6)] who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov]; Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]
Subject: HOLD NIH Therapeutics Briefing
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birx, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); CMS[(b) (6)] Sheehy, Janice; Hahn, Stephen; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Kellogg, Joseph Keith K. Jr. EOP/OVP; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO
Subject: HOLD NIH Therapeutics Briefing
When: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] (b) (6) Vought, Russell T. EOP/OMB [(b) (6)] (b) (6) Bruno, Grace A.
EOP/OMB [(b) (6)] (b) (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@ (b) (6)]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6)] ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6)] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; (b) (6)
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@ (b) (6)] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@ (b) (6)] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; (b) (6) (OS/IOS)
(b) (6) HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@ (b) (6) Pottinger, Matthew F. EOP/WHO (b) (6) who.eop.gov]; Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov]; Riggs, Charlotte R. EOP/WHO (b) (6) who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; DeValliere, Ian C. EOP/WHO (b) (6) who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]

Subject: Therapeutics Update
Location: WHSR

Start: 4/20/2020 2:00:00 PM
End: 4/20/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

Dr. Hahn
Dr. Redfield
Dr. Birx
Matt Pottinger
Chris Liddell

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/30/2020 10:52:54 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; (b) (6) cms.hhs.gov' [(b) (6) cms.hhs.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]

Subject: Confirmed - Dr. Birx call w/ ACOG/AAP Leadership
Location: Dr. Birx office; 877-628-4681; (b) (6)

Start: 4/30/2020 2:15:00 PM
End: 4/30/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Dial In: 877-628-4681

Participant: (b) (6)

ACOG participants:

Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:

Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:

- Opening and thanks (*Mark and Maureen*)
- HHS funding for physicians and hospitals – concerns with distribution (*Mark and Maureen*)
- Immunization rates (*Mark*)
- Continued concerns regarding home birth/birth settings (*Maureen and Mark*)
- Opportunity to partner in the lead up to Mother's Day (*Maureen*)
- PPE & Testing shortages (*Maureen and Mark*)
- Prioritization of L&D for rapid response testing
-

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO [(b) (6) who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO [(b) (6) who.eop.gov]; Riggs, Charlotte R. EOP/WHO [(b) (6) who.eop.gov]; Butterfield, Nicholas W. EOP/WHO [(b) (6) who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@ (b) (6)]
Subject: Therapeutics Meeting
Location: WHSR JFK
Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Busy
Recurrence: (none)

****There will be no dial-in option****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)]] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)]] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]

Subject: Therapeutics and Vaccine Briefing

Location: WHSR

Start: 4/29/2020 2:00:00 PM

End: 4/29/2020 2:50:00 PM

Show Time As: Busy

Recurrence: (none)

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)]] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)]] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValiere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]

Subject: HOLD BARDA/DOD Vaccine Briefing
Location: WHSR

Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Busy

Recurrence: (none)

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] [REDACTED] Vought, Russell T. EOP/OMB [REDACTED] [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValiere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Conant, Ann M. EOP/OMB [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)] Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6)] ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@[(b) (6)] Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)] Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@[(b) (6)] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@[(b) (6)] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov]; Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]
Subject: HOLD NIH Therapeutics Briefing
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birx, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); CMS [(b) (6)] Sheehy, Janice; Hahn, Stephen; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Kellogg, Joseph Keith K. Jr. EOP/OVP; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO
Subject: HOLD NIH Therapeutics Briefing
When: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)]] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)]] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValiere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]

Subject: HOLD BARDA/DOD Therapeutics Briefing
Location: WHSR

Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)]] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)]] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [(b) (6)] (OS/IOS)
[(b) (6)] HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD NIH Therapeutics Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)


[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] Bruno, Grace A.
EOP/OMB [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[(b) (6)]
Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[(b) (6)] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)]
[(b) (6)] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[(b) (6)] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[(b) (6)] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [(b) (6)] who.eop.gov]; DeValiere, Ian C. EOP/WHO [(b) (6)] who.eop.gov];
Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Boyd, Charlton J. EOP/WHO
[(b) (6)] who.eop.gov]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [(b) (6)] (OS/IOS)
[(b) (6)] HHS.GOV]; Jon Woolfolk [gjonwoolfolk@yahoo.com]; DL OVP NSA EXECSEC
[DL.OVP.NSAEXECSEC@OVP.eop.gov]; OVP NSA Plans and Ops Calendar
[OVPNSAPlansandOpsCalendar@OVP.eop.gov]; Woolfolk, Jon J. EOP/OVP [(b) (6)] ovp.eop.gov];
Fisher, Garrett C. EOP/OVP [(b) (6)] ovp.eop.gov]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [REDACTED] (OS/IOS)
[REDACTED] HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

(b) (5)

(b) (5)



From: Droegemeier, Kelvin K. EOP/OSTP [(b) (6)]@ostp.eop.gov]
Sent: 4/3/2020 11:05:14 AM
To: Holt, Brandon T. EOP/NSC [(b) (6)]@nsc.eop.gov]; Clancy, Carolyn [Carolyn.Clancy@va.gov]; Klote, Mary M. [Mary.Klote@va.gov]; Justice, Amy [Amy.Justice2@va.gov]; Bates, Jack (BISL) [Jack.Bates@va.gov]; Francis, Joe [Joe.Francis@va.gov]; Quinn, John F. (NDS) [John.Quinn@va.gov]; Box, Tami [Tamara.Box@va.gov]; Ramoni, Rachel [Rachel.Ramoni@va.gov]; Muralidhar, Sumitra [Sumitra.Muralidhar@va.gov]; Brouillette, Dan [dan.brouillette@hq.doe.gov]; Dabbar, Paul [paul.dabbar@hq.doe.gov]; Abernethy, Amy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c84171967c724ee799bb2658197086bc-Amy.Abernet]; Watson, Ian D. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Pottinger, Matthew F. EOP/WHC [(b) (6)]@who.eop.gov]; Fabina, Lauren C. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC [(b) (6)]@nsc.eop.gov]; Tully, Ryan M. EOP/NSC [(b) (6)]@nsc.eop.gov]; Kratsios, Michael J. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Parker, Lynne E. EOP/OSTP [(b) (6)]@ostp.eop.gov]
CC: Hennessey, Millicent S. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ferro, Phil J. EOP/NSC [(b) (6)]@nsc.eop.gov]
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Hi all,

I'm adding Michael Kratsios and Lynne Parker re (b) (5)

Kelvin

From: Holt, Brandon T. EOP/NSC [(b) (6)]@nsc.eop.gov
Sent: Friday, April 3, 2020 10:36 AM
To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Pottinger, Matthew F. EOP/WHO [(b) (6)]@who.eop.gov]; Fabina, Lauren C. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC [(b) (6)]@nsc.eop.gov]; Tully, Ryan M. EOP/NSC [(b) (6)]@nsc.eop.gov
Cc: Hennessey, Millicent S. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ferro, Phil J. EOP/NSC [(b) (6)]@nsc.eop.gov
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good morning all,

Could we please lock in this call for 12:30pm? Please see call-in information below. Thank you!

Participant Dial-In: (202) 395-6392
Participant Code [(b) (6)]

Best,
Brandon

Brandon T. Holt
Office of the National Security Advisor
D[(b) (6)]

From: Ferro, Phil J. EOP/NSC (b) (6) @nsc.eop.gov>

Sent: Friday, April 3, 2020 10:30 AM

To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP (b) (6) @ostp.eop.gov>; Waterman, Paige E. EOP/OSTP (b) (6) @ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <(b) (6)@ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO (b) (6) @who.eop.gov>; Fabina, Lauren C. EOP/NSC (b) (6) @nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC (b) (6) @nsc.eop.gov>; Tully, Ryan M. EOP/NSC (b) (6) @nsc.eop.gov>

Cc: Holt, Brandon T. EOP/NSC <(b) (6)@nsc.eop.gov>; Hennessey, Millicent S. EOP/NSC (b) (6) @nsc.eop.gov>

Subject: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good Morning Colleagues,

First off, thank you for your robust support to get this initiative off the ground as quickly as possible. (b) (5)

[REDACTED]

[REDACTED]

[REDACTED]

We would like to convene a call this afternoon to coordinate efforts. Brandon Holt who works for APDNSA Pottinger will work with you and your staff to schedule this call. To this end, please feel free to have your staff respond to Brandon. We will send out an agenda shortly.

Please let me know if you have any questions or if I may be of assistance.

All the best,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
202.456.1222 (O) (b) (6) (cell)
Philip.J.Ferro@nsc.eop.gov

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/15/2020 1:56:41 PM
To: Joe Grogan [Joseph.J.Grogan@who.eop.gov]; Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Quick description of our app

Nicely categorized but what should be the next steps?

From: Kratsios, Michael J. EOP/OSTP (b) (6)@ostp.eop.gov>
Date: April 15, 2020 at 8:52:58 AM EDT
To: Liddell, Christopher P. EOP/WHO (b) (6)who.eop.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)niaid.nih.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Seema Verma <(b) (6)cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>, Butterfield, Nicholas W. EOP/WHO <(b) (6)who.eop.gov>, Droegemeier, Kelvin K. EOP/OSTP <(b) (6)ostp.eop.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 5:13:06 PM
To: Liddell, Christopher P. EOP/WHO [REDACTED] (b) (6) who.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6) Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]
CC: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Seema Verma [REDACTED] (b) (6) @cms.hhs.gov]; Sharpless, Norman E (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d860d490594f4675960aad587639ed9c-HHS-norman.]; Tromberg, Bruce J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089fb4d6fa44f82bea7b1016d4d4d5d-HHS-bruce.t]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]; Butterfield, Nicholas W. EOP/WHO [REDACTED] (b) (6) who.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [REDACTED] (b) (6) ostp.eop.gov]
Subject: RE: Quick description of our app

Michael,

[REDACTED] (b) (5)? I am happy to facilitate.
Steve

From: Liddell, Christopher P. EOP/WHO <[REDACTED] (b) (6) who.eop.gov>
Date: April 14, 2020 at 5:11:38 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Fauci, Anthony S (NIH) <[REDACTED] (b) (6) niaid.nih.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Seema Verma <[REDACTED] (b) (6) cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>, Butterfield, Nicholas W. EOP/WHO <[REDACTED] (b) (6) who.eop.gov>, Droegemeier, Kelvin K. EOP/OSTP <[REDACTED] (b) (6) ostp.eop.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 6:51:47 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Debi Birx MD [Deborah.L.Birx@nsc.eop.gov]; Jared Kushner [Jck@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Joe Grogan [Joseph.J.Grogan@who.eop.gov]; Seema Verma [sv1@cms.hhs.gov]
CC: Sharpless, Norman E (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d860d490594f4675960aad587639ed9c-HHS-norman.]; Tromberg, Bruce J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089fb4d6fa44f82bea7b1016d4d4d5d-HHS-bruce.t]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
Subject: RE: Quick description of our app

Thanks, Tony. (b) (5)
Steve

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>
Date: April 13, 2020 at 10:08:28 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Debi Birx MD <Deborah.L.Birx@nsc.eop.gov>, Jared Kushner <Jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Joe Grogan <Joseph.J.Grogan@who.eop.gov>, Seema Verma <(b) (6)cms.hhs.gov>
Cc: Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 9:12:55 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
CC: Tyler Ann McGuffee [Tyler.A.McGuffee2@ovp.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: Quick description of our app

Debi,

Follow up for you re: the Abbott meeting. They completely understood your point about the usage of the PoC serology test.

The CEO wanted me to pass along that the sensitivity/specificity information they gave us was a composite of IgG and IgM. [REDACTED] (b) (4) [REDACTED] (b) (5)

I also had a conversation with them about manufacturing ramp up and there is some flexibility. [REDACTED] (b) (5)

Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 14, 2020 at 6:56:23 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Fauci, Anthony S (NIH) <[REDACTED] (b) (6)niaid.nih.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Seema Verma <[REDACTED] (b) (6)cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>
Subject: Re: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/13/2020 8:24:39 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: list of essential tests and items from China

Joe,
Thank you. [REDACTED] (b) (5)? Keagan, let's talk.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 13, 2020 at 8:23:50 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: list of essential tests and items from China

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/12/2020 5:07:20 PM
To: Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Suggest you get set-up as [REDACTED] (b) (5)

Perhaps we can discuss?

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 12, 2020 at 12:54:00 PM EDT
To: Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Suggest you get set-up as [REDACTED] (b) (5)

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/12/2020 4:55:45 PM
To: Joe Grogan [Joseph.J.Grogan@who.eop.gov]
Subject: Fwd: Suggest you get set-up as [REDACTED] (b) (5)

We definitely need some help here.

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 12, 2020 at 2:28:00 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Suggest you get set-up as a [REDACTED] (b) (5)

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/7/2020 5:57:38 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Joe Grogan [Joseph.J.Grogan@who.eop.gov]
Subject: Fwd: Potential Adverse Impact of (b) (5) Policy

FYSA

(b) (5)

?

Steve

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 7, 2020 at 5:20:56 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: Potential Adverse Impact of (b) (5) Policy

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/7/2020 6:21:41 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: Potential Adverse Impact of (b) (5) Policy

Will do

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: April 7, 2020 at 6:20:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: RE: Potential Adverse Impact of (b) (5) Policy

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/6/2020 5:29:24 PM
To: Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Finger sticks

FYSA

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 3, 2020 at 1:16:36 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Beckham, Tammy (OS) <Tammy.Beckham@hhs.gov>
Subject: RE: Finger sticks

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/21/2020 1:40:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: FYI: Information request to ANSM on CV risks from chloroquine/hydroxychloroquine

Yes and I called Mark Meadows and left him a message.

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 21, 2020 at 1:33:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: FYI: Information request to ANSM on CV risks from chloroquine/hydroxychloroquine

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/6/2020 12:06:15 PM
To: Adams, Jerome (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; Deborah.L.Birx@nsc.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]
CC: marc.t.short@ovp.eop.gov
Subject: Re: Discussion with Montana, Idaho, NH, VT

Thanks, Jerome. This is really helpful.
Steve

From: Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>
Date: April 6, 2020 at 10:57:10 AM EDT
To: Deborah.L.Birx@nsc.eop.gov <Deborah.L.Birx@nsc.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Kadlec, Robert P (OS) <Robert.Kadlec@hhs.gov>
Cc: marc.t.short@ovp.eop.gov <marc.t.short@ovp.eop.gov>
Subject: Discussion with Montana, Idaho, NH, VT

I had a phone call last night with the State Health Directors from Montana, Idaho, NH, and VT regarding their clusters.

ALL shared concerns about testing- they say because they are considered "low risk/ impacted" areas, they are at the back of the line for getting testing processed (many days to weeks to get results), and they also are at the back of the line for reagents for testing. The latter point about lack of access to reagents was universally and vigorously shared.

They would also like more guidance from CDC/ the task force about a testing strategy- Diagnostic vs surveillance, when and where to use the Abbott rapid tests, when and where (and how) to stand up antibody testing, etc.

NH was worried about staffing- much of their staff is out due to exposure. VT and NH were worried about nursing homes as clusters. Montana and Idaho were worried about weak local public health capacity in affected areas that may be isolated. In Idaho they actually had to shut down an entire hospital for a bit due to infections spreading through. █

I can share more, but wanted you to have these major points ASAP.

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/3/2020 7:15:38 AM
To: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Adams, Jerome (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; Birx, Deborah L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2e45952d70d4e2d84d839843f3cda9f-HHS-emg5-cd]; Deborah.L.Birx@nsc.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (5) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]
Subject: RE: Mask

Jerome,

[REDACTED] (b) (5)
[REDACTED]
[REDACTED]

Steve

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Date: April 3, 2020 at 6:42:41 AM EDT
To: Adams, Jerome (OS) <Jerome.Adams@hhs.gov>, Birx, Deborah L (CDC) <emg5@cdc.gov>, Deborah.L.Birx@nsc.eop.gov <Deborah.L.Birx@nsc.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Kadlec, Robert P (OS) <Robert.Kadlec@hhs.gov>
Subject: RE: Mask

[REDACTED] (b) (5)
[REDACTED]

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

-----Original Message-----

From: Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>
Sent: Friday, April 3, 2020 6:41 AM
To: Birx, Deborah (CDC/OD) <emg5@cdc.gov>; Deborah.L.Birx@nsc.eop.gov; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Stephen Hahn <SH1@fda.hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Subject: Mask

(b) (5)

Jerome

VADM Jerome Adams
20th US Surgeon General

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/4/2020 8:52:13 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Re: Hydroxychloroquine

Yes 5 minutes

Sent from my iPhone

On Apr 4, 2020, at 8:42 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Joe,
FYI. Do you have time for a call this morning?
Steve

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>
Date: April 3, 2020 at 5:15:31 PM EDT
To: Schuchat, Anne (CDC) <acs1@cdc.gov>, Messonnier, Nancy E (CDC) <nar5@cdc.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Brooks, John T (CDC) <zud4@cdc.gov>
Subject: RE: Hydroxychloroquine

Afternoon all,

Studies described in the attached

Dosing in each as follows:

- Gautret: Hydroxychloroquine sulfate (HCQ) 200 mg tid (600 mg/d) for ten days
- Chen J: HCQ 400 mg/d for 5 days (in Chinese and so can't tell if 400 mg was 200 mg bid)
- Chen Z: HCQ 400 mg/d (200 mg bid) between days 1 and 5
- Molina: HCQ 600 mg/d for 10 days using the same dosing regimen reported by Gautret et al.

Cheers,

-john

John T. Brooks, MD

Chief Medical Officer, CDC COVID-19 Response

Email: zud4@cdc.gov

Apologies for errors in my messages that may be due to my need to dictate.

<image002.jpg>

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Sent: Friday, April 3, 2020 5:04 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: RE: Hydroxychloroquine

Can you resend me your science update – it has dose from the trial in IJAA anyway...

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Sent: Friday, April 3, 2020 5:02 PM

To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Subject: RE: Hydroxychloroquine

Hard to know. It was specifically removed from the CDC online document because of concerns that persons might prescribe outside of established study protocols.

I can [REDACTED] (b) (5)

[REDACTED] I know at least five infectious disease doctors now who have had COVID-19 and chose to try hydroxychloroquine. Which by the way i did not endorse :)

John T. Brooks, MD

Chief Medical Officer, CDC COVID-19 Response

Email: zud4@cdc.gov

Apologies for errors in my messages that may be due to my need to dictate.

<image006.jpg>

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Sent: Friday, April 3, 2020 5:00 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: FW: Hydroxychloroquine

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, April 3, 2020 4:59 PM

To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>

Cc: Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>

Subject: RE: Hydroxychloroquine

(b) (5)

Can I get help from CDC?

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Sent: Friday, April 3, 2020 4:54 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>

Subject: RE: Hydroxychloroquine

Think CDC would have to give you that, since this would be considered off label use.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, April 3, 2020 4:37 PM

To: Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Subject: Hydroxychloroquine

(b) (5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

<COVID-19 Science Update - Special Topic CQ-HCQ - 2020-04-03 - FINAL.pdf>

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/11/2020 7:52:03 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6) Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Adams, Jerome (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]
CC: Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
Subject: Re: testing, testing, testing

Morning all,

(b) (5)
Brett, very much appreciate all of the work that has gone into our testing efforts.
Steve

From: Tony Fauci <(b) (6)niaid.nih.gov>
Date: Sunday, May 10, 2020 at 8:41 PM
To: Brett Giroir <Brett.Giroir@hhs.gov>, Debi Birx <Deborah.L.Birx@nsc.eop.gov>, Robert Redfield <olx1@cdc.gov>, Stephen Hahn <SH1@fda.hhs.gov>, Jerome Adams <Jerome.Adams@hhs.gov>, Robert Kadlec <Robert.Kadlec@hhs.gov>
Cc: Francis Collins <(b) (6)od.nih.gov>
Subject: RE: testing, testing, testing

Brett:
Thanks for the note. I look forward to discussing this with you.
Best regards,
Tony

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Sunday, May 10, 2020 5:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; SH1 (fda.hhs.gov) <SH1@fda.hhs.gov>; Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Cc: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: testing, testing, testing

Tony,

(b) (5)

(b) (5)

Happy to discuss next time we meet.

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>
Sent: Sunday, May 10, 2020 4:28 PM
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; SH1 (fda.hhs.gov) <SH1@fda.hhs.gov>; Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Subject: testing, testing, testing

Folks:

The link below is an article by Harold Varmus representing the deliberations of 10 world-class scientists. It

(b) (5)

(b) (5) This article is worth a read. Maybe we can discuss it the next time we meet, which might be virtual.

<https://www.theatlantic.com/ideas/archive/2020/05/lack-testing-holding-science-back/611422/>

Thanks,
Tony

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/3/2020 1:05:22 PM
To: Polowczyk, John P RADM USN JS J4 (USA) [john.p.polowczyk.mil@mail.mil]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]
CC: Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Pete Gaynor [pete.gaynor@fema.dhs.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS (b) (6)]
Subject: Re: Remdesivir Allocation

John

(b) (5)

On 5/2/20, 9:19 AM, "Polowczyk, John P RADM USN JS J4 (USA)" <john.p.polowczyk.mil@mail.mil> wrote:

Dr Birx

(b) (5)

V/r John
John Polowczyk
Rear Admiral USN
(C) 571 423 6676
John.p.polowczyk.mil@mail.mil

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/13/2020 10:49:04 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; FDA Commissioner [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1e34b2c290a94c4a8d7af884727cd0f8-Commissione]
Subject: Re: (b) (5)

(b) (5). Deb

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)niaid.nih.gov>
Date: Wednesday, May 13, 2020 at 10:39 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen (FDA)" <Stephen.Hahn@fda.hhs.gov>
Subject: RE: (b) (5)

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Sent: Wednesday, May 13, 2020 10:24 AM
To: Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>; Hahn, Stephen (FDA) <Stephen.Hahn@fda.hhs.gov>
Subject: (b) (5)

(b) (5)

deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 6:21:32 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: [REDACTED] (b) (5)

Will do

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: April 7, 2020 at 6:20:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: RE: [REDACTED] (b) (5)

Thank you. [REDACTED] (b) (5)

(b) (5)

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Tuesday, April 7, 2020 5:58 PM
To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: Fwd: [REDACTED] (b) (5)

FYSA

(b) (5)

Steve

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 7, 2020 at 5:20:56 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: [REDACTED] (b) (5)

(b) (5)

From: Ross, Bruce <Bruce.Ross@fda.hhs.gov>

Sent: Tuesday, April 7, 2020 7:40 AM

To: 2019-nCoV FDA IMG Leadership <2019-nCoVFDAIMGLeadership@fda.hhs.gov>; Courtney, Brooke <Brooke.Courtney@fda.hhs.gov>

Cc: Abdoo, Mark <Mark.Abdoo@fda.hhs.gov>; 2019-nCoV FDA IMG Operations Supply Chain <2019-nCoV-FDA-IMG-Operations-Supply-Chain@fda.hhs.gov>; Serrano, Katherine M <Katherine.Serrano@fda.hhs.gov>; Rodriguez, Michelle <Michelle.Rodriguez@fda.hhs.gov>

Subject: FW: Need Help with Supply Chain!

Sharing for awareness....messaging received from AdvaMed regarding challenges in (b) (4) due to lack of PPE....

Bruce Ross, MA, MPH
Director, (Acting)

Office of Global Operations
Office of Global Policy and Strategy

COVID-19 Outbreak Response, FDA IMG Logistics – Repatriation

Tel: 240-402-2866
Mobile: 240-515-5217
E-mail: Bruce.Ross@fda.hhs.gov

From: Ives, Ralph <RIves@AdvaMed.org>
Sent: Tuesday, April 07, 2020 7:22 AM
Subject: Need Help with Supply Chain!

All,

(b) (4)

I did not realize export restrictions were applied across the board for all manufacturers – beyond 3M. We will get more info later.

We would greatly appreciate your help!

Thank you,
Ralph

Ralph F. Ives
Executive Vice President
AdvaMed
701 Pennsylvania Avenue, N.W,
Suite 800
Washington, DC 20004
Direct: (b) (6)

AMERICAN
OVERSIGHT

MULTI-HHS-FDA-20-0400, 20-0415-D, HHS-FDA-20-0498-G-000167

Email: rives@advamed.org

mpact on diversion of PPE for domestic manufacturers as well.

From: [O'Malley, Devin M. EOP/OVP](#)
To: [O'Malley, Devin M. EOP/OVP](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Love, Kelly A. EOP/OVP](#)
Subject: Items for Clearance
Date: Saturday, March 14, 2020 5:03:52 PM

Hi everyone-

It's been a busy week, especially the last couple of days. We appreciate everyone's patience, especially if they experienced delays in getting approval from us during this time. I also want to thank everyone for giving us considerable amount of lead time to review items that you send for clearance. We understand that there will certainly be times where rush review is needed, but definitely appreciate when we have a few hours to look at something. If you are still waiting on clearance for certain items, please resubmit them to the appropriate members of our team now.

On a related note, starting on Monday, the schedule for Task Force related meetings is shifting a bit. This means that Katie and I, and other members of the team, will be harder to get ahold of from the hours of 9:00 am – 11:30 am (instead of 4:00 pm – 6:30 pm). Please consider this when thinking about reviews/clearances. We will also adjust the morning call to a time TBD.

As always, please feel free to call me whenever you have an issue, think something can be done better, or have an idea. We appreciate hearing from you.

Thank you for all you are doing!

Devin

Devin M. O'Malley

(b) (6)

From: [Finnen, April](#)
To: [2019-nCoV FDA IMG JIC Press](#)
Cc: [Lynch, Sarah](#); [2019-nCoV FDA IMG JIC Leadership](#)
Subject: OMA - heads up on VP clearance - FW: NICCL Meeting Call-Out 3.27.2020
Date: Friday, March 27, 2020 2:45:02 PM
Attachments: [image001.png](#)
[image002.png](#)
[ESF15_NICCL_Summary_v2_FINAL_20200327.pdf](#)
[image004.png](#)

From today's NICCL call (full notes attached):

Communications/Messaging Clearance

The Office of the Vice President request you adhere to the following guidance when reviewing press statements, internal/external comms, media appearance requests, etc.

The email address is: DL.OVP.CommsCOVID@ovp.eop.gov

SUBJECT LINE:	APPROVAL: [SUBJECT AND TYPE OF DOCUMENT; e.g., CDC HOSPITAL GUIDANCE PRESS RELEASE; FDA)
GUIDANCE DOCUMENT:	Please use URGENT APPROVAL for short fuse items (i.e., < 1 hour)
Information needed in the Body of email:	
TYPE OF DOCUMENT:	[PRESS RELEASE/EMPLOYEE EMAIL/WEBSITE UPDATE/PRESS INQUIRY/ETC]
DEADLINE:	[DATE/TIME]
REVIEWED BY:	[NAME OF OTHER DEPARTMENT/AGENCY]

From: Brubach, April <April.Brubach@fda.hhs.gov>
Sent: Friday, March 27, 2020 1:22 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>
Subject: NICCL Meeting Call-Out 3.27.2020

NICCL Meeting Call-Out 3.27.2020

WH Comms: *Preparing for Apple to launch its app today, it is a feature that will help people really find the path for what they should do if they have symptoms. It is very user-friendly, that will be something that the Apple team and White House will announce today in conjunction with HHS and CDC.*

(b) (5) [REDACTED] *It will be a helpful tool for the public to help them understand what their potential symptoms may mean and what steps they should take to keep their household healthy and safe. That will be one of the main news items this evening and I will let the Vice President's office give further updates on the task force as of today and this weekend.*

April Brubach, 301-512-0780

From: FEMA-ESF15-Coordination <FEMA-ESF15-Coordination@fema.dhs.gov>
Sent: Friday, March 27, 2020 1:07 PM
To: 2019-nCoV FDA IMG JIC Leadership <2019-nCoV-FDA-IMG-JIC-Leadership@fda.hhs.gov>; Clark, Alaina <alaina.clark@cisa.dhs.gov>; Glenn, Amanda <Amanda.Glenn@cisa.dhs.gov>; Palczewski, Andrew (OS) <Andrew.Palczewski@hhs.gov>; ALFONSO-ROYALS, ANGELICA <ANGELICA.ALFONSO-ROYALS@hq.dhs.gov>; Trevino, Anna <anna.trevino@fema.dhs.gov>; Tatem, Anne (OS) <Anne.Tatem@hhs.gov>; CERAOLO, ANTHONY <ANTHONY.CERAOLO@hq.dhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; BOZA-HOLMAN, SOFIA <SOFIA.BOZA-HOLMAN@hq.dhs.gov>; McPherson, Brendan <Brendan.McPherson@hq.dhs.gov>; Glauser, Brittany (OS) <Brittany.Glauser@hhs.gov>; Brown, Lynn <lynn.brown@fema.dhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; Daniels,

Carla L (OS) <Carla.Daniels@hhs.gov>; Castro, Carmen <carmen.castro@fema.dhs.gov>; carol_danko@ios.doi.gov; McCormick, Chad <Chad.McCormick@fema.dhs.gov>; Howlett, Christine <christine.howlett@fema.dhs.gov>; christopher.b.logan.mil@mail.mil; cole_rojewski@ios.doi.gov; Corbin, Susan <Susan.Corbin@hq.dhs.gov>; Coronavirus-Communicators@state.gov; Bradway, Courtney B (OS) <Courtney.Bradway@hhs.gov>; Dracoulis, Danielle <danielle.dracoulis@fema.dhs.gov>; Stellar, Dante <Dante.Stellar@fema.dhs.gov>; Johnston, Darcie (OS) <Darcie.Johnston@hhs.gov>; Passey, David <david.passey@fema.dhs.gov>; Bauer, Debra <Debra.Bauer@fema.dhs.gov>; DMcGaan@doc.gov; Armstrong, Earl <Earl.Armstrong@fema.dhs.gov>; engagement@hhs.gov; eoevent337@cdc.gov; Erickson, Scott <Scott.Erickson@hq.dhs.gov>; Wiecezorek, Erin <Erin.Wiecezorek@cisa.dhs.gov>; Beck, Gary (OS) <Gary.Beck@hhs.gov>; Genevieve.Giaccardo@bia.gov; Josey, Herbert <Herbert.Josey@cisa.dhs.gov>; HOULTON, TYLER <TYLER.HOULTON@hq.dhs.gov>; isaac.l.taylor.mil@mail.mil; Bass, Jackita D <jackita.bass@cisa.dhs.gov>; Muhammad, Janell M (OS) <Janell.Muhammad@hhs.gov>; Moore, Jeanie <jeanie.moore@cisa.dhs.gov>; Sherman, Jennifer (OS) <Jennifer.Sherman@hhs.gov>; Campora, Jenny W <Jenny.Campora@fema.dhs.gov>; jesus.garcia3@usda.gov; jesus.garcia3@usda.gov; Gountanis, John <John.Gountanis@hq.dhs.gov>; Twomey, John K (OS) <John.Twomey@HHS.GOV>; john_bockmier@ios.doi.gov; Osborne, Jonathan (OS) <Jonathan.Osborne@hhs.gov>; Cox, Jordan (OS) <Jordan.Cox@hhs.gov>; WESTMORELAND, JOSEPH A (OPR) <JOSEPH.A.WESTMORELAND@CBP.DHS.GOV>; Ayala, Juan <juan.ayala@fema.dhs.gov>; Stecker, Judy (OS) <Judy.Stecker@hhs.gov>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Nolan, Kathryn <kathryn.nolan@fema.dhs.gov>; Willcuts, Kathryn <Kathryn.Willcuts@cisa.dhs.gov>; Benacci, Kevin <Kevin.Benacci@cisa.dhs.gov>; Kittrie, Zachary <Zachary.Kittrie@fema.dhs.gov>; Kkilgore@doc.gov; Kneeper@bbg.gov; kpietranton@fbi.gov; Krikava, Richard <Richard.Krikava@fema.dhs.gov>; Kristan Nevins <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Kristina Baum <[\(b\) \(6\)@ostp.eop.gov](mailto:(b) (6)@ostp.eop.gov)>; Kuhns, Daniel (OS) <Daniel.Kuhns@hhs.gov>; Lange, John <John.Lange@hq.dhs.gov>; lashonda.walker@usda.gov; lashonda.walker@usda.gov; Laura Schlapp <laura.a.schlapp.civ@mail.mil>; Laura.J.Brown@faa.gov; Trueman, Laura (OS) <Laura.Trueman@hhs.gov>; Lauren Gorey <lgorey@doc.gov>; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Kotwicki, Lauren (OS) <Lauren.Kotwicki@hhs.gov>; LBGALLAGHER@fbi.gov; leslie.lankster@fns.usda.gov; leslie.lankster@fns.usda.gov; Levine.Carolyn@epa.gov; lhagee@fbi.gov; Litzow, Elizabeth <elizabeth.litzow@fema.dhs.gov>; Ortega, Lorena <lorena.ortega@fema.dhs.gov>; Lori.Irving@dot.gov; Lucero, Mark <Mark.Lucero@fema.dhs.gov>; Lujan, Maria <maria.lujan@fema.dhs.gov>; Lynne.Donahue@usdoj.gov; Macaulay Porter <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; MALIN, STEPHANIE <STEPHANIE.MALIN@cbp.dhs.gov>; mallory bloun <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; RASCHER, MALLORY <MALLORY.RASCHER@hq.dhs.gov>; Mancha, Patricia <Patricia.Mancha@fema.dhs.gov>; Marc Short <Marc.t.short@ovp.eop.gov>; Marc.Raimondi@usdoj.gov; Margaret.Schaefer@dhs.gov; mark hinkle <mark.hinkle@ssa.gov>; Mark Mchale <mark.mchale@gsa.gov>; Mark.Ballesteros@va.gov; Weber, Mark (OS) <Mark.Weber@hhs.gov>; Mary.A.Brandenberger@usdoj.gov; Mary.E.Markos@usace.army.mil; Mary.E.Markos@usace.army.mil; Matt Schuck <Matthew.J.Schuck@hud.gov>; Matt Sheehey <msheehey@peacecorps.gov>; Matthew Lahr <matthew.lahr@dni.gov>; Matthew.Borgia@noaa.gov; Matthew.Burrell@gsa.gov; Maura.Beard@nctc.gov; McBride, Scott A LCDR <Scott.A.McBride@uscg.mil>; McCachrenC@state.gov; McCulloch, Robert <robert.mcculloch@fema.dhs.gov>; MCKENZIE MELISSA M <melissa.mckenzie@ussf.dhs.gov>; MCMURRAY JULIA <Julia.Dagostino@ussf.dhs.gov>; McNeil, Elizabeth <elizabeth.mcneil@fema.dhs.gov>; Meddie.Brown@gsa.gov; Media Inquiry <MediaInquiry@HQ.DHS.GOV>; media@ucia.gov; mediarelations@fcc.gov; Cardin, Megan <Megan.Cardin@fda.hhs.gov>; McSeveney, Megan <Megan.McSeveney@fda.hhs.gov>; Megan.O'Kane@dhs.gov; Meghan Burris <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Meghan.Rodgers@oc.usda.gov; Wilkins, Melissa <melissa.wilkins@fema.dhs.gov>; Good-Cohn, Meredith (CMS) <Meredith.Good-Cohn@cms.hhs.gov>; Merry Lin <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; MGuarracino@supremecourt.gov; Heck, Mia (OS) <Mia.Heck@hhs.gov>; Michael Abboud <abboudmc@state.gov>; Michael Dubray <dubraymr@state.gov>; Pratt, Michael (OS) <Michael.Pratt@hhs.gov>; Dailey, Michael A <Michael.A.Dailey@cisa.dhs.gov>; Michael.Birmingham@dni.gov; <[\(b\) \(6\)@nsc.eop.gov](mailto:(b) (6)@nsc.eop.gov)>; Michael.P.Knight@usdoj.gov; Michael.w.Dendas@hud.gov; Michawn Rich <Michawn.rich@usda.gov>; Michawn.Rich@osec.usda.gov; Bonds, Michelle E (CDC) <meb0@cdc.gov>; Michelle Dawi <[\(b\) \(6\)@ho.eop.gov](mailto:(b) (6)@ho.eop.gov)>; Michelle.Coghill@usdoj.gov; Michelle.Hindmarch@hq.doe.gov; Michelle.laver@nnsa.doe.gov; Midgett, Amy LT <Amy.Midgett@uscg.mil>; Mike Korbey <mike.korbey@ssa.gov>; Mike.Illenberg@oc.usda.gov; MILHOAN CATHERINE L <catherine.milhoan@ussf.dhs.gov>; Miller, Bennett <Bennett.Miller@hq.dhs.gov>; Mina, Peter <Peter.Mina@hq.dhs.gov>; mira.lezell@dot.gov; Mizelle, Chad <Chad.Mizelle@hq.dhs.gov>; Harris, Missy J (NIH) <mjharris@mail.nih.gov>; MNLowry@fbi.gov; Molly Block <block.molly@epa.gov>; molly.meiners@treasury.gov; Morgan Bedan <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Morgan Ortagus <OrtagusMD@state.gov>; msgaine@cybercom.mil; Msiegel@doc.gov; msimms2@peacecorps.gov; Nalepa, Jessica <jessica.nalepa@fema.dhs.gov>; nancy gonzalez <nancy.gonzalez@ssa.gov>; NASON MICHAEL C <michael.nason@ussf.dhs.gov>; Best, Natalia <Natalia.Best@hq.dhs.gov>; Natalie Hurst <[\(b\) \(6\)@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; NationalJIC@dhs.gov; Lemar, Naweed (OS) <Naweed.Lemar@hhs.gov>; nctcpao@nctc.gov; Ndidi.Mojay@va.gov; Nelson, Jason <Jason.Nelson2@fema.dhs.gov>; NewsMedia@nps.gov; ng.ncr.ngb-arng.mbx.ngbjoccpa@mail.mil; Pottebaum, Nicholas (who.eop.gov) <Nicholas.D.Pottebaum@who.eop.gov>; Nicholas.Goodwin@ios.doi.gov; nicole tiggemann <nicole.tiggemann@ssa.gov>; nicole.peckumn@dc.gov; Nicole.Schwegman@pacom.mil; nigel.holderby@redcross.org; Thomas, Nkosi <Nkosi.Thomas@hq.dhs.gov>; nlpitto@nsa.gov; nc.peterson@ncspecialstaff.mbx.usnorthcom-pa-omb@mail.mil; NOC SWO Restricted <NOC.SWO.Restricted@hq.dhs.gov>; NOC.NDD@hq.dhs.gov; Noelker, Tim <tnoelker@cns.gov>; npo@fbi.gov; NSAmedia@nsa.gov; Imhoff, Olivia (who.eop.gov) <[\(b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Olshanski, Thomas <Thomas.Olshanski@fema.dhs.gov>; opa@hq.dhs.gov; osd.pa.dutyofficer@mail.mil; Overton, Kristina <kristina.overton@fema.dhs.gov>; owen.morgan@dot.gov; pacom.i0pac.duty.pao@navy.mil; pacrisisresponse@state.gov; Pallas, Charissa M <Charissa.M.Pallas@ice.dhs.gov>; pamela Pennington <pamela.pennington@gsa.gov>; Pamela.s.kunze@mail.mil; Conrad, Patricia L (NIH) <conradpa@niaid.nih.gov>; El-

Hinnawy, Patricia <Patricia.ElHinnawy@fda.hhs.gov>; Brennan, Patrick (OS) <Patrick.Brennan@hhs.gov>; Patrick.h.cordova.mil@mail.mil; Paul.F.Smith@usps.gov; Formoso, Paula (OS) <Paula.Formoso@hhs.gov>; Gutierrez, Paula <paula.gutierrez@fema.dhs.gov>; Paulk-Buchanan, Crystal <crystal.paulk-buchanan@fema.dhs.gov>; PAYNE, LAWRENCE R <LAWRENCE.R.PAYNE@cbp.dhs.gov>; Payton, Crystal <Crystal.Payton@fema.dhs.gov>; Peter Hoffman <[Peter.Hoffman@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Peter Carr <Peter.Carr@usdoj.gov>; Cassell, Peter <Peter.Cassell@fda.hhs.gov>; Peter Knudson <Peter.Knudson@ntsb.gov>; Peter Krug <Peter.krug@uspto.gov>; Peterson, Mark J <Mark.Peterson2@fema.dhs.gov>; Peterson1W@state.gov; Phillips, James M <James.M.Phillips@hq.dhs.gov>; Phillips, Kimberly <Kimberly.Phillips@fema.dhs.gov>; PicardVM@state.gov; Pierce, Bradley <bradly.pierce@fema.dhs.gov>; Pinkham, Dennis <Dennis.Pinkham@fema.dhs.gov>; pio@supremecourt.gov; PKaplan@ftc.gov; Platt, Michael E CAPT <Michael.E.Platt@uscg.mil>; Pooja Jhunjhunwala <pjhunjhunwala@usaid.gov>; press.office@ssa.gov; PressOffice@dot.gov; Privatesector@hq.dhs.gov; Public.Affairs@socom.mil; publicaffairs.pacom@navy.mil; publicaffairs@doc.gov; Purdy, Adoratia <adoratia.purdy@fema.dhs.gov>; qig3@cdc.gov <qig3@cdc.gov>; Quinn, Cameron <Cameron.Quinn@hq.dhs.gov>; Rachel Semmel <[Rachel.Semmel@omb.eop.gov](mailto:(b) (6)@omb.eop.gov)>; Nutter, Rachel <rachel.nutter@fema.dhs.gov>; rachel_levin@ios.doi.gov; Raini.W.Brunson@usace.army.mil; Ramsay, Cindy <cindy.ramsay@fema.dhs.gov>; Semke, Rand <Rand.Semke@hq.dhs.gov>; randy.ready@pacom.mil; Raymond, Joe W CAPT <Michael.W.Raymond@uscg.mil>; rcparker@usaid.gov; Readinger, Jeff <Jeff.Readinger@HQ.DHS.GOV>; Rebecca Miller <rebecca.miller@treasury.gov>; Armstrong, Rebekah W (OS) <Rebekah.Armstrong@hhs.gov>; Reinhold, Kent R CDR <Kent.R.Reinhold@uscg.mil>; Renee Hudson <[Renee.Hudson@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Richard.a.crusan.civ@mail.mil; Richardson, Yasamie <yasamie.richardson@fema.dhs.gov>; Richardson.RobinH@epa.gov; Rideaux.Chauontra.d@dol.gov; Rob <robbinse@state.gov>; Robert Bozzuto <bozzuto.robert.F@DOL.gov>; robert.l.perino.mil@mail.mil; <[Robert.Bozzuto@omb.eop.gov](mailto:(b) (6)@omb.eop.gov)>; Robert.Nadeau@noaa.gov; robert.sperling@hq.dhs.gov; Robert.Tuttle@hq.doe.gov; Robinson1A2@state.gov; Rochelle.Cohen@fcc.gov; Rodriguez.Juan@dol.gov; ronald.mclendon6.civ@mail.mil; Rossie, Camilla <Camilla.Rossie@fema.dhs.gov>; RRMuhammad@fbi.gov; Russell, Anthony L CAPT <Anthony.L.Russell@uscg.mil>; Russell.Oneill@gsa.gov; Russell.Newell@ios.doi.gov; Clemens, Ruth <Ruth.Clemens@cisa.dhs.gov>; Ryan Essman <ressman@usaid.gov>; Ryan Kaldahl <kaldahlrm@state.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Ryan, Charles <charles.ryan@fema.dhs.gov>; Samantha Schwab <[Samantha.Schwab@ovp.eop.gov](mailto:(b) (6)@ovp.eop.gov)>; samuel.r.souvannason.ctr@mail.mil; Samuels, Jessie <Jessie.Samuels@fema.dhs.gov>; SAPP, STEPHEN <STEPHEN.SAPP@cbp.dhs.gov>; <[STEPHEN.SAPP@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Sara.L.Eguren@irs.gov; Sendek, Sara <Sara.Sendek@cisa.dhs.gov>; Arbes, Sarah C (OS) <Sarah.Arbes@hhs.gov>; sarah.case-herron@dc.gov; Sauerhage.Maggie@epa.gov; SSCI_Press@state.gov; Scott Calhoun <Scott.calhoun@dot.gov>; Blakeman, Scott (OS) <Scott.Blakeman@hhs.gov>; Scott.Smullen@noaa.gov; sean.mcmaster@dot.gov; sean.poole@dot.gov; seth.unger@treasury.gov; sfontaine@usaid.gov; Shaylyn.Hynes@hq.doe.gov; Shefveland, Alan <Alan.Shefveland@fletc.dhs.gov>; Sheila.Johnston@pacom.mil; SHORT, CHERIE <CHERIE.SHORT@hq.dhs.gov>; Myrie, Simone (OS) <Simone.Myrie@hhs.gov>; Simons, Michael <michael.simons@tsa.dhs.gov>; Siwarfield@cns.gov; SMITH, LAUREL <LAUREL.SMITH@CBP.DHS.GOV>; Smith, Yvonne <yvonne.smith@fema.dhs.gov>; Snyder, Elizabeth <Elizabeth.Snyder@fema.dhs.gov>; Socialmedia@faa.gov; southcom.miami.sc-cc.list.cmd-public-affairs@mail.mil; Sscott@cns.gov; Sshero@fbi.gov; Ecoffey, Stacey (OS) <stacey.ecoffey@hhs.gov>; Palosky, Stacey (OS) <Stacey.Palosky@hhs.gov>; StanfordAD@state.gov; StarrKL@state.gov; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; Stephanie Grisham <[Stephanie.Grisham@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Stephanie.c.fila@hud.gov; Zumwalt, Steven <Steven.Zumwalt@fema.dhs.gov>; Stmckee@fbi.gov; Stoneking, Daniel <Daniel.Stoneking@fema.dhs.gov>; Streeter, Ryan <Ryan.Streeter@hq.dhs.gov>; Strouse, Philip <Philip.Strouse@fema.dhs.gov>; Carlson, Sue <Sue.Carlson@fema.dhs.gov>; Sunset.r.Belinsky.mil@mail.mil; Susan Varga <[Susan.Varga@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Susan.b.miller@nctc.gov; Susanna.Marking-Stockl@uscg.gov; Sellman, Suzanne (OS) <Suzanne.Sellman@hhs.gov>; SWIFT, HEATHER <HEATHER.SWIFT@hq.dhs.gov>; Tagliento, Marc <Marc.Tagliento@fema.dhs.gov>; Broido, Tara (OS) <Tara.Broido@hhs.gov>; Bradley, Tasha (OS) <Tasha.Bradley@hhs.gov>; taylor.l.weeks@nasa.gov; TdJagerson@fbi.gov; Terrence.Hayes@va.gov; Terrence.Sutherland@sba.gov; t-hannen3@cranfordnj.org; Corry, Thomas (CMS) <Thomas.Corry@cms.hhs.gov>; Thompson, Christa <Christa.Thompson@fletc.dhs.gov>; Foster, Timothy (OS) <Timothy.Foster@hhs.gov>; timothy_williams@ios.doi.gov; <[timothy_williams@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Vitek, Traci (OS) <Traci.Vitek@hhs.gov>; tracy.a.ogrady-walsh.civ@mail.mil; Travis.Edwards@ice.dhs.gov; trhanna@nsa.gov; Troye, Olivia <Olivia.Troye@nsc.eop.gov>; Trupo.Michael@dol.gov; TUTONI VINCENT A <vincent.tutoni@ussf.dhs.gov>; Urbani, Adrien <adrien.urbani@fema.dhs.gov>; usagovemergency@gsa.gov; USCIS EXA NICCL Group <USCISEXANICCLGroup@uscis.dhs.gov>; Venture, Veronica <Veronica.Venture@HQ.DHS.GOV>; Vermette, Joseph <Joseph.Vermette@fema.dhs.gov>; veronica.davison.civ@mail.mil; Walsh, Brett <brett.walsh@fema.dhs.gov>; Ward, Erin <Erin.Ward@fema.dhs.gov>; Web Publishing <WebPublishing@HQ.DHS.GOV>; Wehagen, Robby <robby.wehagen@fema.dhs.gov>; Crozer, William (who.eop.gov) <[William.Crozer@who.eop.gov](mailto:(b) (6)@who.eop.gov)>; Wilson, Thomas <thomas.wilson2@fema.dhs.gov>; Witmer, Wade <Wade.Witmer@fema.dhs.gov>

Subject: NICCL Summary 3.27.2020

Good afternoon,

Attached is the NICCL Summary for today's call. Thank you for your agency's participation.

Best,

Alexa Fortuna

Emergency Management Specialist | FEMA ESF 15 Coordination | Office of External Affairs

Mobile: <[b\) \(6\)@who.eop.gov](mailto:(b) (6)@who.eop.gov)>

FEMA-ESF15-Coordination@fema.dhs.gov

Federal Emergency Management Agency
[fema.gov](https://www.fema.gov)

From: [O'Malley, Devin M. EOP/OVP](#)
To: [Cacomo, Stephanie](#)
Cc: [Miller, Katie R. EOP/OVP](#); [Fetalvo, Ninio J. EOP/OVP](#); [Manchester, Brittney](#); [Felberbaum, Michael](#); [Caliguiri, Laura](#)
Subject: Re: flag--media response re: n95 sterilization
Date: Sunday, March 29, 2020 1:58:40 PM

I wouldn't post unless you are going to have something to announce tonight or tomorrow

Sent from my iPhone

On Mar 29, 2020, at 1:34 PM, Cacomo, Stephanie
<Stephanie.Cacomo@fda.hhs.gov> wrote:

Hi folks—

Flagging for you that we want to get some information for reporters on an issue that POTUS raised re: N95s. Basically, our team is working quickly!

POTUS tweet:


Hope the FDA can approve Mask Sterilization equipment ASAP. As per Governor

[@MikeDeWine](#)

, there is a company in Ohio,

[@Battelle](#)

, which has equipment that can sterilize masks quickly.



Stephanie Cacomo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: 240.762.8873
stephanie.caccomo@fda.hhs.gov

From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: 3/23/2020 7:54:17 PM
To: Henning, Alexa A. EOP/WHO [Katherine.A.Henning@who.eop.gov]; Love, Kelly A. EOP/OVP (b)(6); Hahn, Julia A. EOP/WHO [Julia.A.Hahn@who.eop.gov]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]; Daravi, Roma S. EOP/WHO [Roma.S.Daravi2@who.eop.gov]; O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]; Gidley, Hogan H. EOP/WHO [Hogan.Gidley@who.eop.gov]; McGuffee, Tyler A. EOP/OVP (b)(6); Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Montesi, Janet (b)(6); Litzow, Elizabeth (b)(6); Baker, Brittany G. EOP/WHO [Brittany.G.Baker@who.eop.gov]; Caccomo, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Caliguirri, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Sherman, Jennifer (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=96ea669491654aba8d4ea6816279e040-HHS-Jennife]

Subject: Principal Media Prep: Primetime/Morning/Daytime Shows
Location: Dial-In: (202) 395-6392 | Code: (b)(6)

Start: 3/23/2020 8:15:00 PM
End: 3/23/2020 8:45:00 PM
Show Time As: Tentative

Recurrence: (none)

Hi all—

This will be a media prep for any principals doing primetime/morning/daytime shows. Please forward this invite to your respective principal's scheduler.

Dr. Hahn

- Tucker Carlson Tonight
- Topics: Therapeutics—vaccines, drugs for treatment Recent press release, CDC just posted information for clinicians treating coronavirus patients, Regulatory flexibility—(b)(5)

Dr. Fauci

- Hannity
- Topics:

Dr. Birx

- NBC TODAY
- Topics: latest government guidelines and social distancing, update on where things stand in combating the virus, any new discoveries about the virus/possible treatments going forward, supplies and working with states
- FBN Mornings w/ Maria
- Topics: the latest on COVID-19, message to millennials

Administrator Gaynor

- ABC Good Morning America
- Topics:
- FNC Fox & Friends
- Topics:

Larry Kudlow

- Varney & Co.
- Topics: Economy, stimulus package, Hill negotiations

If you have any conflicts, please let us know asap.

Thank you,
Ninio

From: O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]
Sent: 3/19/2020 2:05:38 PM
To: Caccomo, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Hall, Bill (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e56218361cd4ffbacdd06ac2d7b809d-HHS-bill.ha]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]; Fetalvo, Ninio J. EOP/OVP (b)(6)
CC: Murphy, Ryan (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c844c911312452e901760ebdd0f3820-HHS-Ryan.Mu]; Oakley, Caitlin B (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b8feed045e954557aa1e0052f925865f-HHS-Caitlin]; McKeogh, Katherine (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c3facab3fd03480f8553892121fd2009-HHS-Katheri]; Caliguiri, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; Felberbaum, Michael [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4819a643ca2945cdb1a2631b83e69673-Michael.Fel]
Subject: RE: FDA release on chloroquine

(b) (5)

From: Caccomo, Stephanie <Stephanie.Caccomo@fda.hhs.gov>
Sent: Thursday, March 19, 2020 2:01 PM
To: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP (b)(6) >
Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>
Subject: RE: FDA release on chloroquine

(b) (5)

. Just clarifying.

Stephanie Caccomo
Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: (b)(6)
stephanie.caccomo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>

MULTI-HHS-FDA-20-0400, 20-0415-D, HHS-FDA-20-0498-G-000178

Date: March 19, 2020 at 1:53:15 PM EDT

To: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>, Hall, Bill (OS) <bill.hall@hhs.gov>, Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>, Fetalvo, Ninio J. EOP/OVP

<(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>, Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>, McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>, Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>, Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

One more. (b) (5)

”

To: (b) (5)

From: Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>

Sent: Thursday, March 19, 2020 1:37 PM

To: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

Will do. With that edit, can we issue?

Stephanie Caccamo

Press Officer

Office of Media Affairs
Office of External Affairs
U.S. Food and Drug Administration
Desk: 301.348.1956
Cell: (b)(6)
stephanie.caccamo@fda.hhs.gov

From: O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>

Sent: Thursday, March 19, 2020 1:35 PM

To: Hall, Bill (OS) <bill.hall@hhs.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B (OS) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>

Subject: RE: FDA release on chloroquine

This release goes right into the quote from (b) (5) about “today’s actions,” (b) (5)
Recommend moving (b) (5).

From: Hall, Bill (HHS/ASPA) <bill.hall@hhs.gov>

Sent: Thursday, March 19, 2020 1:24 PM

To: O'Malley, Devin M. EOP/OVP <(b)(6)>; Miller, Katie R. EOP/OVP <(b)(6)>; Fetalvo, Ninio J. EOP/OVP <(b)(6)>

Cc: Murphy, Ryan (OS/ASPA) <Ryan.Murphy1@hhs.gov>; Oakley, Caitlin B. (OS/ASPA) <Caitlin.Oakley@HHS.GOV>; McKeogh, Katherine (OS/ASPA) <Katherine.McKeogh@hhs.gov>; Caliguiri, Laura (FDA/OC)

<Laura.Caliguiri@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>

Subject: FDA release on chloroquine

All...FDA is ready to issue this. Please let us know if we have the green light. Bill

William Hall

Deputy Assistant Secretary for Public Affairs (Public Health)

Office of the Assistant Secretary for Public Affairs

U.S. Department of Health & Human Services

Washington, DC

Direct: 202-690-6344

Mobile: (b)(6)

Email: bill.hall@hhs.gov

>>>www.hhs.gov<<<



From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: 3/17/2020 10:11:36 AM
To: Caliguiri, Laura [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=aa086f2d6c0346c49e996932d86ac62e-Laura.Calig]; O'Malley, Devin M. EOP/OVP [Devin.M.O'Malley@ovp.eop.gov]; Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC: Cacco, Stephanie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=950c32cebc4b4f80b302c50cf31c8524-Stephanie.C]; Murphy, Ryan (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c844c911312452e901760ebdd0f3820-HHS-Ryan.Mu]; Hall, Bill (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4e56218361cd4ffbaccdd06ac2d7b809d-HHS-bill.ha]; MacInnis, Hannah F. EOP/OVP (b)(6)
Subject: RE: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

+Hannah for potential amplification on op-ed

From: Caliguiri, Laura <Laura.Caliguiri@fda.hhs.gov>
Sent: Tuesday, March 17, 2020 10:10 AM
To: Fetalvo, Ninio J. EOP/OVP (b)(6); O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Cc: Cacco, Stephanie <Stephanie.Cacco@fda.hhs.gov>; Murphy, Ryan (OS) <Ryan.Murphy1@hhs.gov>; Hall, Bill (OS) <bill.hall@hhs.gov>
Subject: RE: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

Can't get into call -all circuits busy – quick update we have enforcement discretion on food inspection guidance coming out today, working through some Q&A on safety/packaging, pushing out support for blood centers and Dr. Hahn's oped on fraud published in USAToday this am.

From: Fetalvo, Ninio J. EOP/OVP (b)(6)
Sent: Monday, March 16, 2020 5:17 PM
To: Fetalvo, Ninio J. EOP/OVP (b)(6)
Cc: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>; O'Malley, Devin M. EOP/OVP <Devin.M.O'Malley@ovp.eop.gov>; Love, Kelly A. EOP/OVP (b)(6)
Subject: 3/16/20 PM Notes from Daily Coronavirus Comms Sync

Notes from Daily Coronavirus Comms Sync 5:00 PM Monday, March 16, 2020

OVP Comms

- (b)(5)

HHS

(b)(5)

NIH

(b)(5)

CMS

(b)(5)

(b) (5)

Surgeon General

(b) (5)

DHS

(b) (5)

FEMA

(b) (5)

DOT

(b) (5)

State

(b) (5)

USAID

(b) (5)

DOD

(b) (5)

HUD

(b) (5)

Treasury

(b) (5)

USDA

(b) (5)

Energy

(b) (5)

Labor

(b) (5)

VA

(b) (5)

NASA

(b) (5)

NSC

(b) (5)

(b) (5)

DNI

(b) (5)

SSA

(b) (5)

###

From: Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
Sent: 4/3/2020 11:05:14 AM
To: Holt, Brandon T. EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Clancy, Carolyn [Carolyn.Clancy@va.gov]; Klote, Mary M. [Mary.Klote@va.gov]; Justice, Amy [Amy.Justice2@va.gov]; Bates, Jack (BISL) [Jack.Bates@va.gov]; Francis, Joe [Joe.Francis@va.gov]; Quinn, John F. (NDS) [John.Quinn@va.gov]; Box, Tami [Tamara.Box@va.gov]; Ramoni, Rachel [Rachel.Ramoni@va.gov]; Muralidhar, Sumitra [Sumitra.Muralidhar@va.gov]; Brouillette, Dan [dan.brouillette@hq.doe.gov]; Dabbar, Paul [paul.dabbar@hq.doe.gov]; Abernethy, Amy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c84171967c724ee799bb2658197086bc-Amy.Abernet]; Watson, Ian D. EOP/OSTP (b) (6) @ostp.eop.gov; Waterman, Paige E. EOP/OSTP (b) (6) @ostp.eop.gov; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Fabina, Lauren C. EOP/NSC (b) (6) Ruggiero, Anthony J. EOP/NSC (b) (6); Tully, Ryan M. EOP/NSC (b) (6); Kratsios, Michael J. EOP/OSTP (b) (6) @ostp.eop.gov; Parker, Lynne E. EOP/OSTP (b) (6) @ostp.eop.gov
CC: Hennessey, Millicent S. EOP/NSC (b) (6); Ferro, Phil J. EOP/NSC (b) (6)
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Hi all,

I'm adding Michael Kratsios and Lynne Parker re the data mining piece.

Kelvin

From: Holt, Brandon T. EOP/NSC <Brandon.T.Holt@nsc.eop.gov>
Sent: Friday, April 3, 2020 10:36 AM
To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>; Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>; Fabina, Lauren C. EOP/NSC <Lauren_C_Fabina@nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC <Anthony.J.Ruggiero@nsc.eop.gov>; Tully, Ryan M. EOP/NSC <Ryan.M.Tully@nsc.eop.gov>
Cc: Hennessey, Millicent S. EOP/NSC <Millicent.S.Hennessey@nsc.eop.gov>; Ferro, Phil J. EOP/NSC <Philip.J.Ferro@nsc.eop.gov>
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good morning all,

Could we please lock in this call for 12:30pm? Please see call-in information below. Thank you!

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Best,
Brandon

Brandon T. Holt
Office of the National Security Advisor
D: 202-456-8705

From: Ferro, Phil J. EOP/NSC <Philip.J.Ferro@nsc.eop.gov>

Sent: Friday, April 3, 2020 10:30 AM

To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>; Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>; Fabina, Lauren C. EOP/NSC <Lauren_C._Fabina@nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC <Anthony.J.Ruggiero@nsc.eop.gov>; Tully, Ryan M. EOP/NSC <Ryan.M.Tully@nsc.eop.gov>

Cc: Holt, Brandon T. EOP/NSC <Brandon.T.Holt@nsc.eop.gov>; Hennessey, Millicent S. EOP/NSC <Millicent.S.Hennessey@nsc.eop.gov>

Subject: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good Morning Colleagues,

First off, thank you for your robust support to get this initiative off the ground as quickly as possible. The objective is for VA, DoE, and FDA to (b) (5)

We would like to convene a call this afternoon to coordinate efforts. Brandon Holt who works for APDNSA Pottinger will work with you and your staff to schedule this call. To this end, please feel free to have your staff respond to Brandon. We will send out an agenda shortly.

Please let me know if you have any questions or if I may be of assistance.

All the best,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
202.456.1222 (O) (b) (6) (cell)
Philip.J.Ferro@nsc.eop.gov

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbddd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6) ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]
Subject: Call: rural testing and surveillance
Location: (202) 395-6392, (b) (6) #
Start: 3/30/2020 8:00:00 PM
End: 3/30/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Birx, Redfield, Verma, Hahn, Fauci, Grogan, Jernigan (CDC)

Attendees (via video conference): Bresee (CDC), Payne (CDC), TBD

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (202) 456-5984 | Mobile: (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]; Brandt, Kimberly (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c27a38a5cf44a9eb4db07014d44f848-HHS-Kimberl]; Moody-Williams, Jean D (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=da4cc691c5f14ba0886d5ff37a036b04-HHS-jean.mo]; Wright, David R (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1532ec98b0c4119b022ba89a7fdb336-HHS-David.W]; Ling, Shari (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=758ba0f601cc4764bda74f5936c87aff-HHS-Shari.L]; Shulman, Evan T (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=263f8a0b23224a2ebb72335688eee1a2-HHS-Evan.Sh]; Hittle, Matthew (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8372c80ded364f19bedb4a769a5fbc09-HHS-Matthew]; Meier, Patricia (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cac8c4884f9d4365a0df1c4a4db0b828-HHS-Patrici]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Dr. Birx, Dr. Redfield, Administrator Verma, Dr. Hahn, Dr. Fauci, Joe Grogan, Dr. Jernigan (CDC)

Attendees (via video conference/phone):

CDC: Dr. Joseph Bresee, Becky Payne

CMS: Kim Brandt, Jean Moody-Williams, David Wright, Shari Ling, Evan Shulman, Matthew Hittle, Patricia Meier

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

AMERICAN
OVERSIGHT

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (b) (6) | Mobil (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Jernigan, Daniel B (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=83b3dd3de35d489aa4012b73d93f133f-HHS-dbj0-cd]; Payne, Rebecca L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6324c4a760be4e4384b75898a3c61e46-HHS-rco0-cd]; Bresee, Joseph S (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a97e60bafd2145e19d9b7e3a465e8cf0-HHS-jsb6-cd]; Brandt, Kimberly (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c27a38a5cf444a9eb4db07014d44f848-HHS-Kimberl]; Moody-Williams, Jean D (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=da4cc691c5f14ba0886d5ff37a036b04-HHS-jean.mo]; Wright, David R (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1532ec98b0c4119b022ba89a7fdb336-HHS-David.W]; Ling, Shari (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=758ba0f601cc4764bda74f5936c87aff-HHS-Shari.L]; Shulman, Evan T (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=263f8a0b23224a2ebb72335688eee1a2-HHS-Evan.Sh]; Hittle, Matthew (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8372c80ded364f19bedb4a769a5fbc09-HHS-Matthew]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees (in person): Dr. Birx, Dr. Redfield, Administrator Verma, Dr. Hahn, Dr. Fauci, Joe Grogan, Dr. Jernigan (CDC)

Attendees (via video conference/phone):

CDC: Dr. Joseph Bresee, Becky Payne

CMS: Kim Brandt, Jean Moody-Williams, David Wright, Shari Ling, Evan Shulman, Matthew Hittle

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**.

This meeting would take place in a conference room that has VTC capabilities (location TBD).

I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (6)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (6)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office (b) (6) | Mobile (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Busy
Recurrence: (none)

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**. This meeting would take place in a conference room that has VTC capabilities (location TBD). I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

. Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee

Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator

Associate Advisor | Office of the Vice President

Office: (b) (6) | Mobile: (b) (6) [no text]

Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Conway, Kellyanne E. EOP/WHO [KAC@who.eop.gov]
Subject: Confirmed -- [post press briefing] Health Strategy Meeting re: reopening
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Agenda:

- Opening Remarks [AMB Deborah Birx, M.D.]
- HHS Briefing [Paul Mango, HHS Deputy Chief of Staff]
- Group Discussion
- Next Steps [AMB Deborah Birx, M.D.]
- Closing Remarks [AMB Deborah Birx, M.D.]

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Jared Kushner
Paul Mango
Brian Harrison
Joseph Grogan (by phone)
Kellyanne Conway

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]

Subject: Confirmed -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Jared Kushner
Paul Mango
Brian Harrison
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]; Harrison, Brian (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac2bfe7febef45ed98c87b83e5bcf8d0-HHS-Brian.H]
Subject: Confirmed -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Brian Harrison
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)]@who.eop.gov; Merkel, Theo W. EOP/WHO [(b) (6)]@who.eop.gov; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)]@who.eop.gov; Giuliani, Andrew H. EOP/WHO [(b) (6)]@who.eop.gov; Sugarman, AJ J. EOP/WHO [(b) (6)]@who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)]@who.eop.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @ [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: [(b) (6)]
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @ [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)]@who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)]@who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)]@who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)]@who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)]@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)]@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)]@who.eop.gov; Merkel, Theo W. EOP/WHO [(b) (6)]@who.eop.gov; D'Angelo, Gregory B. EOP/OMB [(b) (6)]@[(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] [(b) (6)] Bonner, Maria K. EOP/WHO [(b) (6)]@who.eop.gov; Giuliani, Andrew H. EOP/WHO [(b) (6)]@who.eop.gov; Sugarman, AJ J. EOP/WHO [(b) (6)]@who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)]@who.eop.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbddd983419fcd-HHS-olx1-cd] (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS (b) (6)]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/31/2020 7:30:00 AM
End: 3/31/2020 8:00:00 AM
Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@omb.eop.gov]; Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: (202) 395-6392,,, [(b) (6)] #
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: [(b) (6)]

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] (b) (6) Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: Roosevelt Room
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]

Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]
Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room
Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 10:08:14 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC (b) (6) Kanapathy, Ivan J. EOP/NSC (b) (6) Hooker, Allison M. EOP/NSC (b) (6) Sinclair, Michael R. EOP/NSC (b) (6)
Subject: FDA/EOP Call on Exports
Location: Dial-in 202-395-6392; (b) (6)
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

Roosevelt Room for internal participants
Participant Dial-In: (202) 395-6392
Participant Code: (b) (6)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/6/2020 3:28:47 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; SV1@cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Mango, Paul (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; AMA2 (OS/IOS) [AMA2@HHS.GOV]

Subject: HOLD -- [post press briefing] Health Re-opening Strategy Meeting
Location: Roosevelt Room

Start: 4/7/2020 6:30:00 PM
End: 4/7/2020 8:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

AMB Birx, M.D.
Dr. Redfield
Dr. Fauci
Dr. Hahn
Secretary Azar
Administrator Verma
ADM Giroir, M.D.
Paul Mango
Joseph Grogan (by phone)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [(b) (6)] @ [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Tentative

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

*** Please note that Congressman Fortenberry and his staff will be the only external participants on the call.***

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

****For those on the WH campus, we will meet in the Roosevelt Room to get on the call.****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/31/2020 7:30:00 AM

End: 3/31/2020 8:00:00 AM

Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 3/30/2020 4:55:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbddd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6)]; Brookes, Brady (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=be9baf245ae491baa1c01e7e03ad9e4-HHS-Brady.B]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]

Subject: Call: rural testing and surveillance

Start: 3/30/2020 8:00:00 PM

End: 3/30/2020 8:30:00 PM

Show Time As: Tentative

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Follow up from 2 pm meeting re: rural testing and surveillance

Hahn
Birx
Fauci
Giroir
Redfield
Verma
Grogan

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/12/2020 5:14:49 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; CMS SV1 [SV1@cms.hhs.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: HOLD - Meeting with Dr. Birx
Location: Room TBD + video
Start: 4/13/2020 1:45:00 PM
End: 4/13/2020 3:00:00 PM
Show Time As: Tentative
Recurrence: (none)

Good evening,

Dr. Birx would like to convene this group tomorrow at the White House from **1:45pm-3:00pm**. This meeting would take place in a conference room that has VTC capabilities (location TBD). I will follow up with a calendar invite, meeting location details as well as video instructions.

Administrator Verma:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Dr. Redfield:

Dr. Birx is requesting (b) (5)

Please let us know if this is not possible or if you foresee any issues with your team joining via video.

Sincerely,
TAM

Tyler Ann McGuffee
Assistant to Ambassador Birx, M.D. | Office of the White House Coronavirus Response Coordinator
Associate Advisor | Office of the Vice President
Office: (202) 456-5984 | Mobile: (b) (6) [no text]
Email: Tyler.A.McGuffee2@ovp.eop.gov

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/21/2020 12:02:10 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: McGuffee, Tyler A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]
Subject: A couple of edits
Attachments: dbInformation for Clinicians on Therapeutic Options for COVID-19 Patients for posting 03212020.docx

(b) (5)

. Thank you

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/14/2020 7:51:59 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: FW: China Export Ban

From: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Sent: Monday, April 13, 2020 10:31 PM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Boyd, Charlton J. EOP/WHO <Charlton.J.Boyd@who.eop.gov>; Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: RE: China Export Ban

I went through these. If I can get case by case updates I can try to intercede. A lot of these are anecdotal. (b) (5)

[REDACTED]

JK

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Monday, April 13, 2020 8:13 PM
To: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Cc: Boyd, Charlton J. EOP/WHO <Charlton.J.Boyd@who.eop.gov>; Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: FW: China Export Ban

Jared, see the list below, most critically (b) (5)

[REDACTED]

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Monday, April 13, 2020 3:05 PM
To: Hahn, Stephen <SH1@fda.hhs.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: China Export Ban


Sir – attached are talkers I built with NSC on the (b) (5)

[REDACTED]

(b) (5)

[REDACTED]

(b) (5)



From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/31/2020 12:32:58 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]
Subject: Re: Schedule of therapies coming on line

Pages 2 and 3 of the document I gave you yesterday.

S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 31, 2020 at 11:25:28 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: Re: Schedule of therapies coming on line

You mean the CTAP document? He also wanted a flow chart with when therapies come on line and how many people could treated?

Sent from my iPhone

On Mar 31, 2020, at 11:04 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Yes I handed it to you yesterday at the 2 pm meeting. I tried to email it multiple times yesterday (as I mentioned) but couldn't get through the WH gateway. I'm ready to present whenever you want me to do so

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 31, 2020 at 10:45:20 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>
Subject: Schedule of therapies coming on line

Steve, have you guys made any progress on the chart that Liddell requested laying out the schedule Of therapies coming on line?

Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/25/2020 6:11:01 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]
Subject: RE: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

I'll let Bob and Deb respond from a public health point of view. An antibody test is essential for detecting high titers that will enable both convalescent plasma and hyperimmune globulin. both are promising therapies.
S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 5:57:48 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: RE: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Yes that's right. It's an antibody test (b) (5)

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Wednesday, March 25, 2020 4:01 PM
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: Re: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

We don't know anything about this particular test, but if they met the conditions under the recent guidance, which are pretty straightforward, the US government could purchase them for distribution to locations where there is a healthcare worker.

One other thing. The test Mr. Martin refers to appears to be an antibody test not a diagnostic test for COVID-19. It's important to know that under the recent guidance companies can notify us that they are entering the market but we do not have scientific insight into how the tests perform. We have been working with other companies to expedite antibody testing.

We are very happy to provide additional information as well as technical assistance to anyone wishing to purchase these tests.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 25, 2020 at 2:46:32 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Steve

From: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Date: Wednesday, March 25, 2020 at 2:45 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>
Subject: FW: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

John Martin of former Gilead fame told me that Fosun, a Chinese company that he knows well has a \$3 point of care antibody test and the ability to make a ton of them. (b) (5)

From: Lyons, Derek S. EOP/WHO <Derek.S.Lyons@who.eop.gov>
Sent: Wednesday, March 25, 2020 2:30 PM
To: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: FW: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

(b) (5)

From: News Alerts <NewsAlerts@WHO.eop.gov>
Sent: Wednesday, March 25, 2020 2:28 PM
Subject: CORONAVIRUS FLAG: UK to make 15-minute at-home kits available within days

Coronavirus test: UK to make 15-minute at-home kits available within days

The Independent

Kate Ng

March 25, 2020

><https://www.independent.co.uk/news/uk/home-news/coronavirus-test-uk-kit-home-nhs-cases-symptoms-public-health-england-a9424741.html><

'Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community,' says Public Health England director

New 15-minute home test kits for coronavirus will be made available to the British public within days, said a Public Health England (PHE) director.

Thousands of tests will be sold in chemists such as Boots or delivered by Amazon to people with symptoms who are self-isolating as soon as next week.

Professor Sharon Peacock, director of the national infection service at PHE, told MPs on the science and technology committee once the tests are cleared, they will be "distributed to the community".

Matt Hancock, the health secretary, said the government bought millions of the tests on Tuesday and is ordering millions more.

The antibody test involves pricking a finger and analysing a drop of blood in a device that looks like a pregnancy test. It will only tell the person if they have had Covid-19, not if they currently have it.

The test will detect the presence of the antibodies IGM, which emerges in the early stages of infection, and IGG, which increases during the body's response to the virus.

Ms Peacock said the tests would “absolutely” be available within days, rather than weeks or months, when asked by MPs.

She said: “Several million tests have been purchased for use. These are brand new products. We have to be clear they work as they are claimed to do.

“Once they have been tested this week and the bulk of tests arrive, they will be distributed into the community.”

Currently, only patients admitted to hospital are being routinely tested for Covid-19. Between 5,000 to 6,000 people are being tested a day, but the government plans to increase this to 25,000 tests a day within four weeks.

The new antibody tests could help the UK achieve what the [World Health Organisation](#) (WHO) has urged governments to do, which is to “test, test, test”.

Tedros Adhanom Ghebreyesus, director-general of the WHO, said: “We cannot stop this pandemic if we do not know who is infected.”

The antibody tests are also being ordered across Europe and Southeast Asia, said Ms Peacock.

“We are not alone in doing this,” she added.

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/26/2020 8:11:20 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Did Abbott file on its Alere platform

Yes, for sure

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 26, 2020 at 7:50:09 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Did Abbott file on its Alere platform

Let me know – (b) (5)

[REDACTED]

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Thursday, March 26, 2020 at 7:30 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Subject: Re: Did Abbott file on its Alere platform

They tell us today

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: March 26, 2020 at 5:55:36 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Did Abbott file on its Alere platform

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/25/2020 12:38:31 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: When can you present CTAP to the TF?

Yes, pre-brief Thursday. Colin can you make sure that happens?

S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 25, 2020 at 11:52:38 AM EDT
To: Rom, Colin <Colin.Rom@fda.hhs.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: When can you present CTAP to the TF?

Ok. So pre brief Thursday?

Sent from my iPhone

> On Mar 25, 2020, at 11:51 AM, Rom, Colin <Colin.Rom@fda.hhs.gov> wrote:

>

> Will be ready to announce to task force on Friday

>

> -----Original Message-----

> From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>

> Sent: Wednesday, March 25, 2020 11:22 AM

> To: Hahn, Stephen <SH1@fda.hhs.gov>

> Cc: Rom, Colin <Colin.Rom@fda.hhs.gov>

> Subject: When can you present CTAP to the TF?

>

> I'm getting pressed to schedule it.

>

> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/12/2020 6:29:00 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: The Reagents come from Germany

We are in constant contact in the manufacturers of reagents and while we have not had anyone reach out to us about this issue, we are looking into it. I've spoken to Jeff Shuren's team and they will specifically reach out about this.
Steve

Sent from my iPad

> On Mar 11, 2020, at 9:10 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
>
> Guys, I'm being told that the reagents for the tests come from Germany and they have put export controls on everything covid-19. (b) (5)
>
> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 3/8/2020 9:13:31 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
CC: Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; Caro Rivera, Juan A. EOP/WHO [Juan.A.CaroRivera@who.eop.gov]; Watson, Ian D. EOP/OSTP [Ian.D.Watson@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [Paige.E.Waterman@ostp.eop.gov]; Shuren, Jeff [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44335a0c2f834535bc8713dfd643905e-Jeff.Shuren]; Flannery, Ellen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f3a88f0ebdf24b898ccd4814707daedf-Ellen.Flann]
Subject: Re: Devices for surface testing

Very good question. We'll investigate.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 7, 2020 at 8:20:04 PM EST
To: Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Redfield, Robert R (CDC) <olx1@cdc.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>, Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>, Bonner, Maria K. EOP/WHO <Maria.K.Bonner@who.eop.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>, Caro Rivera, Juan A. EOP/WHO <Juan.A.CaroRivera@who.eop.gov>, Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>, Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>
Subject: Re: Devices for surface testing

With Steve Hahn from FDA

Sent from my iPhone

> On Mar 7, 2020, at 8:17 PM, Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov> wrote:
>
> I'm copying Ian and Paige at OSTP to get their thoughts. We also can engage our new National Academy committee.
>
> Kelvin
>
>
>> On Mar 7, 2020, at 8:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:
>>
>> Can we (b) (5) ?
>>
>> We've been (b) (5)

(b) (5)

>>

>> If we (b) (5)

>>

>> Michael or Kelvin, should (b) (5)

>> Joe

>>

>> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/12/2020 5:05:08 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Working on testing strategy

Deb,
This is good.
Some minor comments -

(b) (5)

(b) (5)

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 12, 2020 at 4:49:22 PM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA) <nelson.l.michael2.civ@mail.mil>
Subject: Re: Working on testing strategy

Sorry – here you go

From: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Date: Sunday, April 12, 2020 at 1:04 PM
To: "Fauci, Anthony (NIH/NIAID) [E]" <afauci@niaid.nih.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>
Cc: "Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA)" <nelson.l.michael2.civ@mail.mil>
Subject: Working on testing strategy

Just a draft – all comments welcomed. (b) (5)

Please review. Also Steve (b) (5). Deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/13/2020 8:39:31 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: list of essential tests and items from China

Ok thx

Sent from my iPhone

On Apr 13, 2020, at 8:36 AM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

Individual items

Sent from my iPhone

On Apr 13, 2020, at 8:24 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Joe,
Thank you. Do you want (b) (5)? Keagan, let's talk.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 13, 2020 at 8:23:50 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: list of essential tests and items from China

Can you get me a list (b) (5)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 5:15:07 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
CC: Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]
Subject: Re: Haines masks

Ok thx

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 7, 2020 at 5:14:11 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Kadlec, Robert P (OS) <Robert.Kadlec@hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>
Subject: Re: Haines masks

I think (b) (5)

Sent from my iPhone

On Apr 7, 2020, at 5:08 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Bob

A question arose today at the task force (b) (5)

Jeff,

(b) (5)

Dr. Birx is aware and could possibly provide insight.

Thx

Steve

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 7:46:54 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: Question

I'll check although I do know that there is a ton of variability.
S

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 7, 2020 at 7:46:26 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Question

Pretty sweet. When it reads high thru put is there (b) (5) ?

Sent from my iPhone

On Apr 7, 2020, at 7:44 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

FYSA

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Date: April 6, 2020 at 7:52:46 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Question

Does this work?

SPONSOR	PRODUCT (link to authorization letter)	DESCRIPTION
DIAGNOSTICS		
Center for Disease Control and Prevention	CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel	- Developed by CDC and initially distributed to public health labs across the country - High throughput - Can only be run in high complexity labs
Wadsworth – New York State Public Health	New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR	Developed by Wadsworth based on CDC's

	Diagnostic Panel	published protocol - Run in qualified labs across New York State - High throughput - Can only be run in high complexity labs
Roche Molecular Systems, Inc.	cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Life Technologies (a part of Thermo Fisher Scientific, Inc.)	TaqPath™ COVID-19 Combo Kit, 100 Rxn, TaqPath™ COVID-19 Combo Kit, 1,000 Rxn	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Laboratory Corporation of America	COVID-19 RT-PCR Test	- Developed and run in LabCorp labs only; not for broad lab distribution. - High throughput - Can only be run in high complexity labs
Hologic, Inc.	Panther Fusion SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Quest Diagnostics Infectious Disease, Inc.	SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR	- Developed and run in Quest labs only; not a kit for distribution. - High throughput - Can only be run in high complexity labs
Quidel Corporation	Lyra® SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Abbott Molecular, Inc.	Abbott RealTime SARS-CoV-2 assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
GenMark Diagnostics, Inc.	ePlex SARS-CoV-2 Test	- Reagents commercially distributed as a kit to labs - Can run up to 24 specimens at the same time - Can be run in a moderate or high complexity lab
DiaSorin Molecular LLC	Simplexa COVID-19 Direct	Reagents commercially distributed as a kit to labs

		• Can run 1 specimen at a time • Can be run in a moderate or high complexity lab
Primerdesign Ltd.	Primerdesign Ltd COVID-19 genesig Real-Time PCR	• Reagents commercially distributed as a kit to labs • Requires separate RNA extraction kit and extraction platform not provided with reagents (GenoXtract) • High throughput • Can only be run in high complexity labs
Cepheid	Xpert Xpress SARS-CoV-2 test	• Reagents commercially distributed as a kit to labs • Can run up to 2,000 samples per day • Can be run in a clinical lab or at the Point of Care (POC) near the patient
Mesa Biotech Inc.	Accula SARS-CoV-2 Test	• Reagents commercially distributed as a kit to labs • Runs one specimen at a time • Can be run in a clinical lab or at the Point of Care (POC) near the patient
BioFire Defense, LLC	BioFire COVID-19 Test	• Reagents commercially distributed as a kit to labs • Can run 264 tests per day • Can be run in moderate or high complexity labs
PerkinElmer, Inc.	PerkinElmer New Coronavirus Nucleic Acid Detection kit	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Avellino Labs USA	AvellinoCoV2 test	• Developed and run in Avellino labs; not distributed to other labs • Run in a high complexity lab
BGI Genomics Co. Ltd.	Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab
Luminex Molecular Diagnostics, Inc.	NxTAG CoV Extended Panel Assay	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in a high complexity lab

Abbott Diagnostics Scarborough, Inc.	ID NOW™ COVID-19	• Reagents commercially distributed as a kit • Requires a specific platform (ID NOW), of which there are 18,000 installed across the US • All-in-one; does not require separate RNA extraction kit • Runs one specimen at a time; each takes <13 minutes • Can be run in a clinical lab or at the Point of Care (POC) near the patient
NeuMoDx Molecular, Inc.	NeuMoDx SARS-CoV-2 Assay	• Reagents commercially distributed as a kit • Can run 288 or 96 samples at once, depending on the instrument, and takes 80 minutes per sample • Can be run in high and moderate complexity labs
QIAGEN GmbH	QIAstat-Dx Respiratory SARS-CoV-2 Panel	• Detects multiple other respiratory viral (17) and bacterial (3) organisms • Reagents commercially distributed as a kit to labs • Runs one specimen at a time and takes one hour • Can be run in high and moderate complexity labs
EUA for COVID-19 LDTs	Laboratory developed tests that are authorized are listed below and hyper link to letter granting inclusion under EUA	• Authorizes the use of LDTs that meet certain criteria. • Authorized tests can be used in the lab that developed the test and that is high complexity.
• Massachusetts General Hospital (Mass Gen) • Diagnostic Molecular Laboratory-Northwestern Medicine • Infectious Disease Diagnostics Laboratory-Children's Hospital of Philadelphia • Yale New Haven Hospital, Clinical Virology Laboratory		
Cellex Inc.	Serology Test qSARS-CoV-2 IgG/IgM Rapid Test	• The first serological test authorized under EUA. • Detects SARS-CoV-2 antibodies in blood. • Rapid test, provides results in 15-20 minutes.
Ipsium Diagnostics	COV-19 IDx assay	• Uses commercially available reagents • Can only be run in high complexity labs
Becton, Dickinson & Company (BD)	BioGX SARS-CoV-2 Reagents for BD MAX System	• Reagents commercially distributed as a kit to labs

		- Fully automated, 8 samples per hour - Can be run in moderate and high complexity labs
ScienCell Research Laboratories	<u>ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit</u>	- Qualitative detection kit for nasal/oral/BAL - Testing is limited to laboratories certified to perform high complexity tests
Co-Diagnostics, Inc.	<u>Logix Smart Coronavirus Disease 2019 (COVID-19) kit</u>	- Qualitative detection of upper and lower respiratory tract fluids - Testing is limited to laboratories certified to perform higher complexity tests

Sent from my iPhone

On Apr 6, 2020, at 6:43 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

For task force

Does CDRH have a list of major approved diagnostic COVID tests and what platform is used for each?

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFACOCFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 8:21:14 AM
To: Miller, Katie R. EOP/OVP [Katie.R.Miller@ovp.eop.gov]
CC: Conway, Kellyanne E. EOP/WHO [KAC@who.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]; Hicks, Hope C. EOP/WHO [Hope@who.eop.gov]; Rinat, Ory S. EOP/WHO [Ory.S.Rinat@who.eop.gov]; Troye, Olivia EOP/NSC [Olivia.Troye@nsc.eop.gov]
Subject: Re: Convalescent plasma program

Not sure about the HHS approach but happy to coordinate.

(b) (5)

. Peter, can you add?

Thanks
Steve

From: Miller, Katie R. EOP/OVP <Katie.R.Miller@ovp.eop.gov>
Date: April 7, 2020 at 8:18:56 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Conway, Kellyanne E. EOP/WHO <KAC@who.eop.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Marks, Peter <Peter.Marks@fda.hhs.gov>, Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>, Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>, Troye, Olivia EOP/NSC <Olivia.Troye@nsc.eop.gov>
Subject: Re: Convalescent plasma program

+others.

Yes my only concern is that (b) (5)

My immediate question is (b) (5) dont want (b) (5)

Sent from my iPhone

On Apr 7, 2020, at 8:13 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

KelleyAnne, Joe and Katie,

The convalescent plasma program has ramped up and we are working hard to identify donors. There is a significant shortfall of plasma because of the need to identify additional donors. D (b) (5)

(b) (5)

(b) (5)

We should know more about this today.

In the meantime, we would like to work with you to develop PSAs and other forms of communication to identify donors. We have developed language for a PSA. Is this something we should work through with you?

Thanks

Steve

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/7/2020 1:21:55 PM
To: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: RE: Question

Do you (b) (5) ? So

?
.....

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Tuesday, April 7, 2020 1:19 PM
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Question

Defining High Throughput

- As with many performance terms, there is no well accepted definition.
- High through put typically means that many samples can be run in parallel.
- Many EUA's are run on a 96 well plate format therefore you can run a **max of apx. 90 patient samples in one run.**
- Run times can vary widely depending on the technology the lab is using but **typically 3-4 hours per instrument is a good average.**
- If the lab adds automation and multiple instruments the throughput and time to result can be improved quickly.

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Tuesday, April 7, 2020 7:46 AM
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: Re: Question

Pretty sweet. When it reads (b) (5) ?

Sent from my iPhone

On Apr 7, 2020, at 7:44 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

FYSA

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Date: April 6, 2020 at 7:52:46 PM EDT
 To: Hahn, Stephen <SH1@fda.hhs.gov>
 Subject: Re: Question

Does this work?

SPONSOR	PRODUCT (link to authorization letter)	DESCRIPTION
DIAGNOSTICS		
Center for Disease Control and Prevention	CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel	- Developed by CDC and initially distributed to public health labs across the country - High throughput - Can only be run in high complexity labs
Wadsworth – New York State Public Health	New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel	- Developed by Wadsworth based on CDC's published protocol - Run in qualified labs across New York State - High throughput - Can only be run in high complexity labs
Roche Molecular Systems, Inc.	cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Life Technologies (a part of Thermo Fisher Scientific, Inc.)	TaqPath™ COVID-19 Combo Kit, 100 Rxn, TaqPath™ COVID-19 Combo Kit, 1,000 Rxn	- Commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Laboratory Corporation of America	COVID-19 RT-PCR Test	- Developed and run in LabCorp labs only; not for broad lab distribution. - High throughput - Can only be run in high complexity labs
Hologic, Inc.	Panther Fusion SARS-CoV-2 Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in high complexity labs
Quest Diagnostics Infectious Disease, Inc.	SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR	- Developed and run in Quest labs only; not a kit for distribution. - High throughput - Can only be run in high complexity labs

Quidel Corporation	<u>Lyra® SARS-CoV-2 Assay</u>	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in high complexity labs
Abbott Molecular, Inc.	<u>Abbott RealTime SARS-CoV-2 assay</u>	• Reagents commercially distributed as a kit to labs • High throughput • Can only be run in high complexity labs
GenMark Diagnostics, Inc.	<u>ePlex SARS-CoV-2 Test</u>	• Reagents commercially distributed as a kit to labs • Can run up to 24 specimens at the same time • Can be run in a moderate or high complexity lab
DiaSorin Molecular LLC	<u>Simplexa COVID-19 Direct</u>	• Reagents commercially distributed as a kit to labs • Can run 1 specimen at a time • Can be run in a moderate or high complexity lab
Primerdesign Ltd.	<u>Primerdesign Ltd COVID-19 genesig Real-Time PCR</u>	• Reagents commercially distributed as a kit to labs • Requires separate RNA extraction kit and extraction platform not provided with reagents (GenoXtract) • High throughput • Can only be run in high complexity labs
Cepheid	<u>Xpert Xpress SARS-CoV-2 test</u>	• Reagents commercially distributed as a kit to labs • Can run up to 2,000 samples per day • Can be run in a clinical lab or at the Point of Care (POC) near the patient
Mesa Biotech Inc.	<u>Accula SARS-CoV-2 Test</u>	• Reagents commercially distributed as a kit to labs • Runs one specimen at a time • Can be run in a clinical lab or at the Point of Care (POC) near the patient
BioFire Defense, LLC	<u>BioFire COVID-19 Test</u>	• Reagents commercially distributed as a kit to labs • Can run 264 tests per day

		Can be run in moderate or high complexity labs
PerkinElmer, Inc.	PerkinElmer New Coronavirus Nucleic Acid Detection kit	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in a high complexity lab
Avellino Labs USA	AvellinoCoV2 test	- Developed and run in Avellino labs; not distributed to other labs - Run in a high complexity lab
BGI Genomics Co. Ltd.	Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in a high complexity lab
Luminex Molecular Diagnostics, Inc.	NxTAG CoV Extended Panel Assay	- Reagents commercially distributed as a kit to labs - High throughput - Can only be run in a high complexity lab
Abbott Diagnostics Scarborough, Inc.	ID NOW™ COVID-19	- Reagents commercially distributed as a kit - Requires a specific platform (ID NOW), of which there are 18,000 installed across the US - All-in-one; does not require separate RNA extraction kit - Runs one specimen at a time; each takes <13 minutes - Can be run in a clinical lab or at the Point of Care (POC) near the patient
NeuMoDx Molecular, Inc.	NeuMoDx SARS-CoV-2 Assay	- Reagents commercially distributed as a kit - Can run 288 or 96 samples at once, depending on the instrument, and takes 80 minutes per sample - Can be run in high and moderate complexity labs
QIAGEN GmbH	QIAstat-Dx Respiratory SARS-CoV-2 Panel	- Detects multiple other respiratory viral (17) and bacterial (3) organisms - Reagents commercially distributed as a kit to labs - Runs one specimen at a time and takes one hour

		Can be run in high and moderate complexity labs
EUA for COVID-19 LDTs	Laboratory developed tests that are authorized are listed below and hyper link to letter granting inclusion under EUA	- Authorizes the use of LDTs that meet certain criteria. - Authorized tests can be used in the lab that developed the test and that is high complexity.
Massachusetts General Hospital (Mass Gen) Diagnostic Molecular Laboratory-Northwestern Medicine Infectious Disease Diagnostics Laboratory-Children's Hospital of Philadelphia Yale New Haven Hospital, Clinical Virology Laboratory		
Cellex Inc.	Serology Test qSARS-CoV-2 IgG/IgM Rapid Test	- The first serological test authorized under EUA. - Detects SARS-CoV-2 antibodies in blood. - Rapid test, provides results in 15-20 minutes.
Ipsium Diagnostics	CoV-19 IDx assay	- Uses commercially available reagents - Can only be run in high complexity labs
Becton, Dickinson & Company (BD)	BioGX SARS-CoV-2 Reagents for BD MAX System	- Reagents commercially distributed as a kit to labs - Fully automated, 8 samples per hour - Can be run in moderate and high complexity labs
ScienCell Research Laboratories	ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit	- Qualitative detection kit for nasal/oral/BAL - Testing is limited to laboratories certified to perform high complexity tests
Co-Diagnostics, Inc.	Logix Smart Coronavirus Disease 2019 (COVID-19) kit	- Qualitative detection of upper and lower respiratory tract fluids - Testing is limited to laboratories certified to perform higher complexity tests

Sent from my iPhone

On Apr 6, 2020, at 6:43 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

For task force

Does CDRH have a list of major approved diagnostic COVID tests and what platform is used for each?

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/11/2020 6:32:09 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Redd, Stephen C (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bb0e6496f1af42ce9f8e0d4f92fae009-HHS-scr1-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Gastfriend, Daniel Z. EOP/OMB (b) (6) (b) (6)
Subject: As an alert and maybe it can (b) (5)

(b) (5)

Q: What happens if I do not have the extraction platform referenced in the authorization of CDC's EUA-authorized test?

A: FDA believes that the CDC's EUA-authorized test could be used with the following extraction platforms which FDA cleared with the CDC's RNA-based influenza panel:

- **Roche MagNA Pure LC**

Kit: Roche MagNA Pure Total Nucleic Acid Kit

Protocol: Total NA External lysis

Recommendation(s): Add 100 µL of sample to 300 µL of pre-aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 µL). Elution volume is 100 µL.

- **Roche MagNA Pure Compact**

Kit: Roche MagNA Pure Nucleic Acid Isolation Kit I Protocol: Total_NA_Plasma100_400

Recommendation(s): Add 100 µL of sample to 300 µL of pre-aliquoted TNA isolation kit lysis buffer (total input sample volume is 400 µL). Elution volume is 100 µL.

- **Roche MagNA Pure 96**

Kit: Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit

Protocol: Viral NA Plasma Ext Lys SV Protocol

Recommendation(s): Add 100 µL of sample to 350 µL of pre-aliquoted External Lysis Buffer (supplied separately) (total input sample volume is 450 µL). Proceed with the extraction on the MagNA Pure 96. (Note: Internal Control = None). Elution volume is 100 µL.

- **QIAGEN QIAcube with the QIAamp DSP Viral RNA Mini Kit**

Kit: QIAGEN QIAamp® DSP Viral RNA Mini Kit

Recommendations: Utilize 140 µL of sample and elute with 100 µL of buffer.

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 3/11/2020 6:27:29 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Any chance (b) (5)

From: Droegemeier, Kelvin K. EOP/OSTP [Kelvin.K.Droegemeier@ostp.eop.gov]
Sent: 3/8/2020 9:48:47 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; McGowan, Robert K (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e6175b088b1d49a4bfa2de3862800d4a-HHS-omc2-cd]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]; Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; Caro Rivera, Juan A. EOP/WHO [Juan.A.CaroRivera@who.eop.gov]; Watson, Ian D. EOP/OSTP [Ian.D.Watson@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [Paige.E.Waterman@ostp.eop.gov]
Subject: Re: Devices for surface testing

NIST has some protocols too.

On Mar 8, 2020, at 9:27 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Thanks, Joe. Preliminary read but happy to have a conversation.

We don't think (b) (5)

We think that (b) (5)

We are aware (b) (5). Let us know how we can help further.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: March 7, 2020 at 8:20:04 PM EST
To: Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Redfield, Robert R (CDC) <olx1@cdc.gov>, McGowan, Robert K (CDC) <omc2@cdc.gov>, Pottinger, Matthew F. EOP/WHO <MPottinger@who.eop.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>, Bonner, Maria K. EOP/WHO <Maria.K.Bonner@who.eop.gov>, Campana, Alexandra D. EOP/WHO <Alexandra.D.Campana2@who.eop.gov>, Caro Rivera, Juan A. EOP/WHO <Juan.A.CaroRivera@who.eop.gov>, Watson, Ian D. EOP/OSTP <Ian.D.Watson@ostp.eop.gov>, Waterman, Paige E. EOP/OSTP <Paige.E.Waterman@ostp.eop.gov>
Subject: Re: Devices for surface testing

With Steve Hahn from FDA

Sent from my iPhone

> On Mar 7, 2020, at 8:17 PM, Droegemeier, Kelvin K. EOP/OSTP <Kelvin.K.Droegemeier@ostp.eop.gov> wrote:

>

> I'm copying Ian and Paige at OSTP to get their thoughts. We also can engage our new National Academy committee.

>

> Kelvin

>

>

>> On Mar 7, 2020, at 8:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

>>

>> Can we (b) (5)?

>>

>> We've been (b) (5)

[REDACTED]

>>

>> If we need (b) (5)

[REDACTED]

>>

>> Michael or Kelvin, should (b) (5)

>> Joe

>>

>> Sent from my iPhone

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/13/2020 8:23:13 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Williams, James H. EOP/WHO [(b) (6)] who.eop.gov]; Merkel, Theo W. EOP/WHO [(b) (6)] who.eop.gov]; D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@ (b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] (b) (6) Bonner, Maria K. EOP/WHO [(b) (6)] who.eop.gov]; Giuliani, Andrew H. EOP/WHO [(b) (6)] who.eop.gov]; Sugarman, AJ J. EOP/WHO [(b) (6)] who.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Koroshetz, Walter J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4d97701b01894e15a53709b9df3e08e7-HHS-koroshe]; Davis, May M. EOP/WHO [(b) (6)] who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Walker, Paula J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5230079373904be5a42bac56b97a1a3e-HHS-walkerp]; Scott, Paul A (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=30e3cd5ee9004c8cb9ab1441eb85dede-HHS-ScottP-]; Ward, Jackie M (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9195352dc4c040ca9e98a5434f9b0cca-HHS-jackie.]
Subject: ALS Phone Call
Attachments: Memo for ALS Meeting 4.17.20.docx; ALS Letter from Sandy Morris to the President.docx; HR5480.pdf; FDA ALS Guidance for Industry.pdf; ALS Letter from Fortenberry Quigley Gallagher Suozzi to the President.docx; ALS Agenda.docx
Location: (202) 395-6392,,, (b) (6)
Start: 4/17/2020 9:30:00 AM
End: 4/17/2020 10:00:00 AM
Show Time As: Busy

White House and Agency Participation

Domestic Policy Council; Office of Management and Budget; White House Counsel's Office; National Economic Council; Office of Legislative Affairs; Office of Public Liaison; Food and Drug Administration; National Institutes of Health

* Please note that Congressman Fortenberry and his staff will be the only external participants on the call.*

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

For those on the WH campus, we will meet in the Roosevelt Room to get on the call.

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/9/2020 10:08:14 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@[b] (6)]; Ruggiero, Anthony J. EOP/NSC [b] (6) [b] (6) Kanapathy, Ivan J. EOP/NSC [b] (6) [b] (6) Hooker, Allison M. EOP/NSC [b] (6) [b] (6) Sinclair, Michael R. EOP/NSC [b] (6) [b] (6)
Subject: FDA/EOP Call on Exports
Location: Dial-in 202-395-6392; [b] (6)
Start: 4/9/2020 2:00:00 PM
End: 4/9/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Roosevelt Room for internal participants
Participant Dial-In: (202) 395-6392
Participant Code: [b] (6)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 6:34:08 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: EUA for diagnostics

Glad to talk. I have a couple of ideas

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 26, 2020 at 4:30:28 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Yes we should talk further (b) (5)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Sent from my iPhone

On Apr 26, 2020, at 2:30 PM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

Perfect. Thank you. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Sunday, April 26, 2020 at 2:28 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Re: EUA for diagnostics

Our EUAs are for specific tests and specific lab developers/manufacturers. They require a prescription by a healthcare provider. The indication is for individuals who are 'suspected of COVID19 by their health care provider.' They don't have to be symptomatic. The wording was intended to mirror CDC guidelines. AS the guidelines change we could and would change the indication. As we change the populations of the individuals that we intend to test, the performance of the test may be different than what was provided in the validation data.

Glad to talk further.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 12:26:30 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Is that true Steve?

Sent from my iPhone

> On Apr 26, 2020, at 12:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

>

> The EUA we issued in March for diagnostics [REDACTED] t? (b) (5)

[REDACTED]

[REDACTED]

>

> Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: HOLD - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Busy

Recurrence: (none)

5/7 Agenda

TBD

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO (b) (6) who.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov; Riggs, Charlotte R. EOP/WHO (b) (6) who.eop.gov; Butterfield, Nicholas W. EOP/WHO (b) (6) who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]

Subject: Therapeutics Meeting
Location: WHSR Exec

Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Busy

Recurrence: (none)

****There will be no dial-in option****


From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: HOLD - Follow up discussion with Dr. Birx
Attachments: FW: testing, testing, testing
Location: Dial-in forthcoming
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/10/2020 7:24:55 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: HOLD - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: Dial-in forthcoming

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Tentative

Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 202-395-6392;; (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (5) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (5) cms.hhs.gov' (b) (5) cms.hhs.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Confirmed - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Busy
Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx
Attachments: FW: testing, testing, testing
Location: 1-866-617-3597;; Participant Passcode: (b) (6)
Start: 5/11/2020 2:00:00 PM
End: 5/11/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Dial-In Information

Toll-Free #1-866-617-3597

Participant Passcode: (b) (6)


Leader Passcode: (b) (6)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 202-395-6392;; (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Participant Dial-In: (202) 395-6392

Participant Code: (b) (6)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/10/2020 7:35:59 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: HOLD - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: Dial-in forthcoming

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Tentative

Recurrence: (none)

Attendees:

Dr. Birx
Dr. Fauci
Dr. Hahn
Dr. Redfield

Agenda:

(b) (5)



From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (5) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov' (b) cms.hhs.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: TIME CHANGE: - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 3:30:00 PM
End: 5/7/2020 4:30:00 PM
Show Time As: Tentative

Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: HOLD - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room
Start: 5/7/2020 4:00:00 PM
End: 5/7/2020 5:00:00 PM
Show Time As: Tentative

Recurrence: (none)

5/7 Agenda

TBD

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[b] (6) [b] (6) Vought, Russell T. EOP/OMB [b] (6) [b] (6) Bruno, Grace A.
EOP/OMB [b] (6) [b] (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@omb.eop.gov];
Cytryn, Jen B. EOP/WHO [b] (6) [b] (6) who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] (6) Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [b] (6)
[b] (6) cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@nsc.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [b] (6) [b] (6) ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [b] (6) [b] (6) who.eop.gov]; DeValiere, Ian C. EOP/WHO [b] (6) [b] (6) who.eop.gov];
Williams, Michael B. EOP/WHO [b] (6) [b] (6) who.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]
Subject: Canceled: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Free
Importance: High

Will be combined with the Wednesday Briefing

[b] (5)

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 8:52:13 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]
CC: Kushner, Jared C. EOP/WHO [jck@who.eop.gov]
Subject: Re: Antibody tests

I did talk to Howard Zucker and his answer was that we're NOT counting the antibody + people in their case count for COVID-19. He told me that he would double check on it just to follow up

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 7:35:42 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Cc: Kushner, Jared C. EOP/WHO <jck@who.eop.gov>
Subject: Antibody tests

Would be great to (b) (5)

. Deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/26/2020 6:34:08 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: EUA for diagnostics

Glad to talk. I have a couple of ideas

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 26, 2020 at 4:30:28 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Yes we should talk further because I'm not sure I'm tracking. I know we need to husband resources but for screening DoD recruits for example that isn't as a suspicion of being infected. It's screening. There are certain settings where we may want to do the same. Say a huge meat packing plant. Getting on board a cruise ship... we should think about this. I don't want the worried well getting testing in parking lots but I also think we may want to screen a huge population that interacts all at once. At least by fall.

Sent from my iPhone

On Apr 26, 2020, at 2:30 PM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

Perfect. Thank you. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Sunday, April 26, 2020 at 2:28 PM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Re: EUA for diagnostics

Our EUAs are for specific tests and specific lab developers/manufacturers. They require a prescription by a healthcare provider. The indication is for individuals who are 'suspected of COVID19 by their health care provider.' They don't have to be symptomatic. The wording was intended to mirror CDC guidelines. AS the guidelines change we could and would change the indication. As we change the populations of the individuals that we intend to test, the performance of the test may be different than what was provided in the validation data.

Glad to talk further.

Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 26, 2020 at 12:26:30 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: EUA for diagnostics

Is that true Steve?

Sent from my iPhone

> On Apr 26, 2020, at 12:08 PM, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov> wrote:

>

> The EUA we issued in March for diagnostics (b) (5)

[REDACTED]

[REDACTED]


>

> Sent from my iPhone

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/27/2020 11:49:02 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Verma, Seema (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2096b0c1e7f04e91897765d7ee0ac336-HHS-Seema.V]
Subject: Re: Testing Strategy

I'm pulling in Seema to expand the conversation.
We've been fielding a few questions that I think are unanswered by the document.

For example, (b) (5)



Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 27, 2020 at 7:53:40 AM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: FW: Testing Strategy

Please review redline word document. I did not participate in the PPT. Deb

From: "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Date: Sunday, April 26, 2020 at 8:06 PM
To: "Meadows, Mark R. EOP/WHO" <mrmcos@who.eop.gov>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>, "Gilmartin, Kayleigh M. EOP/WHO" <Kayleigh.McEnany@who.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Boehler, Adam" <Adam.Boehler@dfc.gov>, "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Farah, Alyssa A. EOP/WHO" <Alyssa.A.Farah@who.eop.gov>, "Liddell, Christopher P. EOP/WHO" <Christopher.P.Liddell@who.eop.gov>, "Philbin, Patrick F. EOP/WHO" <Patrick.F.Philbin@who.eop.gov>, "Vought, Russell T. EOP/OMB" <Russell.T.Vought@omb.eop.gov>
Cc: "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "brad.smith@cms.hhs.gov" <brad.smith@cms.hhs.gov>, "Rader, John N. EOP/NSC" <John.N.Rader@nsc.eop.gov>, "Storch, Thomas H. EOP/NSC" <Thomas.H.Storch@nsc.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Butterfield, Nicholas W. EOP/WHO" <Nicholas.W.Butterfield@who.eop.gov>, "Dumbauld, Cassidy M. EOP/WHO" <Cassidy@who.eop.gov>, "Miller, Ovp" <Katie.R.Miller@ovp.eop.gov>, "Keller, Catherine B. EOP/WHO" <Catherine.B.Keller@who.eop.gov>, "Porter, Madison F. EOP/WHO" <Madison.F.Porter@who.eop.gov>
Subject: RE: Testing Strategy

All – Once again, thanks for your input. I've attached the latest documents. We had to implement quite a few comments from the last versions, particularly on the Word Document. My hope is that the changes did not affect the substance, but I've attached a redline for those who might need it. Please review and send any RED FLAGS no later than 700 am tomorrow.

Thanks,
Derek

From: Lyons, Derek S. EOP/WHO
Sent: Saturday, April 25, 2020 7:16 PM
To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; 'Boehler, Adam' <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>; Philbin, Patrick F. EOP/WHO <pfp2dcp@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>
Subject: RE: Testing Strategy

All – Thank you for your input over the past few days. Please find revised documents attached. We are still working on formatting, but the language should be firming up. Please let me know if you have additional comments or edits.

I've added Pat Philbin to this chain for legal review.


Derek

From: Lyons, Derek S. EOP/WHO
Sent: Friday, April 24, 2020 7:59 PM
To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Boehler, Adam <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>
Subject: Testing Strategy

All –

Please see the latest iteration of the testing documents for Monday. If possible, I would appreciate any comments/concerns about noon tomorrow so we can continue to progress. In addition to content, I believe we still need to do the following:

(b) (5)



I also think we probably need to reconvene at some point this weekend to ensure everyone is comfortable with the products before they go live on Monday. We'll work to find a time.

Derek

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/19/2020 1:50:40 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: Re: Germany antibody testing

(b) (4)

S

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 19, 2020 at 1:46:29 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Re: Germany antibody testing

This is (b) (5)

. deb

From: "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Date: Sunday, April 19, 2020 at 1:29 PM
To: Stephen Hahn <SH1@fda.hhs.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Subject: Fwd: Germany antibody testing


Sent from my iPhone

Begin forwarded message:

From: "Hoelscher, Douglas L. EOP/WHO" <Douglas.L.Hoelscher@who.eop.gov>
Date: April 19, 2020 at 11:11:23 AM EDT
To: "Troye, Olivia EOP/NSC" <Olivia.Troye@nsc.eop.gov>, "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "Grogan, Joseph J. EOP/WHO" <Joseph.J.Grogan@who.eop.gov>
Subject: Germany antibody testing

Is there (b) (4)

?



Enable All Features

Find your tools here

Create PDF

Edit PDF

Export PDF

Comment

Organize Pages

Enhance Scans

Protect

Fill & Sign

Store and share files in the Document Cloud

Learn More

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/16/2020 10:28:30 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: PPV

Absolutely correct

Sent from my iPhone

On May 16, 2020, at 6:48 AM, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov> wrote:

If you are (b) (5)

?


From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/14/2020 8:28:47 AM
To: Jones, James J. EOP/OA [James.J.Jones@oa.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Lane, Henry C (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d904337536cf41719032a9359a1ec2ab-HHS-CLANE-n]
CC: Conley, Sean P. CDR USN WHMO/WHMU [Sean.Conley@whmo.mil]; Schmoyer, Michael W. EOP/OSTP [Michael.W.Schmoyer@ostp.eop.gov]; Hartung, Charles S. CAPT USN WHMO/WHMU [Charles.Hartung@whmo.mil]; Ludwig, Michael E. COL USA WHMO/WHMU [Michael.E.Ludwig@whmo.mil]
Subject: Re: Abbott ID Now Testing Question

James,
Here are FDA's responses:

Regarding the Q#1: (b) (5)



(b) (5)




(b) (5)



Question #2 regarding biomedical waste:

A: Although we do not have an objection, FDA would not be the agency to provide this information. We suggest (b) (5)



Glad to provide additional information regarding our answers.
Steve

From: Jones, James J. EOP/OA <James.J.Jones@oa.eop.gov>

Date: May 13, 2020 at 10:25:47 AM EDT

To: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Lane, Henry C (NIH) <clane@niaid.nih.gov>

Cc: Conley, Sean P. CDR USN WHMO/WHMU <Sean.Conley@whmo.mil>, Schmoyer, Michael W. EOP/OSTP <Michael.W.Schmoyer@ostp.eop.gov>, Hartung, Charles S. CAPT USN WHMO/WHMU

<Charles.Hartung@whmo.mil>, Ludwig, Michael E. COL USA WHMO/WHMU <Michael.E.Ludwig@whmo.mil>

Subject: Abbott ID Now Testing Question

Importance: High

Team,

(b) (5). This is time sensitive and we would appreciate your input ASAP on the two questions below. We have received some input from OSD Health Affairs:

#1. For the Abbott Machines (ID NOW), (b) (5)

(b) (5). (b) (5)
? (b) (5)

(b) (5)

Our OSD Health Affairs sent this:

- Per the letter of authorization and instructions for use, the Abbott ID NOW EUA PCR test is for "Authorized laboratories - laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests." AND "Other Authorized Testing Locations - patient care settings using the ID NOW Instrument."

- The FDA website on EUA assays shows the Abbott ID NOW is also a waived test, meaning a Certificate of Waiver is required but the rules on who can perform the test are relaxed (meaning it does not have to be performed by trained laboratory personnel). The device can be used in a high, moderate lab or a waived setting. Waived setting is intended to be a clinic or doctor's office setting under normal circumstances. (Ref: ><https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization><)

- Per the lab SMEs, (b) (5)

(b) (5)
(b) (5)

#2. Biomedical Waste - For the [REDACTED] (b) (5) [REDACTED]
[REDACTED] (b) (5) [REDACTED]
[REDACTED]
[REDACTED]

OSD Health Affairs input:

"CDC and DOT guidance advises to handle laboratory waste from testing suspected or confirmed COVID-19 patient specimens as all other biohazardous waste in the laboratory. Currently, there is no evidence to suggest that this laboratory waste needs any additional packaging or disinfection procedures.

The SARS-CoV-2 is not yet classified by category but SARS-CoV is Per DOT website
(><https://www.phmsa.dot.gov/transporting-infectious-substances/covid-19-information>):<

"The Coronavirus (COVID-19) clinical samples are a "Category B" material for transportation, defined as an infectious substance that is not in a form generally capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure to it occurs. COVID-19 contaminated waste or reusable material derived from the medical treatment of COVID-19 patients is considered regulated medical waste."

In addition the attached PowerPoint document has more detailed information on "Packaging and Shipping SARS-CoV-2 Specimens, Cultures, Isolates, and Waste" states to:

- "Ship suspected and confirmed SARS-CoV-2 patient specimens, isolates, or cultures as UN 3373 Biological Substance, Category B; specimens should be in a sealed, decontaminated primary container

- Handle laboratory waste from testing suspected or confirmed COVID-19 patient specimens as all other biohazardous waste in the laboratory.

Currently, there is no evidence to suggest that this laboratory waste needs any additional packaging or disinfection procedures".

Very Respectfully - James

JAMES J. JONES, MPAS, PhD, PA-C

Chief Medical Advisor

Executive Office of the President

RM 42 EEOB

Office: 202-395-1453

Cell: (b) (6) [REDACTED]

Email: James.J.Jones@oa.eop.gov

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/15/2020 6:01:46 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Subject: Re: Did you all just put out an alert on Abbott ID Now

We put out additional information/guidance. Abbott did as well. We alerted the WH

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: May 14, 2020 at 8:22:43 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: Did you all just put out an alert on Abbott ID Now

Sent from my iPhone

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:25:54 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; Williams, Michael B. EOP/WHO [Michael.B.Williams@who.eop.gov]; DeValliere, Ian C. EOP/WHO [Ian.C.DeValliere@who.eop.gov]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]
Subject: two meetings monday

Steve, could we have two meetings Monday? Another small group follow up with Peter from today, and then our first small group with Dr. Woodcock, on (b) (5). This would be headed another big group on Wednesday.

Janet, Peter understand what Debi is looking for now, but basically it would be (b) (5). Come prepared to tell us what you need to succeed.

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 7:46:16 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]; Shah, Anand [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e2172ebbd96946c08e189fd612855f51-Anand.Shah]
Subject: Re: Remdesivir Distribution Plan

What will be key (b) (5)

. Deb

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Wednesday, May 6, 2020 at 7:35 AM
To: "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Lenihan, Keagan" <Keagan.Lenihan@fda.hhs.gov>, "Shah, Anand" <Anand.Shah@fda.hhs.gov>
Subject: RE: Remdesivir Distribution Plan

Kadlec is involved because this is a donation to the USG which goes through BARDA. FDA, FEMA and the WH have been working with BARDA to facilitate and follow the direction given by Deb. The distribution will not be limited to 7 states. I'm copying Keagan and Anand who have been involved from FDA's perspective.
Steve

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: May 5, 2020 at 6:14:37 PM EDT
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Remdesivir Distribution Plan

Will add to Task Force agenda tomorrow

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Sent: Tuesday, May 5, 2020 5:52 PM
To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Cc: Stephen Hahn (sh1@fda.hhs.gov) <sh1@fda.hhs.gov>
Subject: Re: Remdesivir Distribution Plan

I have not seen the distribution. I asked them (b) (5)

Sent from my iPhone

On May 5, 2020, at 5:45 PM, Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov> wrote:

?? (b) (5) ?

From: Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>
Sent: Tuesday, May 5, 2020 3:26 PM

To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Troye, Olivia EOP/NSC <Olivia.Troye@nsc.eop.gov>
Cc: McMillin, Virginia D. EOP/WHO <Virginia.D.McMillin@who.eop.gov>; Hodgson, Christopher M. EOP/OVP <Christopher.M.Hodgson@ovp.eop.gov>
Subject: Remdesivir Distribution Plan

Hi Marc and Olivia,

Dr. Kadlec told a couple of Senators on a call yesterday that HHS plans to make Remdesivir available in 7 states (including TN). And HHS is supposedly working with FEMA on a joint press release announcing this plan.

Are you or the Task Force tracking anything to this effect?


Thanks,
Nick

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/17/2020 10:25:40 AM
To: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Smith, Brad (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=8533621f52844739852d5dd666488303-HHS-Brad.Sm]; Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA) [nelson.l.michael2.civ@mail.mil]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; CMS SV1 [SV1@cms.hhs.gov]
CC: McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Rinat, Ory S. EOP/WHO [Ory.S.Rinat@who.eop.gov]; Lyons, Derek S. EOP/WHO [Derek.S.Lyons@who.eop.gov]
Subject: Re: By Noon
Attachments: Testing Strategy.pptx

Just a rough draft of what I am working on

From: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>
Date: Friday, April 17, 2020 at 9:31 AM
To: "Giroir, Brett (HHS/OASH)" <Brett.Giroir@hhs.gov>, "Hahn, Stephen" <SH1@fda.hhs.gov>, "Smith, Brad (CMS/OA)" <Brad.Smith@cms.hhs.gov>, "Michael, Nelson L CIV USARMY MEDCOM WRAIR (USA)" <nelson.l.michael2.civ@mail.mil>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, CMS SV1 <SV1@cms.hhs.gov>
Cc: "McGuffee, Tyler Ann A. EOP/OVP" <Tyler.A.McGuffee2@ovp.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Subject: By Noon

We Need for a series of technical briefings today with you all:



Deb

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/27/2020 9:49:58 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-afauci-]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]
Subject: Re: Testing Strategy

Included phase – Bob anything?

From: "Hahn, Stephen" <SH1@fda.hhs.gov>
Date: Monday, April 27, 2020 at 8:29 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Fauci, Anthony S (NIH)" <afauci@niaid.nih.gov>, "Redfield, Robert R (CDC)" <olx1@cdc.gov>
Subject: Re: Testing Strategy

My comments. Sorry, I used my iPad so its a little messy.
What about this for the (b) (5) section?

(b) (5)

Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 27, 2020 at 7:53:40 AM EDT
To: Fauci, Anthony S (NIH) <afauci@niaid.nih.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>
Subject: FW: Testing Strategy

Please review redline word document. I did not participate in the PPT. Deb

From: "Lyons, Derek S. EOP/WHO" <Derek.S.Lyons@who.eop.gov>
Date: Sunday, April 26, 2020 at 8:06 PM
To: "Meadows, Mark R. EOP/WHO" <mrmcos@who.eop.gov>, "Kushner, Jared C. EOP/WHO" <jck@who.eop.gov>, "Hicks, Hope C. EOP/WHO" <Hope@who.eop.gov>, "Gilmartin, Kayleigh M. EOP/WHO" <Kayleigh.McEnany@who.eop.gov>, "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Boehler, Adam" <Adam.Boehler@dfc.gov>, "Short, Marc T. EOP/OVP" <Marc.T.Short@ovp.eop.gov>, "Farah, Alyssa A. EOP/WHO" <Alyssa.A.Farah@who.eop.gov>, "Liddell, Christopher P. EOP/WHO" <Christopher.P.Liddell@who.eop.gov>, "Philbin, Patrick F. EOP/WHO" <Patrick.F.Philbin@who.eop.gov>, "Vought, Russell T. EOP/OMB" <Russell.T.Vought@omb.eop.gov>
Cc: "Kan, Derek T. EOP/OMB" <Derek.T.Kan@omb.eop.gov>, "brad.smith@cms.hhs.gov" <brad.smith@cms.hhs.gov>, "Rader, John N. EOP/NSC" <John.N.Rader@nsc.eop.gov>, "Storch, Thomas H. EOP/NSC" <Thomas.H.Storch@nsc.eop.gov>, "Rinat, Ory S. EOP/WHO" <Ory.S.Rinat@who.eop.gov>, "Butterfield, Nicholas W. EOP/WHO" <Nicholas.W.Butterfield@who.eop.gov>, "Dumbauld, Cassidy M. EOP/WHO" <Cassidy@who.eop.gov>, "Miller, Ovp" <Katie.R.Miller@ovp.eop.gov>, "Keller, Catherine B.

EOP/WHO" <Catherine.B.Keller@who.eop.gov>, "Porter, Madison F. EOP/WHO" <Madison.F.Porter@who.eop.gov>

Subject: RE: Testing Strategy

All – Once again, thanks for your input. I've attached the latest documents. We had to implement quite a few comments from the last versions, particularly on the Word Document. My hope is that the changes did not affect the substance, but I've attached a redline for those who might need it. Please review and send any RED FLAGS no later than 700 am tomorrow.

Thanks,
Derek

From: Lyons, Derek S. EOP/WHO

Sent: Saturday, April 25, 2020 7:16 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; 'Boehler, Adam' <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>; Philbin, Patrick F. EOP/WHO <pfp2dcp@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>

Subject: RE: Testing Strategy

All – Thank you for your input over the past few days. Please find revised documents attached. We are still working on formatting, but the language should be firming up. Please let me know if you have additional comments or edits.

I've added Pat Philbin to this chain for legal review.

Derek

From: Lyons, Derek S. EOP/WHO

Sent: Friday, April 24, 2020 7:59 PM

To: Meadows, Mark R. EOP/WHO <mrmcos@who.eop.gov>; Kushner, Jared C. EOP/WHO <jck@who.eop.gov>; Hicks, Hope C. EOP/WHO <Hope@who.eop.gov>; Gilmartin, Kayleigh M. EOP/WHO <Kayleigh.McEnany@who.eop.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Boehler, Adam <Adam.Boehler@dfc.gov>; Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Farah, Alyssa A. EOP/WHO <Alyssa.A.Farah@who.eop.gov>; Liddell, Christopher P. EOP/WHO <Christopher.P.Liddell@who.eop.gov>
Cc: Kan, Derek T. EOP/OMB <Derek.T.Kan@omb.eop.gov>; 'brad.smith@cms.hhs.gov' <brad.smith@cms.hhs.gov>; Rader, John N. EOP/NSC <John.N.Rader@nsc.eop.gov>; Storch, Thomas H. EOP/NSC <Thomas.H.Storch@nsc.eop.gov>; Rinat, Ory S. EOP/WHO <Ory.S.Rinat@who.eop.gov>; Butterfield, Nicholas W. EOP/WHO <Nicholas.W.Butterfield@who.eop.gov>; Dumbauld, Cassidy M. EOP/WHO <Cassidy@who.eop.gov>

Subject: Testing Strategy

All –

Please see the latest iteration of the testing documents for Monday. If possible, I would appreciate any comments/concerns about noon tomorrow so we can continue to progress. In addition to content, I believe we still need to do the following:

(b) (5)

6. Others?

I also think we probably need to reconvene at some point this weekend to ensure everyone is comfortable with the products before they go live on Monday. We'll work to find a time.

Derek

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/21/2020 8:53:38 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]
Subject: Re: Nation COVID-19 Diagnostic Testing Strategy Needed to Expand Laboratory Test Capacity

Thank you Steve.

Sent from my iPhone

> On Apr 21, 2020, at 8:52 PM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

(b) (5)

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/21/2020 8:34:02 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: What happened to peter Marks?

Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/20/2020 5:37:12 PM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Do we have the neutralization profile on Oxford.

Sent from my iPhone

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/6/2020 6:05:11 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
CC: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd] (b) (6) cms.hhs.gov (b) (6) cms.hhs.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: TIME CHANGE: - Discussion: Clinical Guidelines and Use of Antibody Assays
Location: Ward Room

Start: 5/7/2020 3:30:00 PM
End: 5/7/2020 4:30:00 PM
Show Time As: Busy

Recurrence: (none)

5/7 Agenda

Clinical use of antibody tests

(b) (5)

Attendees:

Dr. Birx
Dr. Hahn
Dr. Redfield
Dr. Fauci
Administrator Verma

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@nsc.eop.gov]; Pottinger, Matthew F. EOP/WHO [MPottinger@who.eop.gov]; Liddell, Christopher P. EOP/WHO [(b) (6)@who.eop.gov]; Riggs, Charlotte R. EOP/WHO [(b) (6)@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; DeValliere, Ian C. EOP/WHO [(b) (6)@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]

Subject: Therapeutics Update

Location: WHSR

Start: 4/20/2020 2:00:00 PM

End: 4/20/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Attendees:

Dr. Hahn

Dr. Redfield

Dr. Birx

Matt Pottinger

Chris Liddell

From: Tyler.A.McGuffee2@ovp.eop.gov [Tyler.A.McGuffee2@ovp.eop.gov]
Sent: 5/11/2020 2:07:34 PM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]

Subject: UPDATED DIAL IN Confirmed - Follow up discussion with Dr. Birx

Attachments: FW: testing, testing, testing

Location: 1-866-617-3597;; Participant Passcode: (b) (6)

Start: 5/11/2020 2:00:00 PM

End: 5/11/2020 2:30:00 PM

Show Time As: Busy

Recurrence: (none)

Dial-In Information

Toll-Free #1-866-617-3597

Participant Passcode: (b) (6)

Leader Passcode: (b) (6)

Attendees:

Dr. Birx

Dr. Fauci

Dr. Hahn

Dr. Redfield

Agenda:

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO (b) (6) who.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO (b) (6) who.eop.gov; Riggs, Charlotte R. EOP/WHO (b) (6) who.eop.gov; Butterfield, Nicholas W. EOP/WHO (b) (6) who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@nsc.eop.gov]
Subject: Therapeutics Meeting
Location: WHSR JFK
Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Tentative
Recurrence: (none)

****There will be no dial-in option****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD BARDA/DOD Vaccine Briefing
Location: WHSR

Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)


[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[b] (6) [b] (6) Vought, Russell T. EOP/OMB [b] (6) [b] (6) Bruno, Grace A.
EOP/OMB [b] (6) [b] (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[b] (6)
Cytryn, Jen B. EOP/WHO [b] (6) who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] (6) Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [b] (6)
[b] (6) cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[b] (6) Pottinger, Matthew F. EOP/WHO [b] (6) who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[b] (6) Kellogg, Joseph Keith K. Jr. EOP/OVP [b] (6) ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [b] (6) who.eop.gov];
Williams, Michael B. EOP/WHO [b] (6) who.eop.gov]

Subject: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Conant, Ann M. EOP/OMB [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@who.eop.gov]; Cytryn, Jen B. EOP/WHO [(b) (6)] Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6)] Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; CMS [(b) (6)] cms.hhs.gov; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@who.eop.gov]; Pottinger, Matthew F. EOP/WHO [(b) (6)] Ferro, Phil J. EOP/NSC [Philip.J.Ferro@ovp.eop.gov]; Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [(b) (6)] DeValliere, Ian C. EOP/WHO [(b) (6)] Williams, Michael B. EOP/WHO [(b) (6)]

Subject: HOLD NIH Therapeutics Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birx, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); CMS [(b) (6)] Sheehy, Janice; Hahn, Stephen; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Kellogg, Joseph Keith K. Jr. EOP/OVP; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO
Subject: HOLD NIH Therapeutics Briefing
When: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [REDACTED] ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [REDACTED] (OS/IOS)
[REDACTED] HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

[REDACTED]

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/17/2020 5:59:06 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@[b] (6) Pottinger, Matthew F. EOP/WHO [b] (6) who.eop.gov]; Liddell, Christopher P. EOP/WHO [b] (6) who.eop.gov]; Riggs, Charlotte R. EOP/WHO [b] (6) who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; DeValliere, Ian C. EOP/WHO [b] (6) who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]

Subject: Therapeutics Update
Location: WHSR

Start: 4/20/2020 2:00:00 PM
End: 4/20/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Attendees:

Dr. Hahn
Dr. Redfield
Dr. Birx
Matt Pottinger
Chris Liddell

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 4/30/2020 10:52:54 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; (b) (6) cms.hhs.gov (b) (6) cms.hhs.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Confirmed - Dr. Birx call w/ ACOG/AAP Leadership
Location: Dr. Birx office; 877-628-4681; (b) (6)
Start: 4/30/2020 2:15:00 PM
End: 4/30/2020 2:30:00 PM
Show Time As: Tentative

Recurrence: (none)

Dial In: 877-628-4681

Participant: (b) (6)

ACOG participants:

Maureen Phipps, MD, MPH, FACOG – CEO
Skye Perryman, JD – Chief Legal Officer and General Counsel
Rachel Tetlow, Federal Affairs Director

AAP participants:

Mark DelMonte, CEO
Tamar Haro, Senior Director, Federal and State Advocacy

ACOG/AAP Agenda:

- Opening and thanks (*Mark and Maureen*)
- HHS funding for physicians and hospitals – concerns with distribution (*Mark and Maureen*)
- Immunization rates (*Mark*)
- Continued concerns regarding home birth/birth settings (*Maureen and Mark*)
- Opportunity to partner in the lead up to Mother's Day (*Maureen*)
- PPE & Testing shortages (*Maureen and Mark*)
- Prioritization of L&D for rapid response testing
-

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 5/1/2020 5:31:38 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6)] Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; (b) (6) cms.hhs.gov; Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6)] Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredith]; Tignor, Beth (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=44f3651e3b164ef786d33dc18b5112a4-HHS-Beth.Ti]; Liddell, Christopher P. EOP/WHO [(b) (6)] who.eop.gov; Riggs, Charlotte R. EOP/WHO [(b) (6)] who.eop.gov; Butterfield, Nicholas W. EOP/WHO [(b) (6)] who.eop.gov; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]; Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@ (b) (6)]
Subject: Therapeutics Meeting
Location: WHSR JFK
Start: 5/4/2020 1:15:00 PM
End: 5/4/2020 2:15:00 PM
Show Time As: Busy
Recurrence: (none)

****There will be no dial-in option****

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValiere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]
Subject: Therapeutics and Vaccine Briefing
Location: WHSR
Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Busy
Recurrence: (none)

[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[b] (6) [b] (6) Vought, Russell T. EOP/OMB [b] (6) [b] (6) Bruno, Grace A.
EOP/OMB [b] (6) [b] (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[b] (6)
Cytryn, Jen B. EOP/WHO [b] (6) who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] (6) Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [b] (6)
[b] (6) cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[b] (6) Pottinger, Matthew F. EOP/WHO [b] (6) who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[b] (6) Kellogg, Joseph Keith K. Jr. EOP/OVP [b] (6) ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [b] (6) who.eop.gov]; DeValiere, Ian C. EOP/WHO [b] (6) who.eop.gov];
Williams, Michael B. EOP/WHO [b] (6) who.eop.gov]
Subject: HOLD BARDA/DOD Vaccine Briefing
Location: WHSR
Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Busy
Recurrence: (none)

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD NIH Therapeutics/Vaccines Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

(b) (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Conant, Ann M. EOP/OMB [(b) (6)] Vought, Russell T. EOP/OMB [(b) (6)] Bruno, Grace A. EOP/OMB [(b) (6)] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@ (b) (6)] Cytryn, Jen B. EOP/WHO [(b) (6)] who.eop.gov; Miller, Stephen EOP/WHO [Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [(b) (6)] ovp.eop.gov; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@ (b) (6)] Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6)] Conrad, Patricia L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith (CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [(b) (6)] cms.hhs.gov; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Holt, Brandon T. EOP/NSC [Brandon.T.Holt@ (b) (6)] Pottinger, Matthew F. EOP/WHO [(b) (6)] who.eop.gov; Ferro, Phil J. EOP/NSC [Philip.J.Ferro@ (b) (6)] Kellogg, Joseph Keith K. Jr. EOP/OVP [(b) (6)] ovp.eop.gov; Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D. EOP/WHO [Alexandra.D.Campana2@who.eop.gov]; DeValliere, Ian C. EOP/WHO [(b) (6)] who.eop.gov; Williams, Michael B. EOP/WHO [(b) (6)] who.eop.gov
Subject: HOLD NIH Therapeutics Briefing
Location: WHSR
Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Busy

-----Original Appointment-----

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Sent: Friday, April 24, 2020 1:43 PM
To: Grogan, Joseph J. EOP/WHO; Conant, Ann M. EOP/OMB; Vought, Russell T. EOP/OMB; Bruno, Grace A. EOP/OMB; D'Angelo, Gregory B. EOP/OMB; Cytryn, Jen B. EOP/WHO; Miller, Stephen EOP/WHO; McGuffee, Tyler Ann A. EOP/OVP; Birx, Deborah L. EOP/NSC; Fauci, Anthony S (NIH); Conrad, Patricia L (NIH); Good-Cohn, Meredith (CMS); CMS [(b) (6)] Sheehy, Janice; Hahn, Stephen; Holt, Brandon T. EOP/NSC; Pottinger, Matthew F. EOP/WHO; Ferro, Phil J. EOP/NSC; Kellogg, Joseph Keith K. Jr. EOP/OVP; Williams, Teresa (CDC); Redfield, Robert R (CDC); Campana, Alexandra D. EOP/WHO; DeValliere, Ian C. EOP/WHO; Williams, Michael B. EOP/WHO
Subject: HOLD NIH Therapeutics Briefing
When: Monday, April 27, 2020 2:00 PM-2:50 PM (UTC-05:00) Eastern Time (US & Canada).
Where: WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[b] (6) [b] (6) Vought, Russell T. EOP/OMB [b] (6) [b] (6) Bruno, Grace A.
EOP/OMB [b] (6) [b] (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[b] (6)
Cytryn, Jen B. EOP/WHO [b] (6) who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] (6) Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [b] (6)
[b] (6) cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[b] (6) Pottinger, Matthew F. EOP/WHO [b] (6) who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[b] (6) Kellogg, Joseph Keith K. Jr. EOP/OVP [b] (6) ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [b] (6) who.eop.gov]; DeValiere, Ian C. EOP/WHO [b] (6) who.eop.gov];
Williams, Michael B. EOP/WHO [b] (6) who.eop.gov]

Subject: HOLD BARDA/DOD Therapeutics Briefing
Location: WHSR

Start: 4/29/2020 2:00:00 PM
End: 4/29/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)

[b] (5)

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [REDACTED] (OS/IOS)
[REDACTED] HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Tentative
Recurrence: (none)

[REDACTED]

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 1:43:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]

Subject: HOLD NIH Therapeutics Briefing
Location: WHSR

Start: 4/27/2020 2:00:00 PM
End: 4/27/2020 2:50:00 PM
Show Time As: Tentative

Recurrence: (none)


[REDACTED]

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[REDACTED] Vought, Russell T. EOP/OMB [REDACTED] Bruno, Grace A.
EOP/OMB [REDACTED] D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[REDACTED]]
Cytryn, Jen B. EOP/WHO [REDACTED] who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[REDACTED]] Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [REDACTED]
[REDACTED] cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[REDACTED]] Pottinger, Matthew F. EOP/WHO [REDACTED] who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[REDACTED]] Kellogg, Joseph Keith K. Jr. EOP/OVP [REDACTED] ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [REDACTED] who.eop.gov]; DeValliere, Ian C. EOP/WHO [REDACTED] who.eop.gov];
Williams, Michael B. EOP/WHO [REDACTED] who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Boyd, Charlton J. EOP/WHO
[REDACTED] who.eop.gov]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [REDACTED] (OS/IOS)
[REDACTED] HHS.GOV]; Jon Woolfolk [gjonwoolfolk@yahoo.com]; DL OVP NSA EXECSEC
[DL.OVP.NSAEXECSEC@OVP.eop.gov]; OVP NSA Plans and Ops Calendar
[OVPNSAPlansandOpsCalendar@OVP.eop.gov]; Woolfolk, Jon J. EOP/OVP [REDACTED] ovp.eop.gov];
Fisher, Garrett C. EOP/OVP [REDACTED] ovp.eop.gov]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

(b) (5)

(b) (5)



From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/24/2020 3:10:17 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Conant, Ann M. EOP/OMB
[b] (6) [b] (6) Vought, Russell T. EOP/OMB [b] (6) [b] (6) Bruno, Grace A.
EOP/OMB [b] (6) [b] (6) D'Angelo, Gregory B. EOP/OMB [Gregory.B.D'Angelo@[b] (6)
Cytryn, Jen B. EOP/WHO [b] (6) who.eop.gov]; Miller, Stephen EOP/WHO
[Stephen.Miller@who.eop.gov]; McGuffee, Tyler Ann A. EOP/OVP [Tyler.A.McGuffee2@ovp.eop.gov]; Birx, Deborah
L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative
Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-[b] (6) Conrad, Patricia
L (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=e30cd6224aeb49c795844f43fd78a049-HHS-conradp]; Good-Cohn, Meredith
(CMS) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=5e06154b83bb4cb8a7b01816905e1300-HHS-Meredit]; CMS [b] (6)
[b] (6) cms.hhs.gov]; Sheehy, Janice [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=f45a6c96f5274724a1be5970eb648ff7-JSheehy]; Hahn, Stephen
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Holt, Brandon T.
EOP/NSC [Brandon.T.Holt@[b] (6) Pottinger, Matthew F. EOP/WHO [b] (6) who.eop.gov]; Ferro, Phil J.
EOP/NSC [Philip.J.Ferro@[b] (6) Kellogg, Joseph Keith K. Jr. EOP/OVP [b] (6) ovp.eop.gov];
Williams, Teresa (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=c32e463e6c48413a9e21cb26fea9251b-HHS-coo4-cd]; Redfield, Robert R
(CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Campana, Alexandra D.
EOP/WHO [b] (6) who.eop.gov]; DeValiere, Ian C. EOP/WHO [b] (6) who.eop.gov];
Williams, Michael B. EOP/WHO [b] (6) who.eop.gov]; Mango, Paul (OS)
[/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=2fe1932caf0249d2a0c6af5fb82c9ec5-HHS-Paul.Ma]; Troye, Olivia EOP/NSC
[Olivia.Troye@nsc.eop.gov]
CC: Bonner, Maria K. EOP/WHO [Maria.K.Bonner@who.eop.gov]; Marks, Peter [/o=ExchangeLabs/ou=Exchange
Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP];
Woodcock, Janet [/o=ExchangeLabs/ou=Exchange Administrative Group
(FYDIBOHF23SPDLT)/cn=Recipients/cn=7b0453354a9a427db0a66a86c7a36f3d-Janet.Woodc]; [b] (6) (OS/IOS)
[b] (6) HHS.GOV]
Subject: Therapeutics and Vaccine Briefing
Attachments: Vaccine Therapeutic Meeting Expectations and Questions_04282020.docx; NYT_In Race for a Coronavirus Vaccine,
an Oxford Group Leaps Ahead_04282020.pdf
Location: WHSR JFK
Start: 4/29/2020 1:45:00 PM
End: 4/29/2020 2:30:00 PM
Show Time As: Busy
Recurrence: (none)

Please note the new start time of 1:45 PM due to conflicts in the WHSR

(b) (5)

(b) (5)



From: Droegemeier, Kelvin K. EOP/OSTP [(b) (6)]@ostp.eop.gov]
Sent: 4/3/2020 11:05:14 AM
To: Holt, Brandon T. EOP/NSC [(b) (6)]@nsc.eop.gov]; Clancy, Carolyn [Carolyn.Clancy@va.gov]; Klote, Mary M. [Mary.Klote@va.gov]; Justice, Amy [Amy.Justice2@va.gov]; Bates, Jack (BISL) [Jack.Bates@va.gov]; Francis, Joe [Joe.Francis@va.gov]; Quinn, John F. (NDS) [John.Quinn@va.gov]; Box, Tami [Tamara.Box@va.gov]; Ramoni, Rachel [Rachel.Ramoni@va.gov]; Muralidhar, Sumitra [Sumitra.Muralidhar@va.gov]; Brouillette, Dan [dan.brouillette@hq.doe.gov]; Dabbar, Paul [paul.dabbar@hq.doe.gov]; Abernethy, Amy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c84171967c724ee799bb2658197086bc-Amy.Abernet]; Watson, Ian D. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Pottinger, Matthew F. EOP/WHC [(b) (6)]@who.eop.gov]; Fabina, Lauren C. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC [(b) (6)]@nsc.eop.gov]; Tully, Ryan M. EOP/NSC [(b) (6)]@nsc.eop.gov]; Kratsios, Michael J. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Parker, Lynne E. EOP/OSTP [(b) (6)]@ostp.eop.gov]
CC: Hennessey, Millicent S. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ferro, Phil J. EOP/NSC [(b) (6)]@nsc.eop.gov]
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Hi all,

I'm adding Michael Kratsios and Lynne Parker re (b) (5)

Kelvin

From: Holt, Brandon T. EOP/NSC [(b) (6)]@nsc.eop.gov
Sent: Friday, April 3, 2020 10:36 AM
To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Waterman, Paige E. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [(b) (6)]@ostp.eop.gov]; Pottinger, Matthew F. EOP/WHO [(b) (6)]@who.eop.gov]; Fabina, Lauren C. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ruggiero, Anthony J. EOP/NSC [(b) (6)]@nsc.eop.gov]; Tully, Ryan M. EOP/NSC [(b) (6)]@nsc.eop.gov
Cc: Hennessey, Millicent S. EOP/NSC [(b) (6)]@nsc.eop.gov]; Ferro, Phil J. EOP/NSC [(b) (6)]@nsc.eop.gov
Subject: RE: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good morning all,

Could we please lock in this call for 12:30pm? Please see call-in information below. Thank you!

Participant Dial-In: (202) 395-6392

Participant Code [(b) (6)]

Best,
Brandon

Brandon T. Holt

Office of the National Security Advisor

D[(b) (6)]

From: Ferro, Phil J. EOP/NSC (b) (6) @nsc.eop.gov>

Sent: Friday, April 3, 2020 10:30 AM

To: Clancy, Carolyn <Carolyn.Clancy@va.gov>; Klote, Mary M. <Mary.Klote@va.gov>; Justice, Amy <Amy.Justice2@va.gov>; Bates, Jack (BISL) <Jack.Bates@va.gov>; Francis, Joe <Joe.Francis@va.gov>; Quinn, John F. (NDS) <John.Quinn@va.gov>; Box, Tami <Tamara.Box@va.gov>; Ramoni, Rachel <Rachel.Ramoni@va.gov>; Muralidhar, Sumitra <Sumitra.Muralidhar@va.gov>; Brouillette, Dan <dan.brouillette@hq.doe.gov>; Dabbar, Paul <paul.dabbar@hq.doe.gov>; Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Watson, Ian D. EOP/OSTP (b) (6) @ostp.eop.gov>; Waterman, Paige E. EOP/OSTP (b) (6) @ostp.eop.gov>; Droegemeier, Kelvin K. EOP/OSTP <(b) (6) @ostp.eop.gov>; Pottinger, Matthew F. EOP/WHO (b) (6) @who.eop.gov>; Fabina, Lauren C. EOP/NSC (b) (6) @nsc.eop.gov>; Ruggiero, Anthony J. EOP/NSC (b) (6) @nsc.eop.gov>; Tully, Ryan M. EOP/NSC (b) (6) @nsc.eop.gov>
Cc: Holt, Brandon T. EOP/NSC <(b) (6) @nsc.eop.gov>; Hennessey, Millicent S. EOP/NSC (b) (6) @nsc.eop.gov>

Subject: Big Data for COVID-19 Insights Coordination Call between EOP, VA, DoE and FDA

Good Morning Colleagues,

First off, thank you for your robust support to get this initiative off the ground as quickly as possible. (b) (5)

We would like to convene a call this afternoon to coordinate efforts. Brandon Holt who works for APDNSA Pottinger will work with you and your staff to schedule this call. To this end, please feel free to have your staff respond to Brandon. We will send out an agenda shortly.

Please let me know if you have any questions or if I may be of assistance.

All the best,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
202.456.1222 (O) (b) (6) (cell)
Philip.J.Ferro@nsc.eop.gov

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/15/2020 1:56:41 PM
To: Joe Grogan [Joseph.J.Grogan@who.eop.gov]; Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Quick description of our app

Nicely categorized but what should be the next steps?

From: Kratsios, Michael J. EOP/OSTP (b) (6)@ostp.eop.gov>
Date: April 15, 2020 at 8:52:58 AM EDT
To: Liddell, Christopher P. EOP/WHO (b) (6)who.eop.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)niaid.nih.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Seema Verma <(b) (6)cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>, Butterfield, Nicholas W. EOP/WHO <(b) (6)who.eop.gov>, Droegemeier, Kelvin K. EOP/OSTP <(b) (6)ostp.eop.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 5:13:06 PM
To: Liddell, Christopher P. EOP/WHO [(b) (6) who.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Kratsios, Michael J. EOP/OSTP [Michael.J.Kratsios@ostp.eop.gov]
CC: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; Seema Verma [(b) (6) @cms.hhs.gov]; Sharpless, Norman E (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d860d490594f4675960aad587639ed9c-HHS-norman.]; Tromberg, Bruce J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089fb4d6fa44f82bea7b1016d4d4d5d-HHS-bruce.t]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]; Butterfield, Nicholas W. EOP/WHO [(b) (6) who.eop.gov]; Droegemeier, Kelvin K. EOP/OSTP [(b) (6) ostp.eop.gov]
Subject: RE: Quick description of our app

Michael,

[(b) (5)]? I am happy to facilitate.
Steve

From: Liddell, Christopher P. EOP/WHO <[(b) (6) who.eop.gov>
Date: April 14, 2020 at 5:11:38 PM EDT
To: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Fauci, Anthony S (NIH) <[(b) (6) niaid.nih.gov>, Kratsios, Michael J. EOP/OSTP <Michael.J.Kratsios@ostp.eop.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>, Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Seema Verma <[(b) (6) cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>, Butterfield, Nicholas W. EOP/WHO <[(b) (6) who.eop.gov>, Droegemeier, Kelvin K. EOP/OSTP <[(b) (6) ostp.eop.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 6:51:47 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Debi Birx MD [Deborah.L.Birx@nsc.eop.gov]; Jared Kushner [Jck@who.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9dd983419fcd-HHS-olx1-cd]; Joe Grogan [Joseph.J.Grogan@who.eop.gov]; Seema Verma [sv1@cms.hhs.gov]
CC: Sharpless, Norman E (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d860d490594f4675960aad587639ed9c-HHS-norman.]; Tromberg, Bruce J (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5089fb4d6fa44f82bea7b1016d4d4d5d-HHS-bruce.t]; Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
Subject: RE: Quick description of our app

Thanks, Tony. (b) (5)
Steve

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>
Date: April 13, 2020 at 10:08:28 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Debi Birx MD <Deborah.L.Birx@nsc.eop.gov>, Jared Kushner <Jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Joe Grogan <Joseph.J.Grogan@who.eop.gov>, Seema Verma <(b) (6)cms.hhs.gov>
Cc: Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>
Subject: RE: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/14/2020 9:12:55 AM
To: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
CC: Tyler Ann McGuffee [Tyler.A.McGuffee2@ovp.eop.gov]; Rom, Colin [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f59636221f4340d697dbd43ee27255fb-Colin.Rom]
Subject: Re: Quick description of our app

Debi,

Follow up for you re: the Abbott meeting. They completely understood your point about the usage of the PoC serology test.

The CEO wanted me to pass along that the sensitivity/specificity information they gave us was a composite of IgG and IgM. [REDACTED] (b) (4) [REDACTED] (b) (5)

I also had a conversation with them about manufacturing ramp up and there is some flexibility. [REDACTED] (b) (5)

Thanks
Steve

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Date: April 14, 2020 at 6:56:23 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Fauci, Anthony S (NIH) <[REDACTED] (b) (6)niaid.nih.gov>, Kushner, Jared C. EOP/WHO <jck@who.eop.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>, Seema Verma <[REDACTED] (b) (6)cms.hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Tromberg, Bruce J (NIH) <bruce.tromberg@nih.gov>, Collins, Francis S (NIH) <collinsf@od.nih.gov>
Subject: Re: Quick description of our app

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/13/2020 8:24:39 AM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
CC: Lenihan, Keagan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee7320ee8c184d66bfd521b0105d17d2-Keagan.Leni]
Subject: Re: list of essential tests and items from China

Joe,
Thank you. [REDACTED] (b) (5)? Keagan, let's talk.
Steve

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 13, 2020 at 8:23:50 AM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Subject: list of essential tests and items from China

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/12/2020 5:07:20 PM
To: Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Suggest you get set-up as [REDACTED] (b) (5)

Perhaps we can discuss?

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 12, 2020 at 12:54:00 PM EDT
To: Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>, Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Suggest you get set-up as [REDACTED] (b) (5)

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/12/2020 4:55:45 PM
To: Joe Grogan [Joseph.J.Grogan@who.eop.gov]
Subject: Fwd: Suggest you get set-up as [REDACTED] (b) (5)

We definitely need some help here.

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 12, 2020 at 2:28:00 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Sharpless, Norman E (NIH) <norman.sharpless@nih.gov>
Cc: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Suggest you get set-up as a [REDACTED] (b) (5)

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/7/2020 5:57:38 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Joe Grogan [Joseph.J.Grogan@who.eop.gov]
Subject: Fwd: Potential Adverse Impact of (b) (5) Policy

FYSA

(b) (5)

?

Steve

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 7, 2020 at 5:20:56 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: Potential Adverse Impact of (b) (5) Policy

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/7/2020 6:21:41 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: Potential Adverse Impact of (b) (5) Policy

Will do

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: April 7, 2020 at 6:20:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: RE: Potential Adverse Impact of (b) (5) Policy

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/6/2020 5:29:24 PM
To: Debi Birx [Deborah.L.Birx@nsc.eop.gov]
Subject: Fwd: Finger sticks

FYSA

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 3, 2020 at 1:16:36 PM EDT
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Beckham, Tammy (OS) <Tammy.Beckham@hhs.gov>
Subject: RE: Finger sticks

From: SH1@fda.hhs.gov [SH1@fda.hhs.gov]
Sent: 4/21/2020 1:40:09 PM
To: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: FYI: Information request to ANSM on CV risks from chloroquine/hydroxychloroquine

Yes and I called Mark Meadows and left him a message.

From: Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Date: April 21, 2020 at 1:33:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: FYI: Information request to ANSM on CV risks from chloroquine/hydroxychloroquine

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/3/2020 7:15:38 AM
To: Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Adams, Jerome (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; Birx, Deborah L (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2e45952d70d4e2d84d839843f3cda9f-HHS-emg5-cd]; Deborah.L.Birx@nsc.eop.gov; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS-(b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]
Subject: RE: Mask

Jerome,

[REDACTED] (b) (5)
[REDACTED]
[REDACTED]

Steve

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Date: April 3, 2020 at 6:42:41 AM EDT
To: Adams, Jerome (OS) <Jerome.Adams@hhs.gov>, Birx, Deborah L (CDC) <emg5@cdc.gov>, Deborah.L.Birx@nsc.eop.gov <Deborah.L.Birx@nsc.eop.gov>, Fauci, Anthony S (NIH) <(b) (6)@niaid.nih.gov>, Redfield, Robert R (CDC) <olx1@cdc.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Kadlec, Robert P (OS) <Robert.Kadlec@hhs.gov>
Subject: RE: Mask

[REDACTED] (b) (5)
[REDACTED]

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

-----Original Message-----

From: Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>
Sent: Friday, April 3, 2020 6:41 AM
To: Birx, Deborah (CDC/OD) <emg5@cdc.gov>; Deborah.L.Birx@nsc.eop.gov; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)@niaid.nih.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Stephen Hahn <SH1@fda.hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Subject: Mask

(b) (5)

Jerome

VADM Jerome Adams
20th US Surgeon General

From: Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Sent: 4/4/2020 8:52:13 AM
To: Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]
Subject: Re: Hydroxychloroquine

Yes 5 minutes

Sent from my iPhone

On Apr 4, 2020, at 8:42 AM, Hahn, Stephen <SH1@fda.hhs.gov> wrote:

Joe,
FYI. Do you have time for a call this morning?
Steve

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>
Date: April 3, 2020 at 5:15:31 PM EDT
To: Schuchat, Anne (CDC) <acs1@cdc.gov>, Messonnier, Nancy E (CDC) <nar5@cdc.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Hahn, Stephen <SH1@fda.hhs.gov>, Brooks, John T (CDC) <zud4@cdc.gov>
Subject: RE: Hydroxychloroquine

Afternoon all,

Studies described in the attached

Dosing in each as follows:

- Gautret: Hydroxychloroquine sulfate (HCQ) 200 mg tid (600 mg/d) for ten days
- Chen J: HCQ 400 mg/d for 5 days (in Chinese and so can't tell if 400 mg was 200 mg bid)
- Chen Z: HCQ 400 mg/d (200 mg bid) between days 1 and 5
- Molina: HCQ 600 mg/d for 10 days using the same dosing regimen reported by Gautret et al.

Cheers,

-john

John T. Brooks, MD

Chief Medical Officer, CDC COVID-19 Response

Email: zud4@cdc.gov

Apologies for errors in my messages that may be due to my need to dictate.

<image002.jpg>

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Sent: Friday, April 3, 2020 5:04 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: RE: Hydroxychloroquine

Can you resend me your science update – it has dose from the trial in IJAA anyway...

From: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Sent: Friday, April 3, 2020 5:02 PM

To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Subject: RE: Hydroxychloroquine

Hard to know. It was specifically removed from the CDC online document because of concerns that persons might prescribe outside of established study protocols.

I can [REDACTED] (b) (5)

[REDACTED] I know at least five infectious disease doctors now who have had COVID-19 and chose to try hydroxychloroquine. Which by the way i did not endorse :)

John T. Brooks, MD

Chief Medical Officer, CDC COVID-19 Response

Email: zud4@cdc.gov

Apologies for errors in my messages that may be due to my need to dictate.

<image006.jpg>

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>

Sent: Friday, April 3, 2020 5:00 PM

To: Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) <zud4@cdc.gov>

Subject: FW: Hydroxychloroquine

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, April 3, 2020 4:59 PM

To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>

Cc: Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>

Subject: RE: Hydroxychloroquine

(b) (5)

Can I get help from CDC?

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Sent: Friday, April 3, 2020 4:54 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Hahn, Stephen <SH1@fda.hhs.gov>

Subject: RE: Hydroxychloroquine

Think CDC would have to give you that, since this would be considered off label use.

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, April 3, 2020 4:37 PM

To: Hahn, Stephen <SH1@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>

Subject: Hydroxychloroquine

(b) (5)

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

<COVID-19 Science Update - Special Topic CQ-HCQ - 2020-04-03 - FINAL.pdf>

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 5/11/2020 7:52:03 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6) Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffbdd983419fcd-HHS-olx1-cd]; Adams, Jerome (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=302991451fc341bf9a7ffa53eba3f81c-HHS-Jerome.]; Kadlec, Robert P (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=70539a2f88924cc8913781ea74278b12-HHS-Robert.]
CC: Collins, Francis S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5257472fae794b85b15c27eb54598d70-HHS-collins]
Subject: Re: testing, testing, testing

Morning all,

[REDACTED] (b) (5)
[REDACTED] Brett, very much appreciate all of the work that has gone into our testing efforts.
Steve

From: Tony Fauci <(b) (6)niaid.nih.gov>
Date: Sunday, May 10, 2020 at 8:41 PM
To: Brett Giroir <Brett.Giroir@hhs.gov>, Debi Birx <Deborah.L.Birx@nsc.eop.gov>, Robert Redfield <olx1@cdc.gov>, Stephen Hahn <SH1@fda.hhs.gov>, Jerome Adams <Jerome.Adams@hhs.gov>, Robert Kadlec <Robert.Kadlec@hhs.gov>
Cc: Francis Collins <(b) (6)od.nih.gov>
Subject: RE: testing, testing, testing

Brett:
Thanks for the note. I look forward to discussing this with you.
Best regards,
Tony

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Sunday, May 10, 2020 5:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>; Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; SH1 (fda.hhs.gov) <SH1@fda.hhs.gov>; Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Cc: Collins, Francis (NIH/OD) [E] <collinsf@od.nih.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Subject: RE: testing, testing, testing

Tony,

(b) (5)

(b) (5)

Happy to discuss next time we meet.

BG

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>
Sent: Sunday, May 10, 2020 4:28 PM
To: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; SH1 (fda.hhs.gov) <SH1@fda.hhs.gov>; Adams, Jerome (HHS/OASH) <Jerome.Adams@hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Kadlec, Robert (OS/ASPR/IO) <Robert.Kadlec@hhs.gov>
Subject: testing, testing, testing

Folks:

The link below is an article by Harold Varmus representing the deliberations of 10 world-class scientists. It

(b) (5)

(b) (5) This article is worth a read. Maybe we can discuss it the next time we meet, which might be virtual.

<https://www.theatlantic.com/ideas/archive/2020/05/lack-testing-holding-science-back/611422/>

Thanks,
Tony

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/3/2020 1:05:22 PM
To: Polowczyk, John P RADM USN JS J4 (USA) [john.p.polowczyk.mil@mail.mil]; Hahn, Stephen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a0afac0cfa3c4b98913833e38a036e9f-Stephen.Hah]; Giroir, Brett (OS) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ee4c4234d3834c77a4a1a7b1a7c176a2-HHS-Brett.G]; Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb983419fcd-HHS-olx1-cd]
CC: Kushner, Jared C. EOP/WHO [jck@who.eop.gov]; Pete Gaynor [pete.gaynor@fema.dhs.gov]; Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS (b) (6)]
Subject: Re: Remdesivir Allocation

John

(b) (5)

On 5/2/20, 9:19 AM, "Polowczyk, John P RADM USN JS J4 (USA)" <john.p.polowczyk.mil@mail.mil> wrote:

Dr Birx

(b) (5)

V/r John
John Polowczyk
Rear Admiral USN
(C) 571 423 6676
John.p.polowczyk.mil@mail.mil

From: Birx, Deborah L. EOP/NSC [Deborah.L.Birx@nsc.eop.gov]
Sent: 5/13/2020 10:49:04 AM
To: Fauci, Anthony S (NIH) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=759a71a9291b47a2bf83b77989d40cc3-HHS- (b) (6) Redfield, Robert R (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0f1ab650905f424381ffb9d983419fcd-HHS-olx1-cd]; FDA Commissioner [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1e34b2c290a94c4a8d7af884727cd0f8-Commissioner]
Subject: Re: (b) (5)

(b) (5). Deb

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)niaid.nih.gov>
Date: Wednesday, May 13, 2020 at 10:39 AM
To: "Birx, Deborah L. EOP/NSC" <Deborah.L.Birx@nsc.eop.gov>, "Redfield, Robert R. (CDC/OD)" <olx1@cdc.gov>, "Hahn, Stephen (FDA)" <Stephen.Hahn@fda.hhs.gov>
Subject: RE: (b) (5)

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases

(b) (6)

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Birx, Deborah L. EOP/NSC <Deborah.L.Birx@nsc.eop.gov>
Sent: Wednesday, May 13, 2020 10:24 AM
To: Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)niaid.nih.gov>; Hahn, Stephen (FDA) <Stephen.Hahn@fda.hhs.gov>
Subject: (b) (5)

(b) (5)

deb

From: Hahn, Stephen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=A0AFAC0CFA3C4B98913833E38A036E9F-STEPHEN.HAH]
Sent: 4/7/2020 6:21:32 PM
To: Short, Marc T. EOP/OVP [Marc.T.Short@ovp.eop.gov]; Grogan, Joseph J. EOP/WHO [Joseph.J.Grogan@who.eop.gov]
Subject: RE: [REDACTED] (b) (5)

Will do

From: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>
Date: April 7, 2020 at 6:20:38 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>, Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: RE: [REDACTED] (b) (5)

Thank you. (b) (5)

(b) (5)

From: Hahn, Stephen <SH1@fda.hhs.gov>
Sent: Tuesday, April 7, 2020 5:58 PM
To: Short, Marc T. EOP/OVP <Marc.T.Short@ovp.eop.gov>; Grogan, Joseph J. EOP/WHO <Joseph.J.Grogan@who.eop.gov>
Subject: Fwd: [REDACTED] (b) (5)

FYSA

(b) (5)

Steve

From: Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Date: April 7, 2020 at 5:20:56 PM EDT
To: Hahn, Stephen <SH1@fda.hhs.gov>
Cc: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>, Shah, Anand <Anand.Shah@fda.hhs.gov>, Rom, Colin <Colin.Rom@fda.hhs.gov>, Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>
Subject: [REDACTED] (b) (5)

(b) (5)

From: Ross, Bruce <Bruce.Ross@fda.hhs.gov>

Sent: Tuesday, April 7, 2020 7:40 AM

To: 2019-nCoV FDA IMG Leadership <2019-nCoVFDAIMGLeadership@fda.hhs.gov>; Courtney, Brooke <Brooke.Courtney@fda.hhs.gov>

Cc: Abdoo, Mark <Mark.Abdoo@fda.hhs.gov>; 2019-nCoV FDA IMG Operations Supply Chain <2019-nCoV-FDA-IMG-Operations-Supply-Chain@fda.hhs.gov>; Serrano, Katherine M <Katherine.Serrano@fda.hhs.gov>; Rodriguez, Michelle <Michelle.Rodriguez@fda.hhs.gov>

Subject: FW: Need Help with Supply Chain!

Sharing for awareness....messaging received from AdvaMed regarding challenges in (b) (4) due to lack of PPE....

Bruce Ross, MA, MPH
Director, (Acting)

Office of Global Operations
Office of Global Policy and Strategy

COVID-19 Outbreak Response, FDA IMG Logistics – Repatriation

Tel: 240-402-2866
Mobile: 240-515-5217
E-mail: Bruce.Ross@fda.hhs.gov

From: Ives, Ralph <Rives@AdvaMed.org>

Sent: Tuesday, April 07, 2020 7:22 AM

Subject: Need Help with Supply Chain!

All,

(b) (4)

I did not realize export restrictions were applied across the board for all manufacturers – beyond 3M. We will get more info later.

We would greatly appreciate your help!

Thank you,
Ralph

Ralph F. Ives
Executive Vice President
AdvaMed
701 Pennsylvania Avenue, N.W,
Suite 800
Washington, DC 20004
Direct: (b) (6)

AMERICAN
OVERSIGHT

MULTI-HHS-FDA-20-0400, 20-0415-D, HHS-FDA-20-0498-G-000335

Email: rives@advamed.org

mpact on diversion of PPE for domestic manufacturers as well.